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Abbreviat ions 
 
AAGN ANCA-associated glom erulonephrit is 
AAV ANCA-associated vasculit is 
ACE angiotensin convert ing enzym e 
ANCA ant ineut rophil cytoplasm ic ant ibodies 
APV ANCA-posit ive vasculit is 
bp base pair 
BVAS Birm ingham  vasculit is act ivit y score 
C-ANCA cytoplasm ic ANCA 
CCA com m on carot id artery 
CI MT carot id int im a m edia thickness 
CMV cytom egalovirus 
CRP C- react ive protein 
CSS Churg-St rauss syndrom e 
CSSRD Cooperat ive System at ic Studies of the Rheum at ic 
Diseases 
CTLA-4 cytotoxic T lym phocyte-associated ant igen 4 
Cu copper 
CYCAZAREM Random ised t r ial of cyclophospham ide versus 
azathioprine during rem ission in ANCA posit ive System ic 
Vasculit is 
EDV endothelium-dependent  vasodilatat ion 
ELISA enzym e- linked im munosorbent  assay 
ENT ear, nose, throat  disease 
ESR erythrocyte sedim entat ion rate 
ESRD end-stage renal disease 
EUVAS European vasculit is study group 
FACS fluorescence act ivated cell sort ing 
GBM glom erular basem ent  m em brane 
GN glom erulonephrit is 
HC healthy cont rols 
HD hem odialysis 
hHSP60 hum an heat  shock protein 60 
HLE hum an leukocyte elastase 
HSP70 heat  shock protein 70 
HWE Hardy Weinberg equilibrium  
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I gG im m unoglobulin G 
I IF indirect  im m unofluorescence 
IMT int im a m edia thickness 
iNCGN idiopathic necrot izing and crescent ic glom erulonephrit is 
KIR2DS1/ 2 killer cell im m unoglobulin- like receptor DS1 /  2 
MAP m ean arterial pressure 
MDA m alondialdehyde 
m HSP65 m ycobacterial heat  shock protein 65 
MIRA Minocycline in Rheum atoid Arthrit is 
MPA m icroscopic polyangiit is 
MPO m yeloperoxidase 
MTX m ethot rexate 
N/ A not  applicable 
oxLDL oxidized low-density lipoprotein 
P-ANCA perinuclear ANCA 
PD-1 program m ed death-1 (also PDCD1)  
PE plasm a exchange 
PR3 proteinase 3 
PTU propylthiouracil 
PWV pulse-wave velocity 
RA rheum atoid arthrit is 
REMAIN Random ized t r ial of prolonged rem ission-m aintenance 
therapy in system ic vasculit is 
RRT renal replacem ent  therapy 
SLE system ic lupus erythem atosus 
SNP single-nucleot ide polym orphism s 
TCR T-cell receptor 
TNF tum or necrosis factor 
TPO thyroid peroxidase 
UA unstable angina 
WG Wegener’s granulom atosis 
  
 
Chapter 1 
Wegener’s granulom atosis  
– an int roduct ion 
Slot  MC, Cohen Tervaert  JW 
 
Published in part  in Autoim m unity 2004; 37: 313-315  
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Wegener’s granulom atosis (WG)  is a disease of presum ed autoim m une 
origin characterized by necrot izing granulom atous inflam m at ion of the 
upper and lower airways and necrot izing vasculit is that  is especially 
likely to involve the kidneys1.  Unt reated, WG results in death within 
weeks to m onths. Since the int roduct ion of cyclophospham ide and 
prednisolone as standard t reatm ent , survival has im proved 
dram at ically from  less than 20%  at  1 year reported in 19582 to at  least  
74%  5-years survival reported in the past  ten years3-6.   
WG and other sm all- vessel vasculit ides, such as m icroscopic 
polyangiit is (MPA)  and the Churg-St rauss syndrom e are st rongly 
associated with ant ineut rophil cytoplasm ic ant ibodies (ANCA)  which are 
either directed to m yeloperoxidase (MPO)  or proteinase 3 (PR3) 7-9.  
There is evidence that  ANCA play a pathophysiologic role in the 
induct ion of these vasculit ides. First , r ises in ANCA level predict  disease 
react ivat ion10,11.  Second, in vit ro it  has been dem onst rated that  ANCA 
induce neut rophil act ivat ion, i.e. degranulat ion and product ion of a 
respiratory burst 12.  I n addit ion, ANCA act ivate other cells in vit ro such 
as m onocytes and endothelial cells13.  Finally, in vivo,  experim ental data 
also suggest  an im portant  role for  ANCA in the pathophysiology of 
vasculit is14,15.   
The m echanism  by which ANCA are induced are as yet  unclear. One 
favored hypothesis is that  infect ions m ay t r igger an ANCA response16.  
Certain drugs have been linked to the induct ion of ANCA and the onset  
of ANCA-associated vasculit is (AAV) 17.  Recent ly, it  has been described 
that  an autoim m une response m ay be induced by the presence of a 
pept ide that  is ant isense or com plem entary to the autoant igen, for 
instance, PR318.  This im m une response m ay induce ant i- idiotypic 
ant ibodies (autoant ibodies)  that  cross- react  with the autoant igen. 
 
Autoant ibodies as diagnost ic m arkers 
I n pat ients with system ic vasculit is and glom erulonephrit is, ANCA were 
first  described in 198219.  The link between ANCA and act ive WG 
em erged in 198520.  Two ANCA pat terns m ay be seen with indirect  
im m unofluorescence ( I I F)  on ethanol- fixed neut rophils:  a cytoplasmic 
pat tern (C-ANCA) , for  which the m ajor ant igen is PR3;  and a 
perinuclear pat tern (P-ANCA) , for which the m ajor ant igen is MPO7-9.  
Several groups have invest igated the sensit ivit y and specificit y of ANCA 
for sm all- vessel vasculit ides. PR3-  and MPO-ANCA have been the 
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subject  of a m eta-analysis on their diagnost ic perform ance in the 
spect rum  of system ic necrot izing vasculit ides21.  This m eta-analysis 
revealed that  MPO-ANCA has a low sensit ivit y for vasculit is on it s own, 
but  since nearly all pat ients with vasculit is have either PR3-  or MPO-
ANCA, a test ing system  com bining P- / MPO-ANCA and C- / PR3-ANCA 
yields a pooled sensit ivit y of 85.5%  and a pooled specificit y of 98.6% . 
However, the sensit ivity and specificit y of an ANCA subtype m ay vary 
with the disease condit ion studied. For Wegener ’s granulom atosis, the 
presence of C-ANCA at  any t im e has a pooled sensit ivit y of  66% 22,  
which increases to 91%  during act ive disease with a specificit y of 99% . 
On I IF, ANCA has been detected in various other rheum at ic diseases23.  
On enzym e- linked im m unosorbent  assay (ELI SA) , sera from  pat ients 
with SLE or RA m ay display react ivit y to MPO, in addit ion to react ivit y 
to m ult iple other neut rophil contents. PR3-ANCA are rarely detected in 
pat ients with rheum at ic autoim m une diseases other than the sm all-
vessel vasculit ides23.  Nevertheless, even in a large cohort  of pat ients 
with connect ive t issue disease, the specificit y of a scoring system  that  
com bines im m unofluorescence and ELISA m ay be as high as 99.5% 24.  
Even though the presence of ANCA is highly specific for the spect rum  of 
sm all- vessel vasculit ides that  includes WG and MPA, a posit ive ANCA 
result  should always be interpreted with considerat ion of the clinical 
set t ing and presentat ion of individual pat ients suspected of vasculit is. 
I n addit ion to the diagnost ic perform ance of the ANCA assays, the 
presence of specific clinical features plays a m ajor role in determ ining 
the diagnost ic probability of vasculit is21.  
 
Autoant ibodies as predict ive  m arkers 
Several large series that  describe pat ients with WG find high relapse 
rates for pat ients with this disease (ZLWKLQ\HDUV3-6.  Relapse 
is m ore com m on in pat ients with WG as com pared to pat ients with 
another ANCA-associated vasculit is subtype, MPA25.  Since WG is m ore 
frequent ly associated with ant ibodies against  PR3 (70-80% )  than to 
MPO (10-30% ) , while the opposite is t rue for MPA, the quest ion is 
whether it  is the ANCA specificit y or the clinical syndrom e that  is 
related to the relapse r isk26.  Higher relapse rates in pat ients with PR3-
ANCA as com pared to pat ients with MPO-ANCA have been 
described27,28.  Moreover, even within the subgroup of pat ients with WG, 
PR3-ANCA specificit y confers a higher r isk of relapse26.  
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Next  to the difference in relapse rates between PR3-  and MPO-ANCA, 
differences in both pat ient  and renal survival have been described for 
the ANCA subtypes. Pat ients with cytoplasm ic ANCA29 or PR3-ANCA30 
have previously been described to have a higher r isk of pat ient  death, 
but  this has been disputed by others31,32.  Vizjak et  al reported a higher 
rate of renal failure in MPO-  when com pared to PR3-AAV33,  in cont rast  
to previous studies that  reported no difference31,32,34.  Causes of 
progression to renal failure m ay differ between PR3-  and MPO-ANCA. In 
pat ients with MPO-ANCA, a slowly progressive course with pat ients 
developing dialysis dependency during follow-up without  signs of 
clinically act ive disease is often observed. I n these pat ients, proteinuria 
is the m ost  im portant  r isk factor for renal failure during follow-up35.  
Whether the sam e is t rue for  pat ients with PR3-ANCA will be studied in 
this thesis. 
I n addit ion to ANCA specificit y, ANCA levels at  diagnosis and during 
follow-up have been shown to be of predict ive value for pat ient , renal 
and disease- free survival. A high PR3-ANCA level at  diagnosis in 
capture ELISA is a r isk factor for both poor pat ient  and renal survival6, 
and a consistent ly elevated MPO-ANCA level is a r isk factor for poor 
renal survival as well35.  
During induct ion t reatm ent  with cyclophospham ide and prednisolone, 
ANCA levels fall or becom e negat ive in 30 to > 80%  of the pat ients 
within the first  few m onths26.  Persistent  or reappearing C-ANCA during 
the first  year, however, is significant ly related to subsequent  relapse in 
WG27,36,37.  Several groups have addressed the predict ive value of 
posit ive, or increasing, ANCA t iters during long- term  follow-up. More 
than 80%  of pat ients, who were ANCA posit ive at  diagnosis and who 
experience a relapse, have a persistent ly or  renewed posit ive ANCA 
t iter at  the t im e of relapse11,27,28,36-38.  The relat ionship between a r ise in 
ANCA t iter, and a subsequent  relapse, has been m ore cont roversial. 
Som e studies clearly show an associat ion between rise in ANCA t iter  
and renewed disease act ivit y10,11,39,  but  this has been disputed by 
others27,36,38.  Nonetheless, two studies show that  when a r ise in ANCA 
t iter of fourfold or greater is found in a pat ient , pre-em pt ive t reatm ent  
reduces the r isk of relapses, and m ay lead to a reduced exposure to 
im m unosuppressive drugs39,40.  
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Aim  of the thesis 
The aim  of this thesis is to invest igate factors involved in disease 
induct ion and factors involved in pat ient , renal and disease- free 
survival. Furtherm ore, a possible long- term  consequence of ANCA-
associated vasculit is was studied:  atherosclerosis. 
Chapters 2 and 3 discuss the associat ion of several drugs with the 
occurrence of ANCA and associated vasculit is. Does the use of 
rheum atoid drugs (m inocycline, sulfasalazine, or penicillam ine)  or the 
use of ant ithyroid drugs (carbim azol, m ethim azol, propylthiouracil)  lead 
to a higher prevalence of ANCA-associated vasculit is? 
In Chapter 4,  the relat ionship between genet ic factors and the 
presence of ANCA-associated vasculit is is invest igated. Several 
inhibitory m olecules that  cont rol the im m une response have been 
described. Are genet ic m utat ions (polym orphism s)  in two of these 
m olecules, CTLA-4 and PD-1, related to t he presence of ANCA-
associated vasculit is? 
One favored theory is that  infect ions m ay t r igger an ANCA response, 
through m olecular m im icry between bacterial and hum an proteins. I n 
Chapter 5 we invest igate the possible role of bacterial and hum an Heat  
Shock Proteins in the induct ion of ANCA. 
After the diagnosis of ANCA-associated vasculit is, aggressive t reatm ent  
is often necessary to save the life of and the renal funct ion in the 
pat ient . I n order t o select  this t reatm ent  only for pat ients who really 
need it , prognost ic factors are sought  that  m ay give insight  in the 
disease course of these pat ients. Chapters 6 and 7 describe the search 
for  such prognost ic factors. 
The need for aggressive t reatm ent  in ANCA-associated vasculit is m ay 
be quest ioned;  for  exam ple, rem ission m aintenance therapy has been 
shown to be less aggressive than rem ission induct ion therapy and 
equally capable of cont rolling disease act ivit y. I n Chapter 8 is studied 
whether less aggressive therapy m ight  lead to a reduced disease- free 
survival. 
With the current  standards of therapy, ANCA-associated vasculit is has 
becom e a chronic illness. Due to the disease, or the given therapy, 
pat ients develop long- term  com plicat ions;  atherosclerosis m ay be one 
of them . In Chapter 9 ,  we invest igated whether ant ibodies against  
oxidized LDL, a m arker for the presence of atherosclerosis, m ay 
already be present  at  diagnosis of ANCA-associated vasculit is. I n 
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Chapter 10 we studied the presence of atherosclerosis using int im a-
m edia thickness and pulse-wave velocity m easurem ents, and 
accom panying im m unological phenom ena ( i.e.,  the presence of T- cells 
related to the presence of atherosclerosis)  in pat ients with ANCA-
associated vasculit is. 
Finally, Chapter 11 reviews the current  concepts regarding 
atherosclerosis, and the presence of atherosclerosis in ANCA-associated 
vasculit is. 
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Object ive. Case reports have suggested that  m inocycline, 
sulfasalazine, and penicillam ine are associated with ant ineut rophil 
cytoplasm ic ant ibody (ANCA)–posit ive vasculit is. This study evaluated 
ANCA seroconversion due to these agents in serum  sam ples 
prospect ively collected in random ized, double-blind, cont rolled t r ials.  
Methods.  The sources of study sera were 3 clinical t r ials:  1)  a 48-week 
t r ial of m inocycline for  early rheum atoid arthrit is, with 64 pat ients 
receiving m inocycline com pared with 68 receiving placebo;  2)  a 37-
week t r ial of sulfasalazine for rheum atoid arthrit is, with 51 receiving 
sulfasalazine com pared with 38 receiving placebo;  and 3)  a 104-week 
t r ial of penicillam ine for early system ic sclerosis, with 15 undergoing 
high-dose penicillam ine t reatm ent  versus 12 receiving low-dose 
penicillam ine. ANCA were m easured in the baseline and study-end 
serum  sam ples by indirect  im m unofluorescence ( I IF)  for perinuclear 
ANCA (P-ANCA)  and cytoplasm ic ANCA (C-ANCA)  pat terns, and by 
ant igen-specific enzym e linked im m unosorbent  assay (ELISA)  for  
ant ibodies to m yeloperoxidase (MPO-ANCA)  and proteinase 3 (PR3-
ANCA) . Laboratory personnel were blinded to the group ident it y of the 
sam ples. ANCA results were interpreted using an ANCA scoring system  
that  com bines the results of I IF and ELISA test ing. 
Results.  No pat ient  in any of the act ive study drug groups 
dem onst rated ANCA seroconversion according to the final 
interpretat ion of the com bined I IF and ELISA results. Twelve of the 248 
pat ients (5% )  were posit ive for MPO-ANCA with P-ANCA at  baseline. No 
subject  was posit ive for PR3-ANCA with C-ANCA. There were no 
findings suggest ive of vasculit is in any of these pat ients. 
Conclusion .  From  our study results, there was no suggest ion of ANCA 
seroconversion induced by m inocycline, sulfasalazine, or penicillam ine. 
However, these findings do not  rule out  the possibilit y of rare, sporadic 
cases of either ANCA seroconversion or t rue drug induced vasculit is 
with these drugs.  
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The t r iggers that  induce ant ineut rophil cytoplasm ic ant ibody (ANCA)–
posit ive vasculit is (APV)  are largely unknown. However, there have 
been a num ber of cases reported of APV associated with prior use of 
certain m edicat ions. The 2 drugs that  have been m ost  oft en im plicated 
in the induct ion of APV are hydralazine and propylthiouracil1-5.  I n 
addit ion, there have been cases linked to other drugs, including 
m inocycline, sulfasalazine, and penicillam ine4,6-16.  Drug associated APV 
can result  in the sam e life- threatening vasculit ic features as observed 
in idiopathic cases2.  Given the clinical severity of APV, even low rates of 
drug- induced disease would have im portant  m edical im plicat ions. 
Seroconversion from  ANCA negat ivit y to ANCA posit ivit y m ay occur 
even in the absence of clinical vasculit is in pat ients who are exposed to 
certain drugs. This process would be sim ilar to that  seen with 
ant inuclear ant ibody seroconversion and would suggest  a parallel 
between the pathogenet ic steps of drug-associated lupus and 
vasculit is. ANCA seroconversion by drugs in the absence of clinical 
vasculit is would, if a real phenom enon, be a cause of false-posit ive 
ANCA findings ( i.e., nonvasculit is condit ion with drug- induced ANCA 
posit ivit y) . Nevertheless, ANCA seroconversion m ight  provide an 
im portant  m eans of ident ifying pat ients at  risk for developing drug-
induced APV. No published report  has addressed this im portant  issue in 
a system at ic way. 
To evaluate ANCA seroconversion in pat ients exposed to m inocycline, 
sulfasalazine, or penicillam ine, we perform ed blinded ANCA test ing of 
prospect ively collected, paired pre-  and postexposure serum  sam ples 
from  pat ients who were enrolled in therapeut ic clinical t r ials for  
rheum at ic diseases.  
 
Pat ients and m ethods 
Clinical t r ials and study groups 
Three double-blind, random ized t r ials provided prospect ively collected 
sera for ANCA test ing in our study:  the Minocycline in Rheum atoid 
Arthrit is (MIRA)  t r ial17,  the Cooperat ive System at ic Studies of the 
Rheum at ic Diseases (CSSRD)  com parat ive study of sulfasalazine, 
injectable gold, and placebo18,  and a t r ial of penicillam ine for early 
system ic sclerosis (scleroderm a t r ial)  (Table 1) 19.  I n the MIRA t r ial, 
pat ients with early rheum atoid arthrit is (RA)  received 200 m g of 
m inocycline or placebo daily for 48 weeks. We used sera from  both 
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MIRA groups for this study. I n the CSSRD t r ial, pat ients with RA 
received 2,000 m g of sulfasalazine, placebo, or  gold sodium  thiom alate 
daily for 37 weeks. Sera from  the first  2 groups were used for this 
study. I n the penicillam ine t rial, pat ients with early system ic sclerosis 
received penicillam ine at  750–1,000 m g (high dose)  or 62.5 m g ( low 
dose)  daily for 2 years. We used the sera from  both of these groups. 
Only sera that  were paired, i.e. , both a baseline (0 weeks)  and a t r ial-
end serum  sam ple were available, were tested for  ANCA. Thus, 132 
paired MIRA sera ( from  64 pat ients receiving m inocycline and 68 
placebo) , 89 paired CSSRD sera ( from  51 pat ients receiving 
sulfasalazine and 38 placebo) , and 27 paired scleroderm a t r ial sera 
( from  15 pat ients receiving high-dose penicillam ine and 12 low-dose 
penicillam ine)  were tested. The total num ber of study subjects was 248 
and total num ber of paired sera was 496 (Table 1) .  
 
Cont rol groups and blinding  
To ensure the qualit y of ANCA test ing in our laboratory, various groups 
of cont rol sera were also tested:  sam ples from  15 pat ients with 
vasculit is that  tested posit ive for ant im yeloperoxidase ant ibodies (MPO-
ANCA)  and perinuclear ANCA (P-ANCA) , sam ples from  15 pat ients with 
vasculit is that  tested posit ive for  ant i–proteinase 3 (PR3-ANCA)  and 
Table 1 . Source of study subjects and sum m ary of drug exposures*  
Source tr ial, t reatment  arm  
(dosage)  
Durat ion of drug exposure, 
mean ±  SD weeks (range)  
Number of subjects 
(n =  248)† 
MI RA t r ia l   
Minocycline 
(200 mg/ day)  
51 ±  7.1 (10 – 72)  64 
Placebo 50 ±  6.7 (6 – 56)  68 
CSSRD RA t r ia l   
Sulfasalzine 
(2000 mg/ day)  
31 ±  11 (4 – 39)  51 
Placebo 30 ±  12 (2 – 49)  38 
Scleroderm a t r ia l   
High-dose penicillam ine 
(750-1000 mg/ day)  
58 ±  4 (51 – 69)  15 
Low-dose penicillam ine 
(62.5 mg/ day)  
61 ±  13 (50 – 100)  12 
*  MIRA, Minocycline in Rheumatoid Arthr it is;  CSSRD, Cooperat ive Systemat ic Studies 
of the Rheumat ic Diseases;  RA, rheumatoid arthr it is 
† Total number of paired sera =  496 
 
 Ant irheum at ic drugs and ANCA induct ion  25 
cytoplasm ic ANCA (C-ANCA) , and sam ples from  30 norm al blood 
donors. All study sera were assigned new, random ized ident ificat ion 
num bers. To keep laboratory personnel blinded to the study group 
ident it y, sam ples were realiquoted into ident ical tubes labeled only with 
study ident ificat ion num bers. The group ident ificat ion of the sera was 
kept  m asked unt il all of the ANCA assay results were collected for the 
final interpretat ion and the analysis was ready to begin. 
 
ANCA assays by indirect  im m unofluorescence ( I I F)  
I IF t est s were done with the use of ethanol- fixed neut rophils as 
described elsewhere20.  The results of staining were classified as having 
1 of 4 pat terns:  C-ANCA, P-ANCA, atypical (neither cytoplasm ic nor 
perinuclear) , or negat ive. Given the subject ive nature of scoring of the 
results of I IF for ANCA, we ut ilized a com prehensive interpretat ion 
system  as described in our previous work20.  Briefly, the interpretat ion 
was decided by agreem ent  of init ial independent  readings by 2 
invest igators (MCS and JLN)  or by resolut ion of their discrepancy by 
taking the m ajorit y as f inal after obtaining a third invest igator’s (CAW)  
reading. I IF staining was repeatedly perform ed to resolve discrepant  
readings. I IF and enzym e- linked im munosorbent  assay (ELISA)  results 
were determ ined independent ly. 
 
ANCA assay by ELI SA  
Each sam ple was tested by direct  ant igen-specific ELISAs that  used 
highly purified ant igens to detect  ant i-MPO and ant i-PR3 ant ibodies, as 
well as a sandwich ant i-PR3 ELISA. These ANCA assays have been 
extensively characterized in prior reports from  our laboratory20-23.  
 
Final interpretat ion by com bining I I F and ELI SA ANCA results 
A final interpretat ion of ANCA test ing was determ ined by com bining the 
I IF and ELISA results. Sam ples were considered ANCA-posit ive when 
posit ive for both PR3-ANCA and C-ANCA or when posit ive for MPO-
ANCA and P-ANCA or atypical ANCA. Therefore, sam ples with I IF 
posit ivit y without  respect ive ELISA posit ivit y or those with ELISA 
posit ivit y without  respect ive I IF posit ivit y were interpreted as negat ive 
in our final interpretat ion. This is consistent  with our previously 
published m ethods20.  
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Stat ist ical analysis  
Com parisons between groups were analyzed by Fisher’s exact  t est  for  
categorical variables. All tests used a 2- tailed significance level of 0.05. 
We derived 95%  confidence intervals (95%  CI )  using exact  m ethods 
for proport ions. Analysis was perform ed using the Stata software 
package (Stata Corporat ion, College Stat ion, TX) . 
 
Results 
ANCA seroconversion by final com bined interpretat ion 
No pat ient  in any of the act ive study drug groups dem onst rated ANCA 
seroconversion according to the final com bined interpretat ion ( table 2) . 
Serum  from  1 pat ient  receiving placebo in the m inocycline t r ial 
Table 2 . ANCA test  results, f inal interpretat ion*  
Study group, t ime point  n PR3-ANCA MPO-ANCA 
MI RA RA t r ia l    
Minocycline    
Start  64 0 (0)  3 (4.7)  
End 64 0 (0)  2 (3.1)  
Placebo    
Start  68 0 (0)  4 (4.4)  
End 68 0 (0)  2 (2.9)  
CSSRD RA t r ia l    
Sulfasalazine    
Start  51 0 (0)  4 (7.8)  
End 51 0 (0)  3 (5.9)  
Placebo    
Start  38 0 (0)  1 (2.6)  
End 38 0 (0)  0 (0)  
Scleroderm a t r ia l    
High-dose penicillam ine    
Start  15 0 (0)  1 (6.7)  
End 15 0 (0)  1 (6.7)  
Low-dose penicillam ine    
Start  12 0 (0)  0 (0)  
End 12 0 (0)  0 (0)  
Control groups    
Normal blood donors 30 0 (0)  0 (0)  
MPO-ANCA vasculit is 15 0 (0)  14 (93.3)  
PR3-ANCA vasculit is 15 15 (100)  0 (0)  
*  Note that  conversion from negat ive to posit ive or posit ive to negat ive 
could occur over the course of the study for each ANCA test . Values are 
the number (% )  of ant ineutrophil cytoplasm ic ant ibody (ANCA)-posit ive 
pat ients. MPO-ANCA, ant imyeloperoxidase ant ibodies;  PR3-ANCA, ant i-
proteinase 3 ant ibodies (see Table 1 for  other definit ions)  
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converted from  ANCA negat ive to ANCA posit ive, with a very low t iter 
of MPO-ANCA and an atypical I IF ANCA pat tern. Twelve other pat ients 
were posit ive for ANCA at  baseline (by final com bined interpretat ion) , 
but  5 of these were found to be MPO-ANCA negat ive at  their end-study 
t im e point . All 13 MPO-ANCA-posit ive pat ients were posit ive for P-ANCA 
or showed an atypical ANCA I IF pat tern, with 2 of the pat ient  serum  
sam ples changing their I IF pat tern from  atypical to P-ANCA and 2 
changing from  P-ANCA to atypical. No study pat ient  was posit ive for 
com bined PR3-ANCA/ C-ANCA at  any t im e. 
 
ANCA seroconversion by I I F alone  
When the results of ANCA test ing by im m unofluorescence were 
analyzed separately from  the ELISA data, seroconversions were found 
only in those sam ples with atypical ANCA ( table 3) . Nineteen of the 248 
serum  sam ples (8% )  seroconverted for atypical ANCA (3 receiving 
sulfasalazine, 2 high-dose penicillam ine, 7 m inocycline, 1 placebo in 
the CSSRD t r ial, 6 placebo in the MIRA t r ial) . No pat ient  in any group 
showed a seroconversion for the P-ANCA or C-ANCA pat terns by I I F 
alone. 
 
ANCA seroconversion by ELI SA alone  
None of the pat ient  sera seroconverted for MPO-ANCA in the absence 
of I IF posit ivit y ( table 4) . One pat ient  was PR3-ANCA negat ive at  
baseline, but  posit ive for PR3-ANCA by sandwich ELISA alone at  follow-
up, represent ing a seroconversion by ELISA only. One pat ient  was 
posit ive for PR3-ANCA by direct  ELISA alone at  baseline, but  negat ive 
at  follow-up. Three addit ional pat ients were PR3-ANCA posit ive by 
sandwich ELISA alone at  baseline, but  negat ive at  follow-up. 
 
Disease classificat ion of ANCA-posit ive pat ients at  baseline  
RA t r ia ls.  Am ong the pat ients in the 2 RA source t r ials, 6 pat ients with 
early RA in the m inocycline study were posit ive for ANCA at  baseline (3 
in the m inocycline group and 3 in the placebo group) , while 5 pat ients 
with RA in the CSSRD t r ial were posit ive for ANCA at  baseline (4 in the 
sulfasalazine group and 1 in the placebo group) . Of these 11 RA 
pat ients with ANCA posit ivit y at  baseline, 7 had a borderline posit ive 
MPO-ANCA ELISA t iter and were posit ive for perinuclear or  atypical I I F 
at  baseline. The rem aining 4 had high MPO-ANCA t iters with 
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perinuclear or atypical I IF pat terns at  baseline. There were no clinical 
findings suggest ive of vasculit is beyond the features of RA (m eet ing 
the study ent ry criteria of source t r ials)  in any of these pat ients. This 
false-posit ive ANCA test ing rate ( for the diagnosis of vasculit is)  am ong 
pat ients with RA (5.4% )  was not  significant ly different  from  our 
previous results20.  
Scleroderm a t r ial.  One pat ient  in the high-dose penicillam ine group 
was ANCA posit ive at  baseline. This was the only pat ient  in the study 
with a high t iter of ANCA. This pat ient  had diffuse scleroderm a with 
lung and gast rointest inal involvem ent . He tolerated 1,000 m g of 
penicillam ine throughout  the t r ial. The MPO-ANCA ELISA t iter rose from  
78 to 2,061 units (norm al < 2.8 ELISA units)  after 14 m onths. No 
Table 3 . ANCA I ndirect  I m m unofluorescence test  results*  
Study group, t ime point  n C-ANCA P-ANCA Atypical ANCA 
MI RA RA t r ia l     
Minocycline     
Start  64 0 (0)  2 (3.1)  26 (40.6)  
End 64 0 (0)  0 (0)  25 (39.1)  
Placebo     
Start  68 0 (0)  1 (1.5)  35 (51.5)  
End 68 0 (0)  1 (1.5)  29 (42.6)  
CSSRD RA t r ia l     
Sulfasalazine     
Start  51 0 (0)  2 (3.9)  23 (45.1)  
End 51 0 (0)  3 (5.9)  19 (37.3)  
Placebo     
Start  38 0 (0)  3 (7.9)  18 (47.4)  
End 38 0 (0)  2 (5.3)  19 (50.0)  
Scleroderm a t r ia l     
High-dose penicillam ine     
Start  15 0 (0)  0 (0)  1 (6.7)  
End 15 0 (0)  1 (6.7)  2 (13.3)  
Low-dose penicillam ine     
Start  12 0 (0)  0 (0)  1 (8.3)  
End 12 0 (0)  0 (0)  1 (8.3)  
Control groups     
Normal blood donors 30 0 (0)  0 (0)  2 (6.7)  
MPO-ANCA vasculit is 15 0 (0)  11 (73.3)  3 (20.0)  
PR3-ANCA vasculit is 15 14 (93.3)  0 (0)  1 (6.7)  
*  Note that  conversion from negat ive to posit ive or posit ive to negat ive could occur 
over the course of the study for each ANCA test . Values are the number (% )  of 
ant ineutrophil cytoplasm ic ant ibody (ANCA)-posit ive pat ients. C-ANCA, cytoplasm ic 
ANCA;  P-ANCA, per inuclear ANCA;  MPO-ANCA, ant imyeloperoxidase ant ibodies;  
PR3-ANCA, ant i-proteinase 3 ant ibodies (see Table 1 for other definit ions)  
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findings suggest ive of vasculit is were observed, even after 4 years of 
clinical follow-up. The finding that  only 1 of 27 pat ients with 
scleroderm a (3.7% )  was posit ive for MPO-ANCA with P-ANCA 
represented a rate that  was also not  significant ly different  from  our 
prior data20.  
Control groups.  Of the 60 cont rol sera (15 with PR3-ANCA/ C-ANCA, 
15 with MPO-ANCA/ P-ANCA, and 30 norm al blood donors) , 59 sera 
were correct ly classified. One sam ple from  an MPO-ANCA/ P-ANCA-
posit ive pat ient  was interpreted as ANCA negat ive by our com bined 
scoring m ethod ( false negat ive) , whereas the other 14 sam ples were 
posit ive for MPO-ANCA/ P-ANCA or atypical ANCA. All PR3-ANCA/ C-
ANCA-posit ive sam ples were confirm ed posit ive, and all blood donor 
sam ples were ANCA negat ive. 
 
Discussion 
The current  study evaluated potent ial ANCA seroconversion by 
m inocycline, sulfasalazine, and penicillam ine in prospect ively collected 
sera from  3 m ajor clinical t rials on rheum at ic disorders. The results do 
not  support  ANCA seroconversion induced by these 3 drugs. 
Our abilit y to dem onst rate drug- induced ANCA seroconversion m ight  
have been affected by a num ber of factors:  1)  t he dosages of the study 
m edicat ions, 2)  the durat ion of drug exposures, and 3)  the potent ial 
frequency of ANCA seroconversion. The dosages of m edicat ions used in 
source t r ials were sim ilar to those used in previously published cases 
that  im plicated these drugs as a cause of ANCA-posit ive 
vasculit is6,7,9,12,13,15.  The durat ion of drug exposure was close to that  
reported in the previously published cases associated with m inocycline 
(12 m onths versus 12–36 m onths) 6.  However, the durat ion was shorter 
than in the reported cases associated with sulfasalazine (7 m onths 
versus 18–40 m onths) 7,15 or penicillam ine (14 m onths versus 17–70 
m onths) 9,12,13.  
The lower bounds of t he frequency of potent ial seroconversion were 
lim ited in this study by the num ber of paired sera available. Thus, this 
study does not  rule out  ANCA seroconversion rates < 1.6%  for 
m inocycline (95%  CI  0–5.8% ) , < 1.7%  for sulfasalazine (95%  CI  0–
7.2% ) , or < 3.7%  for penicillam ine (95%  CI  0–13.7% ) . I n order to 
further invest igate the possibilit y of rare ANCA seroconversion and 
drug-associated APV, case–cont rol studies m ay be m ore feasible than 
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prospect ive cohort  studies;  these would require large sam ple sizes with 
long periods of follow-up to dem onst rate potent ial posit ive results. 
There are several st rengths in our study. By test ing ANCA in pre-  and 
postexposure serum  sam ples, we were able to elim inate the potent ial 
false im pression of ANCA seroconversion that  m ight  be presum ed by 
adm inistering the drugs to pat ients who were already posit ive for  ANCA 
at  baseline. Am ong the reported cases im plicat ing m inocycline, 
sulfasalazine, or penicillam ine in inducing ANCA-associated 
syndrom es6,7,9,12,13,15,  we are aware of only 1 case of APV associated 
with penicillam ine in which a negat ive MPO-ANCA status was 
docum ented prior to drug init iat ion12.  Thus, it  rem ains possible that  the 
Table 4 . ANCA ELI SA test  results*  
Study group, t ime point  n Direct  
PR3-ANCA 
Sandwich 
PR3-ANCA 
Direct  
MPO-ANCA 
MI RA RA t r ia l     
Minocycline     
Start  64 0 (0)  0 (0)  3 (4.7)  
End 64 0 (0)  0 (0)  2 (3.1)  
Placebo     
Start  68 0 (0)  1 (1.5)  3 (4.4)  
End 68 0 (0)  1 (1.5)  2 (2.9)  
CSSRD RA t r ia l     
Sulfasalazine     
Start  51 0 (0)  1 (2.0)  4 (7.8)  
End 51 0 (0)  0 (0)  3 (5.9)  
Placebo     
Start  38 0 (0)  1 (2.6)  1 (2.6)  
End 38 0 (0)  0 (0)  0 (0)  
Scleroderm a t r ia l     
High-dose penicillam ine     
Start  15 1 (6.7)  0 (0)  1 (6.7)  
End 15 0 (0)  0 (0)  1 (6.7)  
Low-dose penicillam ine     
Start  12 0 (0)  0 (0)  0 (0)  
End 12 0 (0)  0 (0)  0 (0)  
Control groups     
Normal blood donors 30 0 (0)  0 (0)  0 (0)  
MPO-ANCA vasculit is 15 0 (0)  0 (0)  14 (93.3)  
PR3-ANCA vasculit is 15 13 (86.7)  15 (100)  0 (0)  
*  Note that  conversion from negat ive to posit ive or posit ive to negat ive could occur 
over the course of the study for each ANCA test . Values are the number (% )  of 
ant ineutrophil cytoplasm ic ant ibody (ANCA)-posit ive pat ients. ELI SA, enzyme-
linked immunosorbent  assay;  MPO-ANCA, ant imyeloperoxidase ant ibodies;  PR3-
ANCA, ant i-proteinase 3 ant ibodies (see Table 1 for  other definit ions)  
 
 Ant irheum at ic drugs and ANCA induct ion  31 
rem aining cases described in the literature6,7,9,12,13,15 could have had 
posit ive ANCA t iters before the respect ive drug therapy was started, as 
dem onst rated in our current  study. I n addit ion, the blinding of 
laboratory personnel to sam ple group assignment  helped elim inate the 
potent ial bias involved in the subject ive nature of the interpretat ion of 
im m unofluorescence results20.  Another st rength of our study is the 
extensive clinical and research experience of our ANCA test ing 
laboratory20,21.   
Our com bined ANCA test ing system  that  ut ilizes both ELISAs and I IF is 
highly specific20,21 and m inim izes the potent ial false im pression of ANCA 
seroconversion that  could result  from  test ing sera by I IF alone. 
Although we different iate atypical from  per inuclear pat terns, I IF 
readings are subject ive, and other laboratories m ay not  read the slides 
the sam e way nor m ay they not  have the sam ples read by at  least  2 
qualified personnel. The apparent  rate of seroconversion am ong study 
subjects exposed to the test  drugs would have been as high as 5%  if 
determ ined by I IF alone, rather than the 0%  found with the m ore 
com prehensive com bined I IF and ELISA scoring m ethod used. 
I n conclusion, our study results do not  support  ANCA seroconversion by 
m inocycline, sulfasalazine, or  penicillam ine, which raises a possibilit y 
that  previous reports of ret rospect ive cases could have been prem ature 
in claim ing the causalit y between these drugs and ANCA. However, 
these data do not  rule out  the possibilit y of rare, sporadic cases of 
either ANCA seroconversion or t rue drug- induced vasculit is with these 
drugs. 
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Object ive .  To test  whether ant ineut rophil cytoplasm ic ant ibodies 
(ANCA)  and ANCA-associated vasculit is (AAV)  are not  only induced 
during t reatm ent  with ant ithyroid drugs, but  can also becom e m anifest  
when m edicat ion has been ceased, possibly after years. 
Methods.  Pat ients who visited our hospital for the t reatm ent  of 
hyperthyroidism  were included (n= 209) . Treatm ent  consisted of 
ant ithyroid m edicat ions, radioact ive iodide, thyroidectom y, or a 
com binat ion of these t reatm ent  opt ions. Pat ients were re- tested 3 to 6 
years later  to evaluate long- term  effects of ant ithyroid drugs. Pat ients 
were tested for the presence of ANCA and, if posit ive, evaluated for the 
presence of AAV. 
Results.  Of 209 pat ients with hyperthyroidism , 12 pat ients (6% )  were 
posit ive for m yeloperoxidase-  (MPO-) , proteinase 3-  (PR3- )  and/ or 
hum an leukocyte elastase-  (HLE- )  ANCA. Seventy-seven of 209 
pat ients were re- tested;  one pat ient , not  t reated with ant ithyroid drugs 
had developed MPO-ANCA. In 3 of 6 pat ients previously posit ive, ANCA 
could st ill be detected. The presence of ANCA was highly associated 
with (previous)  t reatm ent  with ant ithyroid drugs (Odds rat io 11.8 (95%  
confidence interval 1.5 – 93.3) . Of 13 pat ients with a posit ive ANCA 
result  on ELISA, AAV with glom erulonephrit is was diagnosed in 4 
pat ients (31% ) . 
Conclusion .  The presence of ANCA with or without  vasculit is is 
associated with previous t reatm ent  with ant ithyroid drugs, possibly 
after  years.  
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Ant ineut rophil cytoplasm ic ant ibodies (ANCA)  with specificit y for  
proteinase 3 (PR3)  or m yeloperoxidase (MPO)  are st rongly associated 
with sm all-vessel vasculit ides such as Wegener ’s granulom atosis (WG)  
and m icroscopic polyangiit is (MPA) 1-3.  There is evidence that  ANCA play 
a pathophysiologic role in the induct ion of these vasculit ides. First , 
elevat ions in ANCA t iters appear to correlate with r isk of future disease 
flares, although they do not  reliably predict  the t im ing of such flares4,5.  
Second, in vit ro it  has been dem onst rated that  ANCA induce neut rophil 
act ivat ion, i.e., degranulat ion and product ion of a respiratory burst 6.  I n 
addit ion, ANCA act ivate other cells in vit ro such as m onocytes and 
endothelial cells7.  Finally, in vivo,  experim ental data also suggest  an 
im portant  role for ANCA in the pathophysiology of vasculit is8,9.  Certain 
drugs have been linked to the induct ion of ANCA and the onset  of 
ANCA-associated vasculit is (AAV) 10.  There are several case reports 
im plicat ing hydralazine11-14 and propylthiouracil (PTU) 15-19 in the 
induct ion of AAV. Occasionally, other drugs are m ent ioned, including 
other ant ithyroid drugs such as carbim azole17 and m ethim azole20,21.  
ANCA in drug- induced AAV are m ost  frequent ly directed against  MPO11-
16,18-22;  however, cases in which pat ients were PR3-ANCA posit ive are 
also observed12,15,18,20,22.  ANCA in these pat ients m ay also be directed 
against  hum an leukocyte elastase (HLE)  and/ or lactoferr in, and the 
presence of ANCA directed to two or m ore ant igens m ay even be an 
indicat ion of drug- induced disease15,23.  Clinically, drug- induced ANCA-
associated vasculit is can be substant ially m ilder than idiopathic 
vasculit is, and drug- induced AAV m ay resolve in m any cases with 
discont inuat ion of the offending agent . However, severe disease 
courses m ay be observed and t reatm ent  with im munosuppressive 
therapy can be necessary. 
To our knowledge, t im e span between m edicat ion use and induct ion of 
ANCA and AAV has not  been studied. Furtherm ore, whether ANCA are 
induced by hyperthyroidism , or by ant ithyroid m edicat ion is st ill 
uncertain. We hypothesized that  ANCA and AAV m ay not  only be 
induced during t reatm ent  with ant ithyroid drugs, but  can also becom e 
m anifest  when m edicat ion has been ceased, possibly after years. To 
test  this hypothesis, we evaluated pat ients with hyperthyroidism , on 
various ant ithyroid t reatm ent  m odalit ies, for  the presence of ANCA. 
Addit ionally, we evaluated induct ion of ANCA after long- term  follow-up 
by test ing an addit ional sam ple >  3 years after  previous test ing for  
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ANCA.  
 
Pat ients and m ethods 
Pat ients 
All consecut ive pat ients diagnosed with hyperthyroidism  (both new 
diagnosis and relapse)  between January 1994 and July 1996 and 
t reated in our hospital were included. Treatm ent  consisted of 
ant ithyroid m edicat ions (carbim azole, m ethimazole, PTU) , radioact ive 
iodide, thyroidectom y, or a com binat ion of these t reatm ent  opt ions. 
Addit ionally, pat ients who were diagnosed with hyperthyroidism , visited 
the outpat ient  clinic of our hospital in 1999-2000 and had used 
ant ithyroid drugs (carbim azole, m ethim azole, and/ or PTU) , during the 
course of their disease for at  least  three m onths were included. Causes 
of hyperthyroidism  were based on established clinical, laboratory, 
scint igraphy and ult rasonographic findings and are presented in table 
1. Pat ients who were tested for the presence of ANCA between January 
1994 and July 1996 were contacted for consent  on re- test ing in 1999-
2000. I nform ed consent  was obtained from  each pat ient . When 
pat ients were found posit ive for ANCA ( see below) , they were invited 
for evaluat ion including physical and laboratory exam inat ion for signs 
of vasculit ic disease according to our protocol24.  
  
Sera 
Serum  sam ples for ANCA test ing were collected and stored at  -  20°C. 
Sam ples were coded and realiquoted in ident ical tubes. Laboratory 
personnel were blinded to pat ient  ident it y and m edicat ion use.  
Table 1 . Causes of hyperthyroidism  in groups A and B 
 Group A 
N (% )  
Group B 
N (% )  
Graves and other autoimmune 87 (66)  58 (76)  
Mult inodular st ruma 25 (19)  14 (18)  
Toxic adenoma 3 (2)  1 (1)  
Unknown 17 (13)  3 (4)  
Total 132 76 
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Test ing for  ANCA by indirect  im m unofluorescence ( I I F)  
Sera were tested for  the presence of ANCA by I IF as described 
previously25.  Briefly, slides coated with hum an granulocytes were 
incubated with pat ient  sera in two dilut ions (1: 20 and 1: 40)  or with 
posit ive cont rols ( for  P-  and C-ANCA)  or with a negat ive cont rol 
(norm al hum an serum ) . After addit ion of conjugate (FITC- labeled 
rabbit  F(ab’) 2 ant i-hum an IgG, Dako, Denm ark) , slides were read 
independent ly by two experienced readers. Fluorescence pat terns were 
scored as P-ANCA, C-ANCA, atypical, or negat ive. When readings were 
discordant , slides were read independent ly by a third reader without  
knowledge of prior fluorescence results. The I IF score was then decided 
by the m ajorit y. 
 
Test ing for  ANCA by enzym e- linked im m unosorbent  assay (ELI SA)  
Each sam ple was tested by capture ELISA to detect  PR3- , MPO-  and 
HLE-ANCA as previously described1.  
 
Final com bined interpretat ion 
Results of I IF and ELISA were com bined for final interpretat ion. Sera 
were considered posit ive for ANCA when capture ELISA was posit ive for  
MPO- , PR3-  and/ or HLE-ANCA. I IF staining showing C- , P-  or atypical 
ANCA was helpful, but  not  necessary, for ANCA posit ivit y. Sera were 
considered negat ive when I IF was posit ive without  a posit ive ELI SA 
result  or when the results on both assays were negat ive. 
 
Test ing for  thyroid m icrosom al ant ibodies 
Titers of thyroid m icrosom al ant ibodies were determ ined by indirect  
haem agglut inat ion using a com m ercial diagnost ics kit  according to the 
m anufacturer’s inst ruct ions (Murex Biotech, Dart ford, UK) . TPO has 
been determ ined as the thyroid m icrosom al ant igen26.  Sera were 
considered posit ive when agglut inat ion was present  in at  least  a 1: 100 
dilut ion. All pat ients who were tested in 1999-2000 for the presence of 
ANCA were tested for ant i-TPO ant ibodies. 
 
Stat ist ical analysis 
Com parisons between groups were analyzed by Fisher’s exact  t est  for  
categorical variables. All tests used a 2- tailed significance level of 0.05. 
We derived 95%  confidence intervals (95%  CI )  using exact  m ethods 
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for proport ions. Analysis was perform ed using the GraphPad Instat  
software package version 2.04a (GraphPad Software Inc., San Diego, 
CA) . 
 
Results 
Cross-sect ional evaluat ion of ANCA posit ivit y in pat ients with 
hyperthyroidism  
Between January 1994 and July 1996, 131 pat ients with 
hyperthyroidism  were tested for  the presence of ANCA. Addit ionally, 76 
pat ients were tested between 1999 and 2000. Pat ient  characterist ics 
are presented in table 2. 
On im m unofluorescence, C-ANCA was present  in 2 serum  sam ples 
(1.0% ) . P-ANCA was present  in 19 serum  sam ples (9.1% ) . Atypical 
ANCA was present  in 23 serum  sam ples (11.1% ) . All other serum  
sam ples produced negat ive staining. 
By ELISA, 12 pat ients of 132 (6.1% )  reacted posit ive in one or m ore of 
the assays. Four pat ients (1.9% )  were posit ive for MPO only and 4 
pat ients were posit ive for HLE only. Addit ionally, 2 pat ients were 
posit ive for  both PR3 and HLE (1.5% ) , 1 pat ient  (0.8% )  for both MPO 
and HLE, and 1 pat ient  for MPO, PR3 and HLE. Ten pat ients who were 
posit ive by ELISA were also posit ive in I IF, with P-ANCA (n =  6)  or 
atypical (n =  4)  staining.  
 
Table 2 . Pat ient  characterist ics 
Group Age*  Female (% )  Ant ithyroid 
drug use 
All pat ients 
N =  207 
49.8 ±  15.1 165 (80)  107 (52)  
Pat ients on ant ithyroid drugs 
N =  107 
48.5 ±  15.2 84 (79)   
Pat ients without  ant ithyroid drugs 
N =  100 
51.2 ±  15.0 83 (83)   
Pat ients with follow-up sample 
N =  77 
49.1 ±  14.7 65 (84)  56 (77)  
Pat ients without  follow-up sample 
N =  54 
51.8 ±  15.3 44 (81)  43 (80)  
*  Mean ±  standard deviat ion 
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Long- term  follow-up of pat ients with hyperthyroidism  
During follow-up, nine of 132 pat ients previously tested had died (of 
non-vasculit ic causes) .  Forty- five pat ients refused to be re- tested. 
These pat ients did not  differ from  pat ients who were re- tested with 
respect  to age, gender, and ant ithyroid drug use ( table 2) . Seventy-
seven pat ients (6 of whom  were previously posit ive for ANCA on ELISA)  
were re- tested in 2000. Median t im e between first  and follow-up 
sam ple was 4.8 years ( range, 3.3 to 6.0 years) . We found 5 of 6 
pat ients st ill posit ive for  ANCA. One pat ient , who was previously 
posit ive for PR3-  and HLE-ANCA, was now found negat ive. One of 71 
pat ients previously negat ive for ANCA becam e posit ive for MPO-ANCA. 
The rem aining 70 pat ients were persistent ly ANCA negat ive. 
 
The presence of ANCA is associated with previous t reatm ent  with 
ant ithyroid drugs 
Overall, 107 pat ients were or had been t reated with one or m ore 
ant ithyroid drugs (27 with carbim azole, 69 with m ethim azole, and 38 
with PTU) ;  162 pat ients were t reated with radioact ive iodide, and 1 
pat ient  had surgery. Eleven (10.3% )  pat ients t reated with ant ithyroid 
drugs were posit ive for MPO- , PR3 and/ or HLE-ANCA, whereas 2 
pat ients, not  t reated with ant ithyroid drugs (2% )  were posit ive for  
ANCA. Treatm ent  with ant ithyroid drugs was highly associated with the 
presence of ANCA (Odds rat io 11.8 (95%  CI  1.5 – 93.3) ,  P =  0.005) .  
However, when pat ients only posit ive for HLE-ANCA were excluded, 
there was no significant  associat ion between ant ithyroid drug use and 
ANCA posit ivit y (P =  0.17) . ANCA posit ivit y was not  related to any 
individual ant ithyroid drug (data not  shown) . There was no relat ionship 
between t im e on/ off ant ithyroid drugs and the presence of ANCA, nor 
the t im e interval between drug init iat ion and the onset  of vasculit ic 
sym ptom s. Fift y- three percent  of pat ients who were ANCA negat ive had 
ant i-TPO ant ibodies com pared to 67%  of pat ients who were ANCA 
posit ive (P =  0.69) . Forty-one percent  of pat ients who were ANCA 
negat ive had ant i- colloid ant ibodies com pared to 25%  of pat ients who 
were ANCA posit ive (P =  0.65) . Addit ionally, there was no associat ion 
between cause of hyperthyroidism  and the presence of ANCA (P =  1.0) .  
 
Clinical evaluat ion of ANCA-posit ive pat ients 
I n 13 pat ients who tested posit ive for ANCA, 4 pat ients (2 MPO-ANCA, 
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1 MPO-  and HLE-ANCA, and 1 MPO- , PR3-  and HLE-ANCA) , all of whom  
had been or were t reated with ant ithyroid drugs, had signs and 
sym ptom s of vasculit is, and were t reated in our hospital ( tables 3 and 
Table 3 . Laboratory results of ANCA- posit ive pat ients 
Gender 
(age)  
Diagnosis Drug use, durat ion 
( I V)  
1st  ANCA result  2nd ANCA result  
F (68)  Graves MMI , 5 months  
(5 months)  
I I F:  P-ANCA 
ELI SA:  MPO 
negat ive 
F (49)  Graves MMI , 8 months  
(7 years)  
I I F:  P-ANCA 
ELI SA:  MPO 
negat ive 
F (43)  Graves PTU, 21 months  
(23 months)  
I I F:  P-ANCA 
ELI SA:  MPO/  
PR3/  HLE 
I I F:  P-ANCA 
ELI SA:  MPO/  
PR3/  HLE 
F (51)  Graves PTU, 4 years  
(4 years)  
I I F:  P-ANCA 
ELI SA:  MPO/  HLE 
I I F:  P-ANCA 
ELI SA:  MPO/  
HLE 
M (57)  Unknown PTU, unknown I I F:  atypical 
ELI SA:  HLE 
no FU 
F (35)  Graves None I I F:  atypical 
ELI SA:  PR3/  HLE 
no FU 
F (63)  Unknown MMI , unknown I I F:  atypical 
ELI SA:  PR3/  HLE 
negat ive 
F (56)  Unknown PTU, 6 years I I F:  atypical 
ELI SA:  HLE 
I I F :  P-ANCA 
ELI SA :  HLE 
F (88)  MNS None I I F:  atypical 
ELI SA:  negat ive 
I I F:  P-ANCA 
ELI SA:  MPO 
F (31)  MNS PTU, 6 months I I F:  P-ANCA 
ELI SA:  HLE 
no FU 
F (38)  Graves MMI /  PTU, 2 years I I F:  negat ive 
ELI SA:  HLE 
no FU 
M (40)  Graves CM/  MMI , 2 years I I F:  negat ive 
ELI SA:  MPO 
no FU 
F (26)  Graves CM, unknown I I F:  P-ANCA 
ELI SA:  MPO 
no FU 
F, female;  M, male;  MNS, mult inodular st ruma;  I V, t ime interval between drug 
init iat ion and presence of vasculit ic manifestat ions;  MMI , methimazole;  PTU, 
propylthiouracil;  CM, carbimazole;  ANCA, ant ineutrophil cytoplasm ic ant ibodies;  MPO, 
myeloperoxidase;  PR3, proteinase 3;  HLE, human leucocyte elastase;  FU, follow-up 
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4) . During follow-up, two pat ients with vasculit is cont inually tested 
posit ive for ANCA on I IF and ELISA, despite t reatm ent  with 
cyclophospham ide and steroids and discont inuat ion of their ant ithyroid 
Table 4 . Clinical features of ANCA- posit ive pat ients 
Gender 
(age)  
Drug use, durat ion 
( I V)  
ANCA result  Clinical 
F (68)  MMI , 5 months  
(5 months)  
I I F:  P-ANCA 
ELI SA:  MPO 
Pleural effusion, renal funct ional 
deter iorat ion but  no act ive ur ine 
sediment  → CY+ CS 
F (49)  MMI , 8 months  
(7 years)  
I I F:  P-ANCA 
ELI SA:  MPO 
NCGN in renal biopsy → CY+ CS 
F (43)  PTU, 21 months  
(23 months)  
I I F:  P-ANCA 
ELI SA:  MPO/  
PR3/  HLE 
NCGN in renal biopsy, 
pulmonary infilt rates → CY+ CS 
F (51)  PTU, 4 years  
(4 years)  
I I F:  P-ANCA 
ELI SA:  MPO/  HLE 
NCGN in renal biopsy → CY+ CS 
M (57)  PTU, unknown I I F:  atypical 
ELI SA:  HLE 
No signs of vasculit is 
F (35)  None I I F:  atypical 
ELI SA:  PR3/  HLE 
No signs of vasculit is 
F (63)  MMI , unknown I I F:  atypical 
ELI SA:  PR3/  HLE 
No signs of vasculit is  
F (56)  PTU, 6 years I I F:  atypical 
ELI SA:  HLE 
No signs of vasculit is 
F (88)  None I I F:  P-ANCA 
ELI SA:  MPO 
Died of pneumonia and sept ic 
shock 
F (31)  PTU, 6 months I I F:  P-ANCA 
ELI SA:  HLE 
No signs of vasculit is 
F (38)  MMI /  PTU, 2 years I I F:  negat ive 
ELI SA:  HLE 
No signs of vasculit is 
M (40)  CM/  MMI , 2 years I I F:  negat ive 
ELI SA:  MPO 
No signs of vasculit is;  
glomerulosclerosis in biopsy 
F (26)  CM, unknown I I F:  P-ANCA 
ELI SA:  MPO 
No follow-up on clinical signs 
F, female;  M, male;  MNS, mult inodular st ruma;  I V, t ime interval between drug 
init iat ion and presence of vasculit ic manifestat ions;  MMI , methimazole;  PTU, 
propylthiouracil;  CM, carbimazole;  ANCA, ant ineutrophil cytoplasm ic ant ibodies;  CY, 
cyclophosphamide;  CS, cort icosteroids;  NCGN, necrot izing and crescent ic 
glomerulonephr it is 
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m edicat ion. I n the other 2 pat ients with vasculit is, ANCA t iters 
norm alized after t reatm ent  with cyclophospham ide and steroids and 
discont inuat ion of ant ithyroid drugs. I n the rem aining 9 pat ients, one 
pat ient  with MPO-ANCA had im paired renal funct ion and proteinuria 
( table) . His renal biopsy showed changes, typical of hypertension in 
addit ion to focal segm ental glom erulosclerosis of uncertain origin;  
necrot izing and crescent ic glom erulonephrit is was not  observed. He 
had discont inued his ant ithyroid drugs prior t o ANCA test ing. Seven 
other pat ients who had tested posit ive for ANCA did not  show signs of 
vasculit is. I n the ninth pat ient  posit ive for ANCA, follow-up on clinical 
signs was not  possible. Two of these 8 ANCA-posit ive pat ients without  
signs of vasculit is were re- tested in the follow-up study. The first  was 
again found posit ive for  HLE-ANCA, without  evidence of vasculit is, and 
without  the present  use of ant ithyroid drugs. The second pat ient  
(previously PR3-  and HLE-ANCA posit ive)  was now found negat ive, 
without  being t reated with any im m unosuppressive drug such as 
cyclophospham ide and/ or steroids. 
 
Discussion 
I n the current  study, we invest igated the presence of ANCA in pat ients 
diagnosed with hyperthyroidism  on various t reatm ent  m odalit ies. I n 
our cross-sect ional evaluat ion, we found 12 pat ients (5.7% )  posit ive 
for  MPO- , PR3-  and/ or HLE-ANCA on first  t est ing. Furtherm ore, during 
follow-up one pat ient  becam e ANCA-posit ive. ANCA-posit ivit y was 
significant ly related to the use of ant ithyroid drugs. Clinical signs were 
present  in two of six ANCA-posit ive pat ients who had used PTU, in two 
pat ients using other ant ithyroid drugs and in none of the pat ients that  
were not  t reated with ant ithyroid drugs.  
The presence of ANCA, and of ANCA-associated vasculit is in pat ients 
using ant ithyroid drugs for t reatm ent  of hyperthyroidism  have been 
recurrent ly reported15-23,27.  Reported prevalence of ANCA in pat ients 
t reated with ant ithyroid drugs varies from  4%  to 46% ;  prevalence of 
AAV is lower (0 t o 1.4% 22,27-29.  I n our populat ion ANCA and AAV were 
present  in 11%  and 4% , respect ively, of pat ients t reated with 
ant ithyroid drugs. Prevalence of prim ary system ic vasculit is (WG, MPA, 
Churg-St rauss syndrom e, polyarterit is nodosa)  has been est im ated at  
144.5/ m illion (0.01% )  in a populat ion com parable to the general 
populat ion in Groningen30.  Therefore, a prevalence of AAV of 4%  in our 
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pat ients t reated with ant ithyroid drugs clearly suggests a relat ionship 
between these drugs and the presence of AAV. 
Although ANCA are present  relat ively often in pat ients t reated with 
ant ithyroid drugs, the prevalence of AAV is m uch lower22,27-29.  I n our 
study, 7 pat ients out  of 11 t reated with ant ithyroid drugs whom  were 
posit ive for MPO- , PR3 or HLE-ANCA did not  have, or develop, vasculit is 
(64% ) . This ‘false posit ive’ rate is m uch higher than could be expected 
from  our earlier studies in which we found false posit ive results in less 
than 1%  of pat ients with related disorders and/ or healthy cont rols25,31.  
Therefore, the use of PTU, carbim azole and m ethim azole seem s an 
im portant  cause for  posit ive ANCA results not  related to sm all- vessel 
vasculit is. 
The presence of ANCA without  vasculit is indicates that  ANCA alone are 
not  enough for the induct ion of vasculit is. I ndeed, in pat ients with 
clinically quiescent  AAV, high ANCA t iters can persist  without  
react ivat ion of vasculit is5,32-34.  I t  has been suggested that  the 
characterist ics of ANCA present  in act ive disease m ay differ from  those 
present  in disease rem ission and in sera from  pat ients without  
vasculit is, possibly in the m echanism  of neut rophil act ivat ion7,35.   
The m echanism  by which PTU, and other ant ithyroid drugs, m ay induce 
ANCA and AAV rem ains to be elucidated, although som e clues do exist . 
A study by Jiang et  al showed that  propylthiouracil, am ong other drugs, 
was highly cytotoxic in the presence of act ivated neut rophils, at  
concent rat ions that  are therapeut ically relevant 36.  Oxidat ion of PTU by 
act ivated neut rophils provides a way to generate react ive drug 
m etabolites, and the finding of MPO-ANCA in pat ients with drug-
induced lupus and vasculit is is consistent  with an autoim m une react ion 
init iated by drug bioact ivat ion m ediated by neut rophil-derived MPO37.   
I t  is possible that  AAV in the pat ients in our study was not  induced by 
ant ithyroid drugs, but  m erely is associated with hyperthyroidism. 
Unfortunately, we did not  have ANCA t iters prior to the init iat ion of 
t reatm ent  in these pat ients. I n a previous study on the induct ion of 
ANCA by m inocycline, sulfasalazine and penicillam ine, we showed that  
when ANCA were present  in pat ients after t reatm ent  with these drugs, 
they had already been present  prior to t reatm ent  start 38.  The presence 
of MPO-ANCA m ay also be explained by the presence of ant i-TPO 
ant ibodies which, given the part ial hom ology between both proteins, 
m ay cross- react  with MPO39,  although this has been disputed by 
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others40.  I n our pat ients, the presence of MPO-ANCA was not  related to 
ant i-TPO ant ibodies.  Moreover,  cross- react ivity to TPO cannot  explain 
the presence of HLE-  and/ or PR3-ANCA in our pat ients. 
I n conclusion, we showed that  the presence of ANCA, and associated 
vasculit is, is not  uncom m on in pat ients t reated with ant ithyroid drugs. 
The presence of ANCA and AAV extends beyond ant ithyroid t reatm ent  
durat ion. This r isk of using ant ithyroid drugs should be included in the 
decision to use these drugs for the t reatm ent  of hyperthyroidism .  
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Background .  Hum an Heat  Shock Protein 60 (hHSP60)  has been 
im plicated in autoim m unity through m olecular m im icry, based on the 
high degree of hom ology with HSP65 of m icro-organism s leading to 
autoim m une recognit ion of the hum an protein. Addit ionally, sequence 
hom ology between hHSP60 and m yeloperoxidase (MPO)  has been 
described. MPO is a m ajor autoant igen in vasculit is associated with 
ant ineut rophil cytoplasm ic ant ibodies (ANCA). We hypothesized that  
infect ions m ay t rigger the ANCA response against  MPO through 
hHSP60. 
Methods.  I n 86 consecut ive pat ients with ANCA-associated vasculit is 
(AAV) , ant i-hHSP60 and ant i-m ycobacterial HSP65 were m easured by 
ELISA. Pat ients were com pared with 69 healthy cont rols (HC) . 
Cont inuous data between groups were com pared using Wilcoxon signed 
rank test  and Kruskal-Wallis test  with Dunn’s post - test  when 
appropriate. Correlat ions between data were derived using Spearm an 
correlat ion. Odds rat ios and 95%  confidence intervals were obtained 
using Fisher’s exact  test . 
Results.  At  diagnosis, m edian ant i-m HSP65 level was higher in AAV, 
and subsequent ly in MPO-ANCA, com pared to HC. Ant i-hHSP60 
ant ibody levels in AAV were not  higher com pared to HC. However, in 
MPO-ANCA ant i-hHSP60 levels were increased com pared to PR3-ANCA 
and HC. We could not  detect  cross- react ivit y between hHSP60 and 
MPO-ANCA. There was a correlat ion between ant i-m HSP65 and ant i-
hHSP60 ant ibody levels but  not  between ant i-hHSP60 and MPO-ANCA.  
Conclusions.  Ant ibodies against  m HSP65 are higher in AAV com pared 
to HC, and ant i-hHSP60 ant ibodies are higher in pat ients with MPO-
ANCA than in pat ients with PR3-ANCA and HC. Although this finding 
m ay be indicat ive for cross- react ivit y between MPO-ANCA and hHSP60, 
addit ional assays did not  support  this hypothesis. 
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Sm all vessel vasculit ides, such as Wegener’s granulom atosis (WG)  and 
m icroscopic polyangiit is (MPA) , are st rongly associated with 
ant ineut rophil cytoplasm ic ant ibodies (ANCA) , which are either directed 
to m yeloperoxidase (MPO)  or proteinase 3 (PR3) 1-3.  These diseases can 
occur in any organ system  but  the respiratory t ract  and the kidneys are 
m ost  frequent ly involved. Unt reated, WG results in death within weeks 
to m onths. Since the int roduct ion of cyclophospham ide and 
prednisolone as standard t reatm ent , survival has im proved 
dram at ically from  less than 20%  at  1 year reported in 19584 to at  least  
60%  5-years survival reported in the past  ten years5-8.   
The m echanism  by which ANCA are induced is as yet  unclear. Certain 
drugs have been linked to the induct ion of ANCA and the onset  of 
ANCA-associated vasculit is (AAV) 9.  Recent ly, it  has been described that  
an autoim m une response m ay be induced by the presence of a pept ide 
that  is ant isense or com plem entary to the autoant igen, for instance, 
PR310.  This im mune response m ay induce ant i- idiotypic ant ibodies 
(autoant ibodies)  that  cross- react  with the autoant igen. Another favored 
hypothesis is that  infect ions m ay t r igger an ANCA response11.  The 
proposed m echanism s by which infect ions break self tolerance can 
include bystander dam age, unveiling of ‘hidden’ self epitopes, 
determ inant  m olecular spreading and m olecular m im icry11.   
Heat  Shock Protein (HSP)  65 is an im m unodom inant  ant igen in m icro-
organism s. The hum an equivalent , hHSP60, has been im plicated in 
autoim m unity through m olecular m im icry, based on the high degree of 
hom ology with HSP65 of m icro-organism s leading to autoim m une 
recognit ion of the hum an protein12.  I n it s turn, HSP60 shares sequence 
hom ology with MPO13.  Thus, infect ions m ay t r igger the ANCA response 
against  MPO through hHSP60. To test  this hypothesis, we determ ined 
the presence of ant ibodies against  hHSP60 and m ycobacterial HSP65 
(m HSP65)  in pat ients with MPO-ANCA and com pared them  to pat ients 
with PR3-ANCA and healthy cont rols (HC) . 
 
Methods 
Pat ients 
We ret rospect ively ident ified all pat ients in our renal biopsy regist ry14,15 
diagnosed with crescent ic glom erulonephrit is between January 1977 
and July 2003 without  evidence of system ic lupus erythem atosus, I gA 
nephropathy, Henoch Schönlein purpura, post - infect ious 
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glom erulonephrit is or cryoglobulinaem ia.  Serum  sam ples, taken at  the 
t im e of biopsy, were tested for the presence of ANCA, according to a 
m ult istep procedure that  com bines indirect  im m unofluorescence with 
direct  and capture enzym e- linked im m unosorbent  assays (ELISAs) 16.  
We thus ident ified 109 pat ients with AAV with biopsy-proven renal 
involvem ent :  46 pat ients with PR3-ANCA only (42% ) , 49 pat ients with 
MPO-ANCA only (45% ) , 4 pat ients with both PR3-  and MPO-ANCA (4% )  
and 10 pat ients with MPO-ANCA with the presence of ant i-glom erular 
basem ent  m em brane ant ibodies (9% ) . Only pat ients who were single 
posit ive for PR3-  or MPO-ANCA, and had enough serum  available for all 
tests,  were included (n =  86) . Addit ionally, 40 healthy cont rols (HC)  
( laboratory personnel)  were tested to determ ine the cut -off value for 
the ant i-hHSP60 test  and, 69 HC were tested to determ ine the cut -off 
value for the ant i-m HSP65 test . Dem ographic data on pat ients and 
cont rols are presented in table 1. 
 
Sera 
Serum  sam ples, taken at  the t im e of biopsy, were used to determ ine 
the presence of ant i-hHSP60 and ant i-m HSP65 in pat ients with AAV. 
These sera had been stored at  -80°C, in som e pat ients for over 20 
years. However, when test ing the ant ibody response, there was no 
difference in ant ibody level between pat ients included in 2003 and 
pat ients included in earlier years. 
 
ELI SA for the detect ion of ant ibodies against  hum an HSP60 and 
m ycobacterial HSP65 
Recom binant  hHSP60 (St ressgen, Victoria, Canada)  was diluted to 2 
g/ m L in coat ing buffer containing 0.1M NaHCO3-  (pH 9.6) , and 50 
L/ well ( i.e., 0.1 g/ well)  was incubated in wells of m icroplates (Nunc 
Table 1 . Dem ographic data on pat ients and healthy cont rols 
 AAV 
(N =  86)  
MPO-ANCA 
(N =  42)  
PR3-ANCA 
(N =  44)  
HC 
(N =  69)  
Age (years)*  62.2 ±  13.5 65.9 ±  10.9 59.7 ±  15.2 40.4 ±  9.8 
Male gender (% )  69 64 73 59 
AAV, ANCA-associated vasculit is;  MPO-ANCA, ant ineutrophil cytoplasm ic ant ibodies 
against  myeloperoxidase;  PR3-ANCA, ANCA against  proteinase 3;  HC, healthy 
controls 
*  Mean ±  standard deviat ion 
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MaxiSorp™, Rochester,  NY)  overnight  at  4°C. Cont rol wells were 
incubated with coat ing buffer alone. Wells were then incubated 
overnight  at  4°C with 100 L/ well coat ing buffer containing 1%  grade V 
bovine serum  albumin (BSA, Sigm a, St . Louis, MO)  to block non-
specific binding. Plates were then washed 3 t im es with PBS containing 
0.05%  Tween 20 (PBS-T) . Plates were preincubated at  room  
tem perature with 200 L/ well of preincubat ion buffer, containing 
0.05%  Tween 20 and 1%  BSA in PBS, for 1 hour. After  washing 2 
t im es with PBS-T, wells were incubated in t r iplicates with pat ient  serum  
in a previously established opt im al dilut ion of 1: 50, 50 µL/ well, in 
incubat ion buffer and kept  overnight  at  4°C. The next  day, plates were 
washed 5 t im es with PBS-T and incubated with goat  F(ab’) 2 ant i-hum an 
IgG (Fc) -horseradish peroxidase conjugate (Cappel- ICN 
Im m unobiologicals, Costa Mesa, CA) , diluted 1: 2000 in incubat ion 
buffer , for 2 hours at  room  tem perature. After washing 5 t im es with 
PBS-T, 100 L of freshly m ade subst rate (containing 0.5 m g/ m L o-
Phenylenediamine (Sigm a)  and 0.03%  H2O2 in cit rate/ phosphate 
buffer , pH 4.9)  was added to each well. After 10 m inutes, the react ion 
was stopped with 50 L 4N H2SO4 and absorbances were read at  490 
nm . Results are expressed as ant i-hHSP60 levels in arbit rary units (AU)  
/ m L. Hereto, the m ean OD of the t r iplicates was corrected for non-
specific binding by subt ract ion of the m ean OD in uncoated wells. Next , 
a standard curve was created by including in every assay a serial, 2-
step dilut ion from  1: 10 to 1: 640 of a posit ive serum  sam ple with ant i-
hHSP60 react ivit y. The undiluted serum  sam ple was arbit rarily 
assigned 100 AU/ m L. Addit ionally, results are expressed as posit ive or 
negat ive. To establish the cut -off value for this test , the m ean AU/ m L 
and SD of the sera of 40 HC were determ ined, and the cut -off value 
was set  at  the m ean + 2 SD. 
For detect ion of ant ibodies against  m HSP65, essent ially the sam e 
procedure was followed. Recom binant  m HSP65 (St ressgen)  was diluted 
to 2 g/ m L and coated in a concent rat ion of 0.1 g/ well. Serum  was 
diluted 1: 50 prior to incubat ion. To read results in AU, a standard curve 
was created as described for ant i-hHSP60 ant ibodies. To establish the 
cut -off value for this test , the m ean AU/ m L and SD of the sera of 69 
HC were determ ined, and the cut -off value was set  at  the m ean + 2 SD. 
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Myeloperoxidase inhibit ion assays 
To test  cross- react ivit y between MPO and hHSP60, serum  from  one 
pat ient  being posit ive for  both MPO-ANCA and ant i-hHSP60 ant ibodies 
was incubated for 30 m inutes at  37°C with MPO or hHSP60 in 
concent rat ions of 1, 3, 10 and 20 g/ m L. The serum  was then tested in 
the ant i-hHSP60 ELISA as described above, or in the MPO-ANCA ELISA 
using com m ercially available direct  ELISA kits (Euro-diagnost ica, 
Malm ö, Sweden) . Addit ionally, absorpt ion tests were perform ed in 
which ELISA plates were coated with hHSP60 or MPO and incubated 
with serum . The next  day, or the second day, ant i-hHSP60 react ivit y in 
this pre-absorbed serum  was tested as described above for  the ant i-
hHSP60 ELISA. Unfortunately, this was the only pat ient  of whom  
enough serum  was present  to perform  the described tests. 
 
Stat ist ical analyses 
All data are presented as m edian [ range]  unless stated otherwise. 
Cont inuous data between groups were com pared using Wilcoxon signed 
rank test  and Kruskal-Wallis test  with Dunn’s post - test  when 
appropriate. Due to the perceived relevance of the results, we did not  
only perform  Dunn’s post - test  for subgroup analysis, but  we also 
com pared subgroups using Wilcoxon signed rank test . Correlat ions 
between data were derived using Spearm an correlat ion. Odds rat ios 
(OR)  and 95%  confidence intervals (CI )  were obtained using Fisher’s 
exact  test . Analyses were perform ed with GraphPad Prism  version 3.00 
and GraphPad Instat  software package version 2.04a (both GraphPad 
Software Inc., San Diego, CA) . A two-sided p-value < 0.05 was 
considered to indicate stat ist ical significance. 
 
Results 
Eighty-six consecut ive pat ients with AAV (44 PR3-  and 42 MPO-ANCA)  
were included in the study. Mean age was 62.2 ±  standard deviat ion 
13.5 (65.9 ±  10.9 in MPO-ANCA and 59.7 ±  15.2 in PR3-ANCA, P =  
0.07) . Fift y-nine pat ients (69% )  were m ale (27 pat ients (64% )  in MPO-
ANCA and 32 pat ients ( 73% )  in PR3-ANCA, P =  0.49) . 
 
Ant i-m ycobacterial HSP65 ant ibodies are elevated in MPO-ANCA 
com pared to healthy cont rols 
I n pat ients with AAV, m edian ant i-m HSP65 level was 42.5 AU/ m L [ 0 – 
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Figure 2 . Ant i-hHSP60 ant ibody levels in healthy controls (HC)  and in pat ients with 
ANCA-associated vasculit is (AAV) . Ant i-human Heat  Shock Protein 60 (ant i-hHSP60)  
ant ibody levels are not  significant ly higher in AAV compared to HC. Furthermore, ant i-
hHSP60 ant ibody levels are significant ly higher in pat ients with MPO-ANCA compared to 
PR3-ANCA. I n pat ients with MPO-ANCA, ant i-hHSP60 ant ibody level is also significant ly 
higher when compared to HC, whereas in PR3-ANCA, it  is not . Dot ted line represents cut -
off value;  solid line represents median value. 
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Figure 1 . Ant i-mHSP65 ant ibody levels in healthy controls (HC)  and in pat ients with 
ANCA-associated vasculit is (AAV) . Ant i-mycobacter ial Heat  Shock Protein 65 (ant i-
mHSP65)  ant ibody levels are significant ly higher in AAV compared to HC. Furthermore, 
ant i-mHSP65 ant ibody levels in pat ients with PR3-  and MPO-ANCA are shown. Ant i-
mHSP65 is comparable between pat ients with MPO-ANCA and PR3-ANCA. I n pat ients with 
MPO-ANCA, ant i-mHSP65 ant ibody level is significant ly higher when compared to HC. 
Dot ted line represents cut -off value;  solid line represents median value. 
 58   Chapter 4 
figure 1) . I n MPO-ANCA, ant ibody levels were significant ly higher (44 
AU [ 7 – 500] )  com pared to HC (P =  0.006, figure 1) . I n pat ients with 
PR3-ANCA, there was a t rend to a higher ant ibody level (42.5 AU [ 0 – 
500]  com pared to HC (P =  0.10) . With a cut -off value of 88.5 AU/ m L, 
13 of 69 HC (19% )  were posit ive for ant i-m HSP65 com pared to 23 of 
86 (27% )  pat ients with AAV (P =  NS) . Eleven of 44 pat ients (25% )  
with PR3-ANCA were posit ive for ant i-m HSP65 com pared to 12 of 42 
pat ients with MPO-ANCA (29% )  (P =  NS) . 
 
Ant i-hum an HSP60 ant ibodies are elevated in MPO-ANCA com pared to 
PR3-ANCA and healthy cont rols 
I n pat ients with AAV, m edian ant i-hHSP60 level was 18 AU/ m L [ 0 – 
319] , com pared to 18.5 AU/ m L [ 0 – 98]  in healthy cont rols (P =  NS, 
figure 2) . I n MPO-ANCA, ant ibody levels were significant ly higher (32.5 
AU [ 0 – 319] )  com pared to HC (P =  0.02)  and PR3-ANCA (13 AU [ 0 – 
79] )  (P< 0.0001, figure 2) . Pat ients with PR3-ANCA did not  have higher 
ant ibody levels than HC. With a cut -off value of 80 AU/ m L, 2 of 40 HC 
(5% )  were posit ive for ant i-hHSP60 com pared to 12 of 86 (14% ) 
pat ients with AAV (P =  NS) . One of 44 (2.3% )  pat ients with PR3-ANCA 
was posit ive for ant i-hHSP60 com pared to 11 of 42 pat ients with MPO-
ANCA (26% )  (P =  0.001, OR 15.3, 95%  CI  1.9 – 124) . 
 
Myeloperoxidase does not  inhibit  ant i-hHSP60 ant ibody react ivit y 
To test  whether ant i-hHSP60 ant ibodies actually cross- react  with MPO, 
we perform ed inhibit ion assays incubat ing serum  from  the pat ient  with 
the highest  ant i-hHSP60 response with MPO or hHSP60 and test ing for 
hHSP60 and MPO react ivit y. I ncubat ion with increasing concent rat ions 
of MPO inhibited the MPO-ANCA response in a dose-dependent  m anner 
( figure 3A) . However, incubat ion of serum  with hHSP60 did not  inhibit  
the MPO-ANCA react ivity ( figure 3A) . Addit ionally, MPO was unable to 
inhibit  the ant i-hHSP60 ant ibody react ivit y ( figure 3B) . However, 
incubat ion with hHSP60 did not  inhibit  the ant i-hHSP60 response 
( figure 3B) . To test  for the abilit y of hHSP60 to inhibit  ant i-hHSP60 
react ivit y, absorpt ion tests were perform ed. Results now showed 
inhibit ion of the ant i-hHSP60 response by hHSP60 but  not  by MPO 
( figure 4) . 
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Figure 3 A. MPO-ANCA inhibit ion assay. I ncubat ion with increasing concentrat ions of 
myeloperoxidase (MPO) (1 – 20 g/ mL)  leads to a reduct ion in MPO-ANCA react iv ity (   ) . 
I n cont rast , incubat ion with human Heat  Shock Protein 60 (hHSP60)  (1 – 20 g/ mL)  does 
not  decrease MPO-ANCA react iv ity (  ) . 
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Figure 3 B. Ant i-human Heat  Shock Protein 60 (hHSP60)  inhibit ion assay. I ncubat ion 
with increasing concentrat ions of myeloperoxidase (MPO) (1 – 20 g/ mL)  does not  lead 
to a reduct ion in ant i-hHSP60 react iv ity (   ) . However, incubat ion with hHSP60 (1 – 20 
g/ mL)  only slight ly decreases ant i-hHSP60 react iv ity (  ) . 
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Follow-up ant i-hHSP60 levels 
To further exclude cross- react ivit y between hHSP60 and MPO-ANCA, 
we tested whether ant i-hHSP60 ant ibody levels were only present  if 
there was presence of MPO-ANCA. In the pat ient  with MPO-ANCA and 
the highest  ant i-hHSP60 level, follow-up serum  sam ples were available 
to test  for the presence of ant i-hHSP60. As shown in figure 5, ant i-
hHSP60 levels dropped analogous to MPO-ANCA levels once t reatm ent  
has com m enced, but  slight ly increased with tapering of the t reatm ent  
while MPO-ANCA levels rem ained undetectable. 
 
Correlat ion between ant i-m HSP65 and ant i-hHSP60 but  not  between 
MPO-ANCA and ant i-hHSP60 ant ibodies 
Finally, we checked whether correlat ion exists between ant ibody levels 
against  m HSP65, hHSP60, and MPO. There was a correlat ion between 
height  of ant ibody levels against  m HSP65 and hHSP60 (Spearm an r =  
0.32, P =  0.003) , but  no correlat ion existed between MPO-ANCA and 
ant i-hHSP60 (Spearm an r =  -0.064, P =  0.69) . Also, there was no 
correlat ion between ant i-m HSP65 and MPO-ANCA (Spearm an r =  
0.074, P =  0.65) . 
 
Discussion 
The m echanism  by which ANCA are induced are as yet  unclear. One 
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Figure 4 . MPO and hHSP60 absorpt ion assays. I ncubat ion of serum in ELI SA plates 
coated with human Heat  Shock Protein 60 (hHSP60)  for  1 or 2 days leads to a reduct ion 
in ant i-hHSP60 react iv ity (  ) . I n cont rast , incubat ion of serum in ELI SA plates coated 
with myeloperoxidase (MPO) does not decrease ant i-hHSP60 react iv ity (   ) . 
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favored hypothesis is that  infect ions m ay t r igger an ANCA response11.  
We hypothesized that  infect ions m ay t r igger the ANCA response 
against  MPO through hHSP60. We found that  ant i-hHSP60 was alm ost  
exclusively found am ong pat ients with MPO-ANCA when com pared to 
PR3-ANCA, support ing our hypothesis. Nevertheless, there was no 
correlat ion between MPO-ANCA and ant i-hHSP60 ant ibody levels, and 
inhibit ion and absorpt ion assays did not  show cross- react ivit y between 
hHSP60 and MPO-ANCA. Furtherm ore, when we determ ined the ant i-
m HSP65 response in AAV and HC, we found no difference between 
pat ients with MPO-ANCA and pat ients with PR3-ANCA, and only a weak 
correlat ion between ant i-hHSP60 ant ibody levels and ant i-m HSP65 
levels. However, not  every pat ient  who was posit ive for  ant i-hHSP60 
had ant ibodies against  m HSP65, suggest ing that  ant i-hHSP60 and ant i-
m HSP65 are not  the sam e ant ibodies, and that  an ant i-hHSP60 
response m ay not  be t r iggered sim ultaneously with an ant i-m HSP65 
response. 
The shared sequence hom ology described between hHSP60 and MPO is 
a theoret ical one, based on am ino acid sequence. This sequence 
sim ilarit y has a length of 17 am ino acids and is present  on the heavy 
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Figure 5 . Follow-up of a pat ient  posit ive for  ant ibodies against  human Heat  Shock 
Protein 60 (ant i-hHSP60) . Ant i-hHSP60 levels (   )  drop as well as ant ibody levels against  
myeloperoxidase (MPO-ANCA) (  )  once treatment  has commenced, but  increase dur ing 
follow-up, while MPO-ANCA levels remain undetectable. 
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chain of m yeloperoxidase13.  The sequence is present  in a region of 
m yeloperoxidase that  is recognized as an epitope by MPO-ANCA in 
som e pat ients17.  However, it  is unknown whether ant i-hHSP60 
ant ibodies bind to the corresponding amino acid sequence of hHSP60. 
To test  whether ant i-hHSP60 ant ibodies actually cross- react  with MPO, 
we perform ed inhibit ion assays incubat ing serum  from  the pat ient  with 
the highest  ant i-hHSP60 response with MPO or hHSP60 and test ing for 
hHSP60 and MPO react ivit y. We could not  detect  a decrease in hHSP60 
react ivit y when serum  was incubated with MPO, suggest ing that  
although sequence hom ology exists, epitopes recognized by MPO-ANCA 
are different  from  those recognized by ant i-hHSP60 ant ibodies. 
Obviously, this test  cannot  com pletely exclude that  cross- react ivity 
exists in other pat ients, although the absence of correlat ion between 
MPO-ANCA and ant i-hHSP60 also does not  support  such cross-
react ivit y. 
Ant ibodies against  hHSP60 are associated with the presence and 
severity of atherosclerosis18-20,  although this has been disputed by 
others21.  I nterest ingly, we found elevated levels of ant i-hHSP60 
ant ibodies only in pat ients with MPO-ANCA. An explanat ion for this 
finding m ay be that  diagnosis of MPO-AAV is often delayed, and this 
m ay lead to prolonged inflam m at ion and eventually to elevated levels 
of ant i-hHSP60 in MPO-ANCA pat ients when com pared to PR3-ANCA 
pat ients. Our data m ight  indicate that  cardiovascular disease is m ore 
often present  in pat ients with MPO-ANCA. However, follow-up data in 
our sm all study do not  confirm  this. 
I nterest ingly, ant i-hHSP60 react ivit y could not  be inhibited by our first  
inhibit ion assay. This m ay be due to the nature of the inhibit ion assay. 
I n the first  assay, hHSP60 was added to the serum  of the ant i-hHSP60 
posit ive pat ient , whereas in the second assay, hHSP60 was coated to 
the ELISA plate. This second assay clearly dem onst rated inhibit ion of 
the ant i-hHSP60 response. An explanat ion for this phenom enon m ay be 
that  ant i-hHSP60 ant ibodies are unable to bind to fluid phase hHSP60, 
but  can bind to solid phase hHSP60, as dem onst rated by the second 
inhibit ion assay, and the posit ive ant ibody response dem onst rated in 
the ant i-hHSP60 ELISA. 
I n conclusion, we have shown that  ant ibodies against  hHSP60 are 
elevated in pat ients with MPO-ANCA in com parison with PR3-ANCA. 
These findings suggest  a role for  infect ions in the pathogenesis of MPO-
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AAV through m olecular m im icry between bacterial HSP65, hum an 
HSP60 and MPO. Addit ional absorpt ion assays, however, did not  
support  this hypothesis. Whether there is a relat ionship between ant i-
hHSP60 and cardiovascular disease in pat ients with MPO-ANCA rem ains 
to be studied. 
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Background .  T cells have been im plicated in the pathophysiology of 
ANCA-associated vasculit is (AAV) , because increased T cell act ivat ion is 
present  in pat ients with AAV. T cell act ivat ion is regulated by inhibitory 
m olecules such as PD-1 and CTLA-4, whose expression in turn m ay be 
affected by gene polym orphism s. We invest igated the relat ionship 
between polym orphism s in PDCD1 and CTLA4 and the presence of AAV. 
Methods.  Two single-nucleot ide polym orphisms (SNPs)  in PDCD1 and 
five polym orphism s in CTLA4 were invest igated in 102 pat ients with 
AAV and 188 healthy cont rols (HC) . 
Results.  The allelic dist r ibut ions of the PD-1.3 and PD-1.5 SNPs did 
not  differ between pat ients and HC. Addit ionally, the dist r ibut ions of 
the CTLA4  prom oter polym orphism s  
-1722T/ C, -1661A/ G, and -318 C/ T, as well as the (AT) n m icrosatellite 
in the 3’ unt ranslated region of CTLA4,  did not  differ significant ly 
between AAV pat ients and HC. However, the + 49 G allele was 
significant ly m ore often present  in pat ients with AAV (70%  in pat ients 
versus 55%  in HC, P =  0.01) . Furtherm ore, the co-occurrence of the 
PD-1.5 T allele with CTLA4 + 49 AA hom ozygosity was less often 
present  in pat ients com pared to HC (17%  and 32% , respect ively,  
P= 0.007) . 
Conclusions.  AAV is associated with the presence of a G allele at  the 
+ 49 posit ion of CTLA4 and this associat ion is even st ronger if also the 
PD-1.5 T allele is absent  in the genom e. These genet ic polym orphism s 
m ay lead to hyperreact ivit y of T cells and thus m ay cont r ibute to the 
pathogenesis of AAV.  
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Sm all vessel vasculit ides, such as Wegener’s granulom atosis (WG)  and 
m icroscopic polyangiit is (MPA) , are st rongly associated with 
ant ineut rophil cytoplasm ic ant ibodies (ANCA) , which are either directed 
to proteinase 3 (PR3)  or m yeloperoxidase (MPO) 1-3.  Evidence exists 
that  ANCA play a pathophysiological role in the induct ion of these 
vasculit ides. First , elevat ions in ANCA t iters correlate with r isk of future 
disease flares4,5.  Second, in vit ro it  has been dem onst rated that  ANCA 
induce neut rophil act ivat ion, i.e. degranulat ion and product ion of a 
respiratory burst 6.  I n addit ion, ANCA act ivate other cells in vit ro such 
as m onocytes and endothelial cells7.  Finally, in vivo experim ental data 
also indicate an im portant  role for  ANCA in the pathophysiology of 
vasculit is8,9.  
Next  to the role of ANCA, T cells have also been im plicated in the 
pathophysiology of ANCA-associated vasculit is (AAV) . Obviously, 
product ion of I gG ANCA by plasm a cells is dependent  on the presence 
of T helper cells10.  Furtherm ore, PR3-specific and/ or MPO-specific T 
cells are present  in vasculit is pat ients, whether in act ive disease or in 
rem ission11,12.  Addit ionally, in act ive AAV, T cells are present  in 
inflam m atory infilt rates13,14,  suggest ing direct  involvem ent  of T cells in 
the pathogenesis of AAV. Finally, pat ients with vasculit is often have a 
disturbed peripheral blood T cell com partm ent 10.  Several studies found 
increased serum  m arkers of T cell act ivat ion15,16,  and percentages of 
act ivated CD4+  and CD8+  T cells in peripheral blood were higher in 
pat ients with WG than in healthy subjects, both during act ive disease 
and in rem ission17,18.  Why T cells rem ain act ivated in AAV, even in 
rem ission, is not  yet  elucidated. 
The B7-1/ B7-2 – CD28/ CTLA-4 pathway is crucial in regulat ing T cell 
act ivat ion and tolerance. CD28 t ransm its a signal that  synergizes with 
the T cell receptor (TCR)  signal to prom ote T cell act ivat ion, whereas 
CTLA-4 engagem ent  delivers a negat ive signal, inhibit ing TCR-  and 
CD28-m ediated signal t ransduct ion. However, CTLA-4 is not  the only 
m olecule delivering an inhibitory signal;  PD-1 is a second regulatory 
m olecule in the act ivat ion of T cells. PD-1 deficient  m ice show 
autoim m une disease including arthrit is and glom erulonephrit is, disease 
m anifestat ions also found in AAV. In PDCD1,  the gene encoding PD-1, 
several single nucleot ide polym orphism s (SNPs)  have been described19 
and two of these have been associated with autoim m une disease19,20.  
I n addit ion, certain polym orphism s in the CTLA-4 gene (CTLA4)  have 
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been linked to a num ber of autoim m une diseases, including WG21-23;  
these polym orphism s have been shown to reduce the expression or the 
inhibitory funct ion of CTLA-424-26.  We hypothesized that  these 
regulatory genes m ay be involved in the developm ent  of AAV. Thus, we 
com pared the frequencies of the PD-1.3G/ A and PD-1.5C/ T SNPs in 
PDCD1,  and the + 49A/ G, -318C/ T, -1661A/ G, -1722C/ T SNPs and the 
(AT) n polym orphism  in CTLA4 between pat ients with AAV and non-
related healthy cont rols from  the sam e region in the Netherlands. 
 
Table 1 . Pat ient  characterist ics*  
 AAV pat ients 
N =  102 
Healthy controls 
N =  188 
Age (years)  59.0 ±  13.6 39.8 ±  15.8†  
Male gender 65 (64)  76 (40) ‡ 
ANCA specificity  N/ A 
MPO-ANCA 34 (33)   
PR3-ANCA 49 (48)   
both 2 (2)   
none 17 (17)   
Disease subtype  N/ A 
Wegener ’s granulomatosis 50 (49)   
MPA 24 (24)   
Churg-Strauss syndrome 7 (7)   
Renal- lim ited vasculit is 21 (21)   
Disease extent ¶  N/ A 
Locoregional /  lim ited 39 (38)   
Generalized 63 (62)   
AAV, ANCA-associated vasculit is;  ANCA, Ant ineutrophil cytoplasm ic ant ibodies;  MPO, 
myeloperoxidase;  PR3, proteinase 3;  MPA, m icroscopic polyangiit is;  N/ A, not  applicable. 
* Data are given as mean ±  standard deviat ion or N (% )  
† I n 11 healthy controls, age was unknown;  P< 0.0001 
‡I n 10 healthy controls, gender was unknown;  P =  0.0002  
¶Pat ients with renal- lim ited vasculit is were categor ized as having generalized vasculit is.  
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Methods 
Study populat ion 
One hundred and two pat ients with ANCA-associated vasculit is and 188 
healthy cont rols (HC)  were included. All pat ients fulfilled the definit ions 
for  WG, MPA, or the Churg-St rauss syndrom e (CSS)  as proposed by 
the Chapel Hill Consensus Conference27.  Addit ionally, diseased pat ients 
were categorized according to their disease extent :  generalized when 
there was renal involvem ent , otherwise, pat ients were said to have 
lim ited disease. Pat ients with renal- lim ited vasculit is were categorized 
as having generalized vasculit is. Pat ients’ spouses were included as 
healthy age-m atched cont rols to exclude survival bias in our analysis. 
Furtherm ore, healthy volunteers from  the southeast  of the Netherlands 
were included. Characterist ics of pat ients and cont rols are presented in 
table 1. 
 
DNA ext ract ion 
EDTA-  or heparin-ant icoagulated venous blood sam ples were drawn 
and DNA was ext racted using the Wizard®  Genom ic DNA purificat ion kit  
(Prom ega, Leiden, the Netherlands) . I n som e pat ients, blood sam ples 
were not  available and DNA was ext racted from  renal biopsy m aterial. 
 
PDCD1 genotyping 
A 381 bp fragm ent  containing the PD-1.3G/ A polym orphism  (+ 7146G/
A)  was created using a forward prim er 5’-GATCCACTGTGCCTTCCTTC-3’ 
and reverse prim er 5’-CAAGCTCTCCTGTCTCCAATG-3’ (both 
Eurogentec, Liège, Belgium ) . The SNP was determ ined by digest ion of 
the product  with the rest r ict ion enzym e Pst I  (Ferm entas Inc., Hanover, 
MD) , result ing in two fragm ents of 314 and 67 bp if the G nucleot ide is 
present  and three fragm ents of 216, 98 and 67 bp when the A 
nucleot ide is present . 
The PD-1.5C/ T polym orphism  (+ 7785C/ T)  was determ ined in a 329 bp 
fragm ent  created using a forward prim er 5'-ACGGAGTATG-
CCACCATTGTC-3' and reverse prim er 5'-CTGTGGGCATTGAGACATGAG-
3' (both Eurogentec) . Digest ion of the product  with the rest r ict ion 
enzym e PvuI I  (Ferm entas)  only results in two fragm ents of 261 and 68 
bp when the T nucleot ide is present . All digest ion products were 
analyzed by elect rophoresis in a 2%  agarose gel. 
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CTLA-4 genotyping 
The + 49G/ A polym orphism 28,  the -318C/ T polym orphism 29,  and the  
-1661G/ A and the -1722 C/ T polym orphism s30 were determ ined as 
described previously. All digest ion products were analyzed by 
elect rophoresis in a 2%  agarose gel. 
The (AT) n polym orphism  was determ ined using a 6-FAM labeled 
forward prim er 5’-GCCAGTGATGCTAAAGGTTG-3’31,  and reverse prim er 
5’-CCTCCACAAAACTTCCCTGGG-3’ (both Sigm a) . These prim ers created 
a fragm ent  of 171 – 215 bp depending on the length of the AT- repeat .  
The fragm ents were size- resolved on an ABI3100 capillary sequencer 
using the GeneScan Analysis v3.7 software package (Applied 
Biosystem s) . Alleles were m anually called by a technician and 
successively checked by an expert . Using this m ethod we found that  
am plificat ion of the fragm ent  containing the shortest  (AT) n repeat  
(m ost ly 171 bp)  was highly favored over am plificat ion of the longer 
fragm ent , possibly leading to an underrepresentat ion of heterozygosity 
for the shortest  allele 171 and a longer allele. Therefore, we analyzed 
the Hardy Weinberg Equilibrium  (HWE)  dividing our cont rol sam ples in 
3 groups:  hom ozygous for the shortest  allele (171/ 171) , heterozygous 
for the shortest  allele (171/ x) , and carrying two longer alleles (x/ x) . 
Since HWE was present  in our cont rols, we analyzed our pat ients and 
cont rols according to this m ethod. 
 
Stat ist ical analyses 
Genotype frequencies were com pared between pat ients and cont rols 
using a Chi-square test  for independence and Fisher's exact  test  when 
appropriate. Since AAV is a disease that  m anifests at  an older age, we 
desired to exclude survival bias. Therefore, we also com pared pat ients 
with age-m atched healthy cont rols only. All analyses were perform ed 
with the GraphPad Instat  software package version 2.04a (GraphPad 
Software, San Diego, CA) . HWE was determ ined using the test  
provided by the Inst itute of Hum an Genet ics, Technical University 
Munich, Germ any (ht tp: / / ihg.gsf.de/ cgi-bin/ hw/ hwa1.pl) . A two- tailed 
P-value ZDVFRQVLGHUHGWRLQGLFDWHVWDWLVWLFDOVLJQLILFDQFH 
 
Results 
PDCD1 polym orphism s 
The genotype frequencies in pat ients and cont rol subjects conform ed to 
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the frequencies expected under condit ions of HWE (P> 0.05) . The 
dist ribut ions of the PD-1.3 and PD-1.5 SNPs did not  differ between 
pat ients and cont rols ( t able 2) . Subgroup analysis did not  reveal any 
associat ions between disease extent , diagnosis or ANCA specificit y and 
PDCD1 genotype. 
 
CTLA4 polym orphism s 
The genotype frequencies in pat ients and cont rol subjects conform ed to 
the frequencies expected under condit ions of HWE (P> 0.05) . The 
dist ribut ions of the newly described prom oter polym orphism s, -1722T/
C and -1661A/ G, did not  differ significant ly between AAV pat ients and 
healthy subjects ( table 3) . The dist r ibut ion of the -318C/ T SNP also did 
not  differ between pat ients and cont rols ( table 3) . However, the + 49 G 
allele was significant ly overrepresented in pat ients with AAV (70%  in 
pat ients versus 55%  in HC, P =  0.01, table 4) . The frequency 
dist ribut ion of the (AT) n m icrosatellite in the 3’ unt ranslated region of 
CTLA4 did not  differ  between pat ients and cont rols. These results did 
not  change when we used age-m atched cont rols only (data not  shown) . 
 
Subgroup analyses for CTLA4 polym orphism s 
Fifty pat ients with WG were included in this study. Since an associat ion 
Table 2 . PDCD1  polym orphism s and ANCA- associated vasculit is 
PDCD1 
polymorphism 
Pat ients 
N (% )  
Healthy controls 
N (% )  
P OR (95%  CI )  
PD- 1 .3 : + 7 1 4 6      
GG 85 (83)  168 (82)    
GA 16 (16)  34 (17)    
AA 1 (1)  2 (1)    
A allele carr ier  17 (17)  36 (18)  1.0 N/ A 
PD- 1 .5 : + 7 7 8 5      
CC 45 (44)  78 (38)    
CT 41 (40)  102 (50)    
TT 16 (16)  24 (12)    
T allele carr ier  57 (56)  126 (62)  0.32 N/ A 
PDCD1, programmed death 1;  OR, Odds rat io;  95%  CI , 95%  confidence interval;  N/ A, 
not  applicable. 
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between WG and the –318C/ T SNP has been previously described22,  we 
perform ed an analysis including WG pat ients only. When analyzing 
these pat ients, we found no difference in this genotype between 
pat ients and cont rols (P =  0.15) .  Other CTLA4 polym orphism s were 
also not  associated with the presence of WG in this pat ient  populat ion. 
When pat ients were analyzed according to ANCA specificit y, we found a 
difference in dist r ibut ion of the G allele at  the + 49 posit ion between 
pat ients with MPO-ANCA (N =  34)  and HC (76%  and 55% , 
respect ively, P =  0.02)  and pat ients with PR3-ANCA (N =  49)  and HC 
(69%  in pat ients with PR3-ANCA, P =  0.009)  ( table 5) . There were no 
significant  differences in dist ribut ion in the other polym orphism s 
studied. 
I n addit ion to diagnosis and ANCA specificit y, we analyzed pat ients with 
generalized vasculit is (defined as vasculit is with renal involvem ent )  and 
Table 3 . CTLA4  polym orphism s and ANCA- associated vasculit is 
CTLA4 promoter 
polymorphism 
Pat ients 
N (% )  
Healthy controls 
N (% )  
P OR (95%  CI )  
- 3 1 8      
CC 87 (84)  160 (85)    
CT 16 (15)  28 (15)    
TT 1 (1)  0 (0)    
T allele carr ier  17 (16)  28 (15)  0.74 N/ A 
- 1 6 6 1      
AA 70 (68)  125 (68)    
AG 30 (29)  50 (27)    
GG 3 (3)  9 (5)    
G allele carr ier  33 (32)  59 (32)  1.0 N/ A 
- 1 7 2 2      
TT 94 (90)  171 (91)    
CT 10 (10)  16 (9)    
CC 0 (0)  1 (1)    
C allele carr ier  10 (10)  17 (10)  1.0 N/ A 
CTLA4, cytotoxic T- lymphocyte-associated ant igen 4;  OR, Odds rat io;  95%  CI , 
95%  confidence interval;  N/ A, not  applicable. 
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pat ients with lim ited vasculit is ( vasculit is without  renal involvem ent ) .  
We found that  pat ients with generalized vasculit is m ore often had a G 
allele at  the + 49 posit ion than HC (76%  and 55% , respect ively, P =  
0.003) . Addit ionally, pat ients with lim ited vasculit is less often had the 
shortest  allele in the (AT) n- repeat  and thus were m ore often 
hom ozygous for a longer allele com pared to HC (49%  and 28% , 
respect ively, P =  0.02)  and com pared to pat ients with generalized 
vasculit is (25%  hom ozygous for  a longer allele, P =  0.02)  ( table 5) . 
 
The com binat ion of CTLA4 and PDCD1 polym orphism s 
When com bining the CTLA4 with the PDCD1 polym orphism s, we found 
that  in pat ients the co-occurrence of CTLA4  + 49AA and the PD-1.5 T 
allele was less often present  in pat ients com pared to HC (17%  and 
32% , respect ively, P= 0.007) . Addit ionally, the com binat ion of the 
CTLA4 171 allele and PD-1.5 T allele tended to be less often present  in 
pat ients (32% )  com pared to HC (44% , P= 0.06) . 
 
Discussion 
The B7-1/ B7-2 – CD28/ CTLA-4 pathway is crucial in regulat ing T cell 
Table 4 . CTLA4  polym orphism s and ANCA- associated vasculit is 
CTLA4 
polymorphism 
Pat ients 
N (% )  
Healthy 
controls 
N (% )  
P OR (95%  CI )  
+ 4 9      
AA 31 (30)  83 (45)    
GA 51 (49)  73 (39)    
GG 22 (21)  29 (16)    
G allele carr ier  73 (70)  102 (55)  0.01 1.9 (1.2 – 3.2)  
( AT) n repeat      
171/ 171 25 (24)  49 (28)    
171/ x 44 (42)  77 (44)    
x/ x 35 (34)  49 (28)    
x allele carr ier  79 (76)  126 (72)  0.49 N/ A 
CTLA4, cytotoxic T- lymphocyte-associated ant igen 4;  OR, Odds rat io;  95%  CI , 95%  
confidence interval;  N/ A, not  applicable;  x, allele fragment  longer than 171 base 
pairs. 
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act ivat ion and tolerance. CD28 t ransm its a signal that  synergizes with 
the T cell receptor (TCR)  signal to prom ote T cell act ivat ion, whereas 
CTLA-4 engagem ent  delivers a negat ive signal, inhibit ing TCR-  and 
CD28-m ediated signal t ransduct ion32.  CTLA-4 deficiency in m ice leads 
to lym phoproliferat ive disorder, autoim m une disease, and early 
m ortalit y33.  Certain polym orphism s in CTLA4 have been associated with 
reduced funct ion of CTLA-4 as well. The presence of a G allele at  the 
+ 49 posit ion leads to a significant ly higher proliferat ion of T cells26 and 
less expression of cell-surface CTLA-424 com pared to the presence of 
an A allele. The –318C/ T polym orphism , like the + 49G/ A, influences 
the availabilit y of CTLA-4. When the C allele is present  reduced cell-
surface expression of CTLA-4 and reduced CTLA-4 m RNA is described 
com pared to the presence of a T allele24.  Addit ionally, a dinucleot ide 
repeat , when elongated possibly leading to m ore unstable m RNA34,  is 
present  in the 3’ unt ranslated region of CTLA435.  Such an elongated 
(AT) n repeat  has been shown to lead to T cell hyper- react ivit y25.  These 
Table 5 . CTLA4  genotype frequencies in pat ient  subgroups 
Subgroup Pat ients 
N (% )  
Healthy controls 
N (% )  
P OR (95%  CI )  
ANCA specificity     
+ 49 G allele carr ier      
MPO-ANCA (N =  34)  26 (74)  102 (55)  0.02 2.6 (1.1 – 6.2)  
PR3-ANCA (N =  49)  34 (69)   0.009 2.4 (1.2 – 4.6)  
Disease severity     
+ 49 G allele carr ier      
generalized (N =  63)  48 (76)  102 (55)  0.003 2.7 (1.4 – 5.3)  
lim ited (N =  39)  23 (59)   0.71 N/ A 
generalized vs. lim ited   0.10 N/ A 
(AT) n repeat  x/ x carr ier      
generalized (N =  63)  16 (25)  49 (28)  0.74 N/ A 
lim ited (N =  39)  19 (49)   0.02 2.4 (1.2 – 4.9)  
generalized vs. lim ited   0.04 2.8 (1.2 – 6.5)  
CTLA4, cytotoxic T- lymphocyte-associated ant igen 4;  ANCA, ant ineutrophil 
cytoplasm ic ant ibodies;  MPO, myeloperoxidase;  PR3, proteinase 3;  (AT) n repeat x/ x, 
homozygous for alleles longer than 171 base pairs;  OR, Odds rat io;  95%  CI , 95%  
confidence interval;  N/ A, not  applicable. 
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–318C/ T, + 49G/ A, and (AT) n polym orphism s in CTLA4 have previously 
been associated with a variety of autoim m une diseases, like SLE36,37,  
Graves’ disease and Hashim oto’s thyroidit is26,31,38 and m ult iple 
sclerosis39.  The –318C/ T SNP and the (AT) n m icrosatellite have been 
related to WG21-23.  I n our study, the (AT) n m icrosatellite was associated 
with the presence of lim ited AAV. Furtherm ore, the presence of a G 
allele at  the + 49 posit ion was associated with AAV. In cont rast ,  a 
Swedish study did not  reveal an associat ion between the + 49G/ A 
polym orphism  and WG in 32 pat ients22.  However, in our study not  only 
WG pat ients were included, but  also pat ients with MPA, CSS and renal-
lim ited vasculit is as these diseases are also associated with the 
presence of ANCA. There were no other associat ions with 
polym orphism s in CTLA4 and AAV in this pat ient  populat ion. 
The prom oter polym orphism s –1722T/ C and –1661A/ G have recent ly 
been described in pat ients with SLE. Pat ients with SLE m ore often were 
hom ozygous for the T allele at  the -1722 posit ion30.  We could not  
detect  this associat ion in AAV. Furtherm ore, we detected large 
differences between our cont rol populat ion and the Korean populat ion 
as tested by Hudson et  al30.  I n their study, cont rols were m ore often 
hom ozygous for the C allele, in our populat ion only one person was 
hom ozygous for this allele, and heterozygosity also was far less 
present . This clearly shows how different  allele dist r ibut ions can be 
between ethnically different  populat ions and highlights the necessity of 
an ethnically m atched cont rol populat ion. Our pat ients and cont rols all 
are from  the southeast  of the Netherlands and therefore, any disease 
associat ion is less likely to be due to ethnic differences. This m ay also 
explain why we could not  confirm  earlier associat ions between 
polym orphism s in CTLA4 and WG. 
Recent ly it  was discovered that  not  only CTLA-4 provides an inhibitory 
signal, but  program m ed death (PD) -1 also is involved in negat ive T cell 
regulat ion40.  Mice deficient  for  PD-1 develop a lupus- like disease 
including arthrit is and glom erulonephrit is41,  disease m anifestat ions also 
present  in AAV. Polymorphism s in PDCD1 have been associated with 
SLE19,42 and rheum atoid arthrit is20,43.  We therefore hypothesized that  
next  to polym orphism s in CTLA4,  polym orphism s in PDCD1 m ay be 
associated with the presence of AAV. We could not  detect  differences in 
genotype frequencies between pat ients with AAV and HC when 
analyzing PDCD1 alone;  however, in com binat ion with CTLA4,  we did 
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find an associat ion with vasculit is. Both PD-1 and CTLA-4 regulate T 
cell responses once they are init iated, although PD-1 seem s to be less 
potent  than CTLA-444.  This m ay explain why PD-1 alone is not  
associated with AAV. On the other hand, the (AT) n m icrosatellite in 
CTLA-4 alone is not  associated with AAV in this study, but  in 
com binat ion with PD-1 an associat ion seem s to be present . We 
therefore postulate that  for autoim m une disease, a m utat ion in m ore 
than one inhibitory receptor predisposes to the developm ent  of 
disease, for instance, AAV. 
I n conclusion, we found that  ANCA-associated vasculit is is associated 
with the presence of a G allele at  the + 49 posit ion of CTLA4;  other 
genet ic associat ions that  were previously described could not  be 
confirm ed in our populat ion. Addit ionally, the absence of the PD-1.5 T 
allele is associated with AAV in com binat ion with CTLA4.  The 
com binat ion of these genet ic polym orphism s m ay lead to 
hyperreact ivit y of T cells and thus m ay cont r ibute to the pathogenesis 
of AAV. 
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pat ients with PR3-ANCA associated 
vasculit is with renal involvem ent  
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Background .  Severe renal disease is a feature of ANCA-associated 
sm all- vessel vasculit is. We evaluated pat ient  and renal survival and 
prognost ic factors in pat ients with PR3-ANCA associated vasculit is with 
renal involvem ent  at  diagnosis during long- term  follow-up. 
Methods.  Eighty- five pat ients were diagnosed between 1982 and 1996 
and followed unt il 2001 allowing   \HDUV RI IROORZ-up. All pat ients 
were t reated with prednisolone and cyclophospham ide. Univariate and 
m ult ivariate analyses with pat ient  and renal survival as dependent  
variables were perform ed. 
Results.  Of 85 pat ients included 17 (20% )  died within 1 year after  
diagnosis. Of 25 pat ients (29% )  dialysis dependent  at  diagnosis, 2 
rem ained and 2 again becam e dialysis dependent  <  1 year;  9 died 
early without  renal recovery. Risk factors for  death occurring within one 
year in univariate analysis (RR, 95%  CI )  were age >  65 years (6.5, 
1.6-13.7)  and dialysis dependency at  diagnosis (3.6, 1.0-13) . Twenty 
pat ients died beyond 1 year during long- term  follow-up. Male gender 
(4.7, 1.6-10)  and developing dialysis dependency during follow-up 
(4.1, 1.4-12)  were associated with poor outcom e.  
Risk factor for renal failure within one year was dialysis dependency at  
diagnosis (29, 3.6-229) . Of 64 pat ients dialysis independent  1 year 
after  diagnosis, 12 pat ients becam e dialysis dependent  during follow-
up. A renal relapse was st rongly associated with developm ent  of renal 
failure in long- term  follow-up (17, 3.5 – 81) . 
Conclusions.  Early death and failure to recover renal funct ion in PR3-
ANCA associated vasculit is is associated with age >  65 years and 
dialysis dependency at  diagnosis. Long- term  renal survival is 
determ ined by renal relapses during follow-up only. Slow, progressive 
renal failure without  relapses is rarely observed in this group. 
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Sm all vessel vasculit ides, such as Wegener’s granulom atosis (WG)  and 
m icroscopic polyangiit is (MPA) , are st rongly associated with 
ant ineut rophil cytoplasm ic ant ibodies (ANCA) , which are either directed 
to m yeloperoxidase (MPO)  or proteinase 3 (PR3) 1-3.  These diseases can 
occur in any organ system  but  the respiratory t ract  and the kidneys are 
m ost  frequent ly involved. Unt reated, WG results in death within weeks 
to m onths. Since the int roduct ion of cyclophospham ide and 
prednisolone as standard t reatm ent , survival has im proved 
dram at ically from  less than 20%  at  1 year reported in 19584 to at  least  
60%  5-years survival reported in the past  ten years5-8.  
Although life-saving in m any pat ients, t reatm ent  with 
cyclophospham ide and prednisolone is associated with severe m orbidity 
and m ortalit y, both at  short - term  and during long- term  follow-up. 
I nit iat ing aggressive imm unosuppressive therapy in order to regain or 
conserve independent  renal funct ion in pat ients with ANCA-associated 
vasculit is with renal involvem ent  is, therefore, dependent  on the 
perceived prognosis of the pat ient . Previous studies have associated 
serum  creat inine9,10 and kidney biopsy findings9-12 at  diagnosis, and the 
occurrence of renal relapses13 with reduced renal survival in pat ients 
with pauci- im m une necrot izing glom erulonephrit is. Recent ly, we and 
others observed differences between groups associated with the 
different  ant igenic specificit y of ANCA ( reviewed by Franssen et  al14) . 
Previously, we studied long- term  outcom e in pat ients with MPO-ANCA 
associated glom erulonephrit is and found that  proteinuria at  diagnosis 
and during follow-up was the m ost  im portant  r isk factor for  the 
developm ent  of renal insufficiency15.  So far , none of the studies have 
focused on long- term  outcom e of pat ients with PR3-ANCA associated 
vasculit is with renal involvem ent .  
I n the present  study, we ret rospect ively analyzed pat ient  and renal 
survival in pat ients with PR3-ANCA associated vasculit is with renal 
involvem ent  that  were diagnosed and followed in one single center.  We 
invest igated predictors of outcom e at  diagnosis and during follow-up, 
and we exam ined the role of non- renal and renal relapses on long- term  
survival and renal outcom e in this pat ient  populat ion. 
 
Methods 
Pat ients 
We ret rospect ively ident ified all consecut ive pat ients diagnosed with, 
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t reated and followed in our hospital for PR3-ANCA posit ive vasculit is 
with evidence of renal involvem ent  (as determ ined by a biopsy showing 
necrot izing and/ or crescent ic glom erulonephrit is1 and/ or by 
deteriorat ion of renal funct ion with glom erular erythrocyturia,  
erythrocyte casts and proteinuria)  between January 1982 and January 
1996. Pat ients were followed unt il January 2001. Surviving pat ients 
were thus followed for at  least  5 years.  
 
Treatm ent  and follow-up 
Pat ients were t reated according to a standardized protocol15.  The 
t reatm ent  consisted of oral cyclophospham ide (2 m g/ kg)  and 
prednisolone (1 m g/ kg body weight )  daily with a m axim al oral 
prednisolone dose of 60 m g/ day. Doses of cyclophospham ide were 
adjusted to m aintain the leukocyte count  above 4 x 109/ L. Pat ients who 
presented with severe vasculit ic m anifestat ions such as alveolar 
hem orrhage, rapidly r ising serum  creat inine or gast rointest inal 
sym ptom s, were init ially t reated with int ravenous m ethylprednisolone 
1000 m g daily for 3 days. Plasm a exchange was added to the 
t reatm ent  regim en in case of disease progression or persistence of 
act ive disease. The lat ter was defined as persistence of m ajor 
ext rarenal sym ptom s or the presence of act ive necrot izing renal lesions 
in a repeat  renal biopsy after  2 to 4 weeks of im m unosuppressive 
therapy. After 4 to 6 weeks, the daily prednisolone dose was tapered 
by 10 m g every 2 weeks unt il the dose reached 30 m g, and thereafter 
by 5 m g every 2 to 4 weeks. Once rem ission was achieved the daily 
dose of oral cyclophospham ide was tapered by 25 m g every 3 m onths. 
Pat ients who experienced a renal relapse, or  a life- threatening non-
renal relapse, were t reated according to the sam e protocol. Minor non-
renal relapses were t reated with 1 m g/ kg body weight  
cyclophospham ide daily and a m axim al oral prednisolone dose of 40 
m g/ day. 
Pat ients were hospitalized for at  least  2 to 3 weeks or longer when 
indicated. After discharge, pat ients visited our outpat ient  clinic at  least  
every 2 weeks during the first  3 m onths after diagnosis, every 4 weeks 
unt il 1 year after diagnosis, and every 6 weeks thereafter. At  each 
visit , pat ients were evaluated by the sam e physician for signs and 
sym ptom s of vasculit ic disease and/ or adverse effects of t reatm ent . I n 
addit ion, blood pressure and weight  were m easured, serum  creat inine, 
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erythrocyte sedim entat ion rate (ESR)  and C- react ive protein (CRP)  
levels, and ANCA t iter16 were determ ined, m icroscopic urinalysis was 
perform ed, and proteinuria and creat inine were determ ined in a 24-
hour urine collect ion.  
  
Definit ions 
Rem ission was defined as a stabilizat ion or improvem ent  of creat inine 
clearance in com binat ion with the absence of glom erular erythrocyturia 
and erythrocyte cell casts and sym ptom s or signs at t r ibutable to act ive 
ext ra- renal vasculit is with CRP < 10 m g/ l. A non- renal relapse was 
defined as new or recurrent  findings indicat ive of vasculit ic disease 
without  signs of renal involvem ent 17.  A renal relapse was defined either 
histopathologically by the presence of new necrot izing lesions in a renal 
biopsy or clinically by recurrence of m icroscopic glom erular 
erythrocyturia, erythrocyte cell casts, proteinuria and a decrease in 
creat inine clearance in a pat ient  with a previously stable renal 
funct ion17.  Microscopic glom erular erythrocytur ia was defined as 10 or 
m ore red blood cells, with m ore than 50%  dysm orphic cells, per high 
power field (m agnificat ion 400x)  in the absence of a urinary t ract  
infect ion or an indwelling catheter. 
 
Stat ist ical analyses 
Data are presented as m ean ±  standard deviat ion unless stated 
otherwise. Cont inuous data between groups were com pared using 
Student ’s t - test  and the Wilcoxon signed rank test  when appropriate. 
Survival curves for pat ient  and renal survival were calculated using 
Kaplan-Meier est im ates for survival dist r ibut ion. End point  for renal 
survival analysis was the start  of renal replacem ent  therapy or death 
due to renal failure. Differences between groups in survival were 
analyzed with log- rank test , and m ult ivariate analysis with Cox 
proport ional hazards analysis with survival t ime as dependent  variable 
was perform ed. Renal survival rates (survival without  end-stage renal 
disease (ESRD))  are calculated and analyzed with subjects dying with 
independent  renal funct ion censored.  
Analyzing pat ient  and renal survival, a large difference between both 
pat ient  and renal survival   \HDU DQG !  \HDU DIWHU GLDJQRVLV
becam e apparent . Survival differences between groups were, therefore, 
analyzed separately for  the t im e period  \HDU DQG! \HDU DIWHU
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diagnosis ( long- term  follow-up) , to ident ify r isk factors for these 
specific t im e periods. I ndependent  variables tested in the analysis of 
pat ient  and renal survival   \HDU ZHUH DJH JHQGHU SXOPRQDU\
involvem ent  (with or without  need for m echanical vent ilat ion) , CRP 
level, serum  creat inine level, dialysis dependency, and Birm ingham 
Vasculit is Act ivit y Score (BVAS) 18 at  diagnosis. Variables addit ionally  
tested for their associat ion with long- term  pat ient  and renal survival (>  
1 year)  were the occurrence of non- renal and renal relapses, 
cum ulat ive doses of m edicat ion, m ean arterial pressure (MAP) , 
creat inine clearances and proteinuria at  12 m onths and use of ACE 
inhibitors. I n m ult ivariate analysis the occurrence of non- renal and 
renal relapses were tested as t im e-dependent  variables. Analyses were 
perform ed with SPSS version 10.0 (SPSS Inc., Chicago, I L) . A two-
sided p-value < 0.05 was considered to indicate stat ist ical significance.  
 
Results 
Between April 1982 and January 1996, 85 pat ients (55 m ale, 30 
fem ale)  were diagnosed with PR3-ANCA posit ive vasculit is with renal 
involvem ent  in our hospital. I n all pat ients, a diagnosis of sm all- vessel 
vasculit is was confirm ed by biopsy. Renal involvem ent  was confirm ed 
in 64 by renal biopsy;  in the rem aining pat ients renal failure, 
erythrocyturia and erythrocyte casts, and proteinuria was present . Age 
Table 1 . Dist r ibut ion of disease m anifestat ions at  
diagnosis by organ system  
Organ system N %  
Renal 85 100 
ENTa 72 85 
Musculoskeletal 64 75 
Pulmonary 47 55 
Cutaneous 37 44 
Neurologic 34 40 
Ocular 29 34 
Otherb 19 22 
a
 ENT, ear nose throat  disease 
b I ncluding heart  and gastrointest inal t ract  
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at  diagnosis was 56 ±  17 years. Twenty- five pat ients (29% )  were 
dialysis dependent  at  diagnosis. Forty-seven pat ients (55% )  had 
pulm onary involvem ent , of which 9 pat ients (19% )  needed m echanical 
vent ilat ion. Organ m anifestat ions are presented in table 1. 
 
Overall 
For the ent ire group of 85 pat ients, est im ated pat ient  survival at  5 and 
10 years was 73 and 62% , respect ively ( figure 1) . Causes of death are 
presented in table 2. Est im ated m edian survival was significant ly 
shorter in pat ients >  65 years at  diagnosis (3.6 years)  when com pared 
to those <  51 years (17.8 years)  and those 51 -  65 years of age (17.0 
years)  (p< 0.0001, figure 2) . Est im ated m edian survival for pat ients 
who were dialysis dependent  at  diagnosis was also significant ly shorter 
than survival in pat ients who were not  (9.4 vs. 17.0 years, 
respect ively, p= 0.013, figure 3) . Survival with independent  renal 
funct ion was 65%  at  5 years and 51%  at  10 years ( figure 1) .  
 
Mortalit y PRQWKV 
Of the 85 pat ients, 17 pat ients (20% )  died within 1 year. Main causes 
Figure 1 . Pat ient  survival (  )  and survival without  need for renal replacement  therapy 
(  )  in 85 pat ients diagnosed with PR3-ANCA associated vasculit is with renal involvement.  
Numbers indicate number at  r isk at  1, 5 and 10 years after  diagnosis. 
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of death ( table 2)  were act ive vasculit is, usually within days after  
diagnosis (n= 7) , and infect ious com plicat ions of therapy, between 3 
and 6 m onths (n= 6) . Of 7 pat ients who died of uncont rolled vasculit is, 
5 pat ients required dialysis at  diagnosis;  of 6 pat ients who died of 
infect ious causes, 2 pat ients were dialysis dependent  at  diagnosis. 
Survival within the first  year after diagnosis was age dependent :  
com pared to pat ients <  51 years (n= 26)  and 51-65 years of age 
Fgure 2 . Pat ient  survival in 85 pat ients diagnosed with PR3-ANCA associated vasculit is 
with renal involvement  according to age at  diagnosis. (  )  indicates pat ients aged <  51 at 
diagnosis, (  )  indicates pat ients aged 51 – 65;  (  )  indicates pat ients aged >  65 at  
diagnosis. 
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Table 2 . Causes of death 
 N (% )  Within 1 year Follow-up >  1 yr  
Act ive vasculit is 7 (19)    7 0 
I nfect iona 12 (32)    6 6 
Malignancy 3 (8)    0 3 
Cardiovascular 13 (35)    4 9 
Renal insufficiency 2 (5)    0 2 
Total 37 17 20 
a
 10 dur ing immunosuppressive t reatment  
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(n= 31)  at  diagnosis, pat ients >  65 years (n= 28)  had a significant ly 
higher r isk for death PRQWKVZLWKDUHODWLYHULVN55RI
CI , 1.6 – 13.7)  and 4.0 (1.4 – 10.5) , respect ively. Severe renal 
involvem ent  was also associated with death   PRQWKV GLDO\VLV
dependency at  diagnosis:  RR 2.9 (1.3 – 10.8) ;  serum  creat inine >  500 
m ol at  diagnosis:  RR 2.2 (0.9 – 6.9) ) . I n m ult ivariate analysis, CRP 
level at  diagnosis, age, and dialysis dependency at  diagnosis were 
Figure 3 . Pat ient  survival in 85 pat ients diagnosed with PR3-ANCA associated vasculit is 
with renal involvement  according to dialysis dependency at  diagnosis. (  )  indicates 
pat ients who were not dialysis dependent  at  diagnosis, (  )  indicates pat ients who were. 
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Table 3 . Predictors of pat ient  m ortality in m ult ivariate analysis 
Predictor RR 95%  CI  P value 
Pat ient  m orta lity   1  year ( n= 8 5 )  
Age at  diagnosis 1 yr increase 1.10 (1.04 -  1.16)  0.001 
Dialysis dependency diagnosis 3.58 (1.01 -  12.7)  0.05 
CRP level 1 mg/ L increase 1.01 (1.00 -  1.02)  0.045 
Pat ient  m orta lity >  1  year ( n= 6 8 )  
Age at  diagnosis 1 yr increase 1.09 (1.03 -  1.15)  0.002 
Male gender 5.75 (1.25 -  26.5)  0.025 
Dialysis dependency follow-up 4.15 (1.43 -  12.0)  0.009 
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associated with m ortality PRQWKVWDEOH 
 
I ndependence of renal replacem ent  therapy PRQWKV 
Of 25 pat ients dialysis dependent  at  diagnosis, 2 did not  regain renal 
funct ion (8% )  but  survived at  1 year and 9 pat ients (36% )  died within 
1 year (m edian 1 m onth, range 4 days – 5 months)  without  regaining 
independent  renal funct ion. Of 14 pat ients (56% )  who regained 
independent  renal funct ion, 2 where only tem porarily dialysis 
independent  but  needed dialysis again within 1 year, and 1 died within 
12 m onths. Only 11 of 25 pat ients dialysis dependent  at  diagnosis  
(48% )  were alive at  12 m onths with funct ional renal status. I n these 
11 pat ients creat inine clearance at  12 m onths after  diagnosis was 38 ±  
14 m l/ m in. Only 1 of 60 pat ients dialysis independent  at  diagnosis 
(2% )  developed renal failure requir ing dialysis therapy within 1 year 
after diagnosis. With univariate and m ult ivariate analysis dialysis 
dependency at  diagnosis (RR 29, 95%  CI  3.6 -  229)  was the only 
variable associated with persistent  or renewed dialysis dependency 
12 m onths after  diagnosis ( table 4) . 
 
Long- term  pat ient  survival 
Of 68 pat ients alive at  1 year,  27 pat ients (40% )  did not  relapse, 10 
pat ients (15% )  experienced only non- renal relapses, and 31 pat ients 
(46% )  had at  least  1 renal relapse, of which 10 also had one or m ore 
non- renal relapses. All relapses were accom panied by the presence of 
PR3-ANCA at  the t im e of relapse. The m edian t im e to the first  non-
renal relapse was 3.3 years ( range 1.6 – 10.5) . The m edian t im e to the 
first  renal relapse was 4.3 years ( range 0.8 – 12.2) . Twenty pat ients 
Table 4 . Predictors of renal fa ilure in m ult ivariate analysis 
Predictor RR  95%  CI  P value 
	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  

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Age at  diagnosis 1 yr increase   NS 
Dialysis dependency 28.6 (3.58 -  229)  0.002 
Renal fa ilure >  1  year ( n= 6 4 )  
Renal relapse 16.8 (3.51 – 80.8)  < 0.001 
Creat inine clearance at 12 months  
1 m l/ m in decrease 
1.14 (1.04 -  1.22)  0.002 
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died >  1 year after diagnosis. I n univariate analysis, age >  65 years at  
diagnosis was associated with m ortalit y beyond 1 year of follow-up 
com pared to age <  51 (RR 10.5, 3.6 -  51)  and age 51-65 (RR 2.9, 1.3 
-  11) , as was m ale gender (RR 4.7, 1.6 -  10) . I n m ult ivariate analysis, 
developm ent  of dialysis dependency was addit ionally associated with 
death, but  occurrence of renal or non- renal relapses was not  ( table 3) . 
 
Long- term  renal survival 
Of 68 pat ients alive 1 year after diagnosis, 64 were dialysis 
independent  with a creat inine clearance of 64 ±  31 m l/ m in (m edian 60 
m l/ m in, range 18 – 142 m l/ m in)  and proteinuria 0.8 ±  1.0 g/ 24h 
(m edian 0.3 g/ 24h, range 0 – 5 g/ 24h)  at  1 year. Mean MAP was 101 
±  10 (m edian 100, range 83 – 127)  at  1 year and did not  change 
throughout  the study period (data not  shown) . Forty- four pat ients 
(65% )  were t reated with ant ihypertensives, of which 24 with an ACE-
inhibitor and/ or angiotensin I I  antagonist . Twelve of 64 pat ients (19% )  
who were dialysis independent  at  1 year progressed to ESRD during 
the study period;  m edian t im e to ESRD in those 12 pat ients was 4.3 
years after diagnosis ( range, 2.0 – 10.4 years) . Five pat ients who had 
to start  RRT with the occurrence of a renal relapse (4 pat ients at  the 
first  renal relapse, 1 at  the third)  did not  regain renal funct ion during 
t reatm ent  of the relapse. Five pat ients developed ESRD after a m edian 
follow-up of 3.0 years after their first  renal relapse. Only 2 pat ients 
progressed to ESRD without  any signs of a renal relapse;  these 
pat ients had been dialysis dependent  at  diagnosis. I n m ult ivariate 
analysis the occurrence of a renal relapse and creat inine clearance, but  
not  proteinuria at  12 months were highly associated with developm ent  
of dialysis dependency ( table 4) . I n cont rast , non- renal relapses were 
not  associated with reduced renal surv ival (p= 0.98) . Dialysis 
dependency at  diagnosis was also not  associated with the developm ent  
of ESRD in long- term  follow-up. 
 
I nfluence of non- renal and renal relapses on renal funct ion 
We further analyzed the influence of renal and non- renal relapses on 
renal funct ion by com paring creat inine clearance and proteinuria 
before, at  the m om ent  of, and following a first  relapse. I n addit ion, the 
slope of the change in creat inine clearance over t im e was calculated 
unt il 3 m onths before the relapse and com pared with the slope start ing 
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3 m onths after a relapse. I n 31 pat ients with a first  renal relapse, 
creat inine clearance at  the m om ent  of relapse had decreased by 15 ±  
13.0 m l/ m in com pared to 12 m onths before relapse. At  12 m onths 
following the first  renal relapse clearance was st ill 11 ±  11.0 m l/ m in 
lower than 12 m onths before the relapse (Figure 4A) . Proteinuria 
increased from  0.9 ±  1.2 g/ 24h 12 m onths before, to 2.0 ±  1.6 g/ 24h 
at , and 1.1 ±  1.1 g/ 24h 12 m onths after  relapse (Figure 4B) . The 
slopes of the change in creat inine clearance, excluding the 4 pat ients 
who becam e dialysis dependent  at  their first  renal relapse, t ended to 
be m ore negat ive following as com pared to prior to a renal relapse  
( -1.8 ±  4.5 m l/ m in/ year before and –3.1 ±  5.2 m l/ m in/ year after renal 
relapse;  p= 0.06) . I n cont rast , a first  non- renal relapse was not  
associated with renal funct ion loss or increased proteinuria at  the 
m om ent  of or following the relapse (Figures 4A and B) . The slopes of 
the change in creat inine clearance after the first  non- renal relapse were 
not  different  before and after a non- renal relapse ( -1.3 ±  2.0 m l/ m in/
year before and -0.4 ±  1.5 m l/ m in/ year after non- renal relapse) . 
 
Discussion 
I n the present  study, we evaluated pat ient  and renal survival in 85 
pat ients with PR3-ANCA associated vasculit is with renal involvem ent  
during long- term  follow-up. Age >  65 years and dialysis dependency at  
diagnosis were indicat ive of both poor pat ient  and renal survival. I n our 
Figure 4 A. Creat inine clearances in 44 pat ients diagnosed with PR3-ANCA associated 
vasculit is before, dur ing and after the first  non- renal or renal relapse. ( $ )  indicates 
pat ients with a renal relapse, ( % )  indicates pat ients with a non-renal relapse. Error bars 
represent  SD. 
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Figure 4 B. Proteinur ia in 44 pat ients diagnosed with PR3-ANCA associated vasculit is 
before, dur ing and after the first  non-renal or  renal relapse. ( $ )  indicates pat ients with a 
renal relapse, ( % )  indicates pat ients with a non-renal relapse. Error bars represent  SD. 
long- term  follow-up analysis, renal funct ion deteriorated during and 
after  a renal relapse, and the occurrence of a renal relapse was the 
only predictor of an unfavorable long- term  renal prognosis. 
The pat ient  survival in our study is com parable to previous studies 
considering pat ients with sm all- vessel vasculit ides with renal 
involvem ent  where it  varied from  59 to 95%  in various pat ient  groups 
during various follow-up periods5,6,8,10,12,13,15,19.  The m ortalit y rate in 
our series m ay be som ewhat  higher as our departm ent  is a tert iary 
referral center and pat ients with severe disease at  diagnosis are 
referred to our hospital, while pat ients with less severe disease are 
often m anaged at  their prim ary hospital. Mortalit y short ly after  
diagnosis is m ost ly due to uncont rolled vasculit is, while the other 
im portant  cause is severe infect ious com plicat ions of the t reatm ent , 
usually occurring within 3 to 6 m onths after the init iat ion of t reatm ent . 
These findings clearly highlight  the dilem m a the clinician t reat ing these 
pat ients faces. Prognost ic tools in this respect  are therefore im portant  
to guide the intensity of t reatm ent . Unfortunately, as reported by 
others5,7,10,13,19,  early m ortalit y is st rongly associated with older age 
and m ore advanced organ dysfunct ion caused by the vasculit ic process. 
I n our study dialysis dependency at  diagnosis was associated with ear ly 
m ortalit y, but  in cont rast  to som e other studies9,13,  lung involvem ent  
(with or without  the need for m echanical vent ilat ion)  was not . 
As can be appreciated from  the est im ated survival curve, m ortalit y in 
the first  year after diagnosis is different  com pared to follow-up beyond 
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1 year. We therefore chose to m ake separate analyses for the t im e 
periods within and beyond 1 year after diagnosis. For long- term  pat ient  
survival, we found no associat ion of m ortalit y with act ive vasculit is 
defined as the occurrence of a non- renal or renal relapse;  no pat ients 
died from  act ive vasculit is beyond 1 year. Long- term  m ortalit y was 
associated with advanced age (as reported previously7,8,10,20) , m ale 
gender and developm ent  of need for dialysis during follow-up.  
Fourteen pat ients (16% )  developed ESRD during follow-up (of whom  2 
within one year) , and 2 pat ients did not  recover from  dialysis. Dialysis 
dependency at  diagnosis was highly associated with unfavorable renal 
outcom e, as described previously12,19,20.  However, 11 of 25 pat ients 
dialysis dependent  at  diagnosis, who regained independent  renal 
funct ion, had a m ean creat inine clearance of 38 m l/ m in at  1 year after  
diagnosis. We found that  dialysis dependency at  diagnosis, and not  
serum  creat inine was associated with the developm ent  of ESRD which 
cont rasts our study to others8-10,21.  Renal funct ion at  1 year after  
diagnosis was associated with progression to ESRD for pat ients who 
experienced a renal relapse during follow-up. 
I n long- term  follow-up, it  does seem  that  relat ively m ore pat ients who 
were dialysis dependent  at  diagnosis progress to end-stage renal 
disease (ESRD) . Five pat ients of 11 who were dialysis dependent  at  
diagnosis but  had funct ional renal status at  1 year progressed to ESRD 
versus 5 pat ients of 53 who were dialysis independent  at  diagnosis and 
at  1 year. However, only 2 pat ients developed ESRD gradually, without  
the occurrence of a renal relapse. The other 3 pat ients progressed to 
ESRD after the occurrence of 1 or m ore renal relapses. The occurrence 
of a renal relapse was the st rongest  independent  indicator of a worse 
renal outcom e and carried a high risk for developing ESRD in our 
pat ient  populat ion. Dialysis dependency at  diagnosis per se was not  
associated with progression to ESRD beyond 1 year.  Long- term  renal 
survival was not  associated with blood pressure or proteinuria at  12 
m onths after  diagnosis, and renal survival was only related to 
creat inine clearance at  12 m onths in m ult ivariate analysis in 
com binat ion with renal relapse during follow-up. At  12 m onths after 
diagnosis renal funct ion was rather well preserved with a m edian 
creat inine clearance of 60 m l/ m in. I n addit ion, proteinuria was low 
(m edian 0.3 g/ 24h)  and blood pressure well cont rolled (m edian MAP 
100) , characterist ics suggest ing a low risk for gradual loss of renal 
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funct ion. As the occurrence of renal relapses of PR3-ANCA associated 
vasculit is was so st rongly associated with renal failure, we analyzed the 
renal funct ion loss associated with renal relapses and the possible 
influence on progressive renal funct ional decline. A renal relapse 
caused a m ean long- term  loss of creat inine clearance of 11 m l/ m in and 
an increase in proteinuria of 0.2 g/ 24h. I n addit ion, renal funct ion 
tended to deteriorate m ore rapidly after a renal relapse (as m easured 
by the slopes of the change in creat inine clearance) . I t  has been 
suggested before that  the repet it ive insults to the renal parenchym a 
would result  in perm anent  dam age13.  Our observat ions clearly indicate 
the am ount  of dam age that  a renal relapse in PR3-ANCA associated 
vasculit is inflicts. 
I n our study, only 2 pat ients progressed to ESRD without  signs of a 
renal relapse. I n all other pat ients, we did not  observe deteriorat ion of 
renal funct ion in long- term  follow-up unless pat ients had a renal 
relapse, even if pat ients had been dialysis dependent  at  diagnosis. This 
is clearly in cont rast  to our findings in MPO-ANCA associated 
glom erulonephrit is, where pat ients can have insidious renal disease 
ult im ately leading to ESRD in about  one third of the pat ients without  
signs of a renal relapse. I n these pat ients, proteinuria is an im portant  
indicator of deteriorat ing renal funct ion15,  whereas in our PR3-ANCA 
vasculit ic pat ients it  is not . I n the lat ter, close clinical follow-up for the 
occurrence of a relapse is needed22,23.   
I n conclusion, for pat ients with PR3-ANCA associated vasculit is with 
renal involvem ent , there are no useful prognost ic tools to guide the 
intensity of t reatm ent .  I n long- term  follow-up, our data dem onst rate 
that  renal relapses are highly associated with unfavorable renal 
outcom e, and a renal relapse has a significant  effect  on renal funct ion 
after this relapse. Since nearly half of the pat ients with PR3-ANCA 
experience relapses, physicians should be alert  on the occurrence of a 
renal relapse and on possible consequences, and efforts t o prevent  
relapses m ay be the way to preserve long- term  renal funct ion in this 
disease. 
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Chapter 7 
Differences in renal biopsies do not  
lead to difference in outcom e between 
pat ients with PR3-ANCA and pat ients 
with MPO-ANCA  
Slot  MC, van Paassen P, van Breda Vriesm an PJC, Cohen Tervaert  JW 
 
Subm it ted 
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Background .  Risk factors for the developm ent  of chronic renal 
insufficiency differ between MPO-  and PR3-ANCA associated vasculit is 
(AAV)  with renal involvem ent . We tested in a large group of pat ients 
with AAV with renal involvem ent  whether differences already exist  at  
diagnosis, and whether these differences explain dist inct ive outcom es 
in AAV.  
Methods.  All consecut ive pat ients with biopsy-proven renal disease in 
AAV in the southeast  of the Netherlands were included. Biopsies were 
scored for the presence of act ive and chronic lesions, and an act ivity  
index and chronicity index were calculated. Addit ionally, survival curves 
were est im ated, and univariate and m ult ivariate analysis with pat ient  
and renal survival as dependent  variables was perform ed. 
Results.  Seventy- two pat ients (41 with MPO-  and 31 with PR3-ANCA)  
were included. Overall pat ient  and renal survival were 55%  and 43%  at  
5 years, respect ively. Risk factors for death were age > 65 years, 
serum  creat inine level and dialysis dependency at  biopsy. The 
developm ent  of renal failure during follow-up was associated with 
serum  creat inine, fem ale gender, and renal biopsy findings. Evaluat ing 
pat ients with PR3-  and MPO-ANCA, we found that  m ore act ive lesions 
and a higher act ivit y index were present  in PR3-ANCA, whereas MPO-
ANCA pat ients showed m ore chronic lesions, and a higher chronicity 
index. Despite the overt  differences in renal biopsies, ANCA specificit y 
was not  a r isk factor for pat ient  death or the developm ent  of renal 
failure during long- term  follow-up.  
Conclusion .  Renal lesions differ between pat ients with PR3-  and MPO-
ANCA, being m ore acute in PR3-ANCA, and m ore chronic in MPO-ANCA. 
These differences support  the hypothesis that  already at  diagnosis 
m ore irreversible kidney dam age exists in pat ients with MPO-ANCA 
com pared to PR3-ANCA. The variat ion at  diagnosis, however, does not  
result  in differences in pat ient  and renal outcom e in PR3-  and MPO-
ANCA. 
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Sm all vessel vasculit ides, such as Wegener’s granulom atosis (WG)  and 
m icroscopic polyangiit is (MPA) , are st rongly associated with 
ant ineut rophil cytoplasm ic ant ibodies (ANCA) , which are either directed 
to m yeloperoxidase (MPO)  or proteinase 3 (PR3) 1-3.  These diseases can 
occur in any organ system  but  the respiratory t ract  and the kidneys are 
m ost  frequent ly involved. Unt reated, WG results in death within weeks 
to m onths. Since the int roduct ion of cyclophospham ide and 
prednisolone as standard t reatm ent , survival has im proved 
dram at ically from  less than 20%  at  1 year reported in 19584 to at  least  
60%  5-years survival reported in the past  ten years5-8.  
Although life-saving in m any pat ients, t reatm ent  with 
cyclophospham ide and prednisolone is associated with severe m orbidity 
and m ortalit y, both at  short - term  and during long- term  follow-up. 
I nit iat ing aggressive imm unosuppressive therapy in order to regain or 
conserve independent  renal funct ion in pat ients with ANCA-associated 
vasculit is with renal involvem ent  is, therefore, dependent  on the 
perceived prognosis of the pat ient . Previous studies have associated 
serum  creat inine8-10 and kidney biopsy findings9-15 at  diagnosis, and the 
occurrence of proteinuria15,16 and renal relapses17,18 with reduced renal 
survival in pat ients with pauci- im m une necrot izing glom erulonephrit is. 
Recent ly, we and others observed differences between groups 
associated with the different  ant igenic specificit y of ANCA both with 
respect  to clinical m anifestat ions and follow-up ( reviewed by Franssen 
et  al19) .  
Previously, we studied long- term  outcom e in pat ients with ANCA-
associated glom erulonephrit is and found that  clinical r isk factors for the 
developm ent  of renal insufficiency differ between pat ients with MPO-  
and PR3-ANCA associated glom erulonephrit is (AAGN) . I n PR3-AAGN, 
renal funct ion is stable during rem ission, but  declines with every renal 
relapse18.  I n MPO-AAGN, proteinuria at  diagnosis and during follow-up 
was the m ost  im portant  r isk factor for developing renal insufficiency16.  
I t  is unclear whether these different  disease courses can be explained 
by biopsy findings at  diagnosis. 
We hypothesized that  the differences in renal outcom e in PR3-  and 
MPO-AAV could be explained by differences in renal lesions. To test  
this, we ret rospect ively analyzed pat ient  and renal survival in pat ients 
with biopsy-proven ANCA-associated glom erulonephrit is in the 
southeast  of the Nether lands. We invest igated predictors of outcom e in 
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renal biopsies and com pared pat ients with PR3-  and MPO-AAGN for the 
detect ion of differences at  diagnosis and outcom e. 
 
Methods 
Pat ients 
We ret rospect ively ident ified all pat ients in our renal biopsy regist ry20,21 
diagnosed with crescent ic glom erulonephrit is between January 1977 
and July 2003 without  evidence of system ic lupus erythem atosus 
(SLE) , I gA nephropathy, Henoch Schönlein purpura, post - infect ious GN 
or cryoglobulinaemia. Serum  sam ples, taken at  the t im e of biopsy, 
were tested for the presence of ANCA. We thus ident ified 113 pat ients 
with AAGN:  47 pat ients (38% )  with PR3-ANCA, 51 pat ients (46% )  with 
MPO-ANCA, 5 pat ients (5% )  with both PR3-  and MPO-ANCA and 10 
pat ients (10% )  with MPO-ANCA with the presence of ant i-glom erular 
basal m em brane ant ibodies. Only pat ients whose biopsy was taken at  
the first  disease episode and who were single posit ive for PR3-  or MPO-
ANCA were included in the current  analysis (N =  72) . 
 
Treatm ent  and follow-up 
Pat ients were biopsied in 4 different  hospitals in the southeast  of the 
Netherlands. I n m ost  cases, follow-up was in the hospital where the 
biopsy was taken. I nduct ion t reatm ent  consisted of prednisolone 1 
m g/ kg/ day, usually com bined with cyclophospham ide 2 m g/ kg/ day. I n 
severe ( renal)  and /  or life- threatening disease, m ethylprednisolone 
and /  or plasm a exchange were added. During follow-up, prednisolone 
was tapered and stopped;  cyclophospham ide was tapered and stopped, 
or switched to azathioprine with or without  ciclosporin A depending on 
the t reat ing specialist . 
 
Histological scoring 
Renal biopsies were processed for  light  m icroscopy and 
im m unofluorescence as described elsewhere20.  Biopsies had to contain 
five or m ore glom eruli per sect ion to qualify for evaluat ion. To assess 
the act ivit y and chronicity of the lesions serial 1 m m  sect ions were 
stained with silver m ethenam in and counter stained with hem atoxylin 
eosin. Num bers of norm al glom eruli and num bers of glom eruli with 
global sclerosis were counted. Each glom erulus was separately 
assessed for the presence of necrosis and cellular and fibrous crescents 
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( the lat ter two had to cover at  least  25 percent  of the glom erular 
surface area) . Percentages of affected glom eruli were calculated by 
dividing the num ber of glom eruli with lesions by the total num ber of 
glom eruli. I nterst it ial lesions, such as interst it ial inflam m at ion, 
interst it ial fibrosis and tubular at rophy, were graded sem iquant itat ively 
on a scale of 0 t o 3 (absent , m ild, m oderate, and severe, respect ively) .  
The presence of vasculit is of renal arteries and arterioles and 
(periglom erular)  granulom atous inflam m at ion was noted. 
For calculat ion of act ivity scores, the presence of fibrinoid necrosis and 
cellular crescents was scored separately in a range of 0 to 3 (absent , 
less than 25%  of glom eruli involved, 25 to 50%  of glom eruli involved, 
and m ore than 50%  of glom eruli involved, respect ively) . Addit ionally, 
the grade of interst it ial inflam m at ion (0 – 3, see above)  was included in 
the act ivit y score, result ing in a m axim um  score of 9. The chronicity  
score included the percentage of sclerosed glom eruli, the percentage of 
glom eruli with fibrous crescents and the grade of interst it ial fibrosis 
and tubular at rophy, result ing in a m axim um chronicity score of 12. 
Scoring m ethods are adapted from  Franssen et  al22.  All biopsies were 
scored by one nephropathologist  (PvBV)  who was blinded to clinical 
diagnosis and ANCA specificit y. 
 
Stat ist ical analyses 
Data are presented as m ean ±  standard deviat ion unless stated 
otherwise. Cont inuous data between groups were com pared using 
Student ’s t - test  and the Wilcoxon signed rank test  when appropriate. 
Survival curves for pat ient  and renal survival were calculated using 
Kaplan-Meier est im ates for survival dist r ibut ion. End point  for renal 
survival analysis was the start  of renal replacem ent  therapy or death 
due to renal failure. Differences between groups in survival were 
analyzed with log- rank test , and m ult ivariate analysis with Cox 
proport ional hazards analysis with survival t im e as dependent  variable. 
Renal survival rates (survival without  end-stage renal disease (ESRD) )  
are calculated and analyzed with subjects dying with independent  renal 
funct ion censored. 
Analyzing pat ient  and renal survival, a large difference between both 
pat ient  and renal survival   \HDU DQG !  \HDU DIWHU GLDJQRVLV
becam e apparent . Survival differences between groups were, therefore, 
analyzed separately for  the t im e period  \HDU DQG! \HDU DIWHU
 106   Chapter 7 
diagnosis ( long- term  follow-up) , to ident ify r isk factors for these 
specific t im e periods. Variables analyzed included age, serum  creat inine 
and dialysis dependency at  the t im e of biopsy, gender, ANCA 
specificit y, PR3-ANCA level in direct  and capture ELISA (enzym e- linked 
im m unosorbent  assay) , and renal biopsy findings. Analyses were 
perform ed with GraphPad Prism  version 3.00 (GraphPad Software Inc., 
San Diego, CA)  and SPSS version 10.0 (SPSS Inc., Chicago, I L) . A two-
sided P value < 0.05 was considered to indicate stat ist ical significance. 
 
Results 
Of 113 renal biopsies, 72 biopsies were eligible for inclusion (31 PR3-  
and 41 MPO-ANCA) . Fift y- three pat ients were m ale (74% ) . Age at  
biopsy was 61.9 ±  13.1 years. Serum  creat inine level at  biopsy was 
445 ±  274 m ol/ L;  eight  pat ients had serum  creat inine levels below 
120 m ol/ L, 36 pat ients had creat inine levels between 120 and 500 
m ol/ L, and 28 pat ients had creat inine levels above 500 m ol/ L. 
Seventeen pat ients (21% )  were dialysis dependent  at  the t im e of renal 
biopsy;  15 of these had creat inine levels above 500 m ol/ L. I n four 
pat ients, it  was unknown whether they required dialysis at  biopsy ( two 
pat ients had serum  creat inine levels below 500 m ol/ L, two pat ients 
above 500 m ol/ L) . Four pat ients were t reated with cort icosteroids 
alone, 57 pat ients were t reated with cyclophospham ide and steroids;  in 
two of these 57 pat ients plasm a exchange was added. One pat ient  was 
t reated with m ethot rexate and steroids;  one with m ycophenolate and 
steroids;  in seven pat ients t reatm ent  was withheld and in two pat ients, 
t reatm ent  is unknown.  
 
Renal disease in PR3-  and MPO-ANCA at  diagnosis 
I n pat ients with PR3-ANCA, age at  biopsy was 60.2 ±  12.4 versus 63.2 
±  13.7 in MPO-ANCA (P =  0.07) . Mean serum  creat inine with PR3-
ANCA was 429 ±  273 m ol/ L com pared to 456 ±  277 m ol/ L with 
MPO-ANCA (P =  NS) . Proteinuria was 1.9 ±  1.5 g/ 24h in pat ients with 
PR3-ANCA and 2.7 ±  2.6 g/ 24h in pat ients with MPO-ANCA (P =  NS) . 
Glom erular necrosis and cellular crescents were m ore often observed in 
PR3-ANCA posit ive biopsies ( table 1, figures 1A and B) , whereas in 
MPO-ANCA posit ive biopsies, fibrous crescents and glom erular sclerosis 
were m ore often present  ( table 1, figures 1C and D) . Chronic interst it ial 
injury, such as interst it ial fibrosis and tubular at rophy, was also m ore 
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com m on in MPO-ANCA. This resulted in a t rend to a higher act ivit y 
score in pat ients with PR3-ANCA and a higher chronicity score in MPO-
ANCA. There were no differences in the frequency of granulom as in 
renal biopsies (8 in PR3-  and 5 in MPO-ANCA)  or vasculit is (7 and 3 for 
PR3-  and MPO-ANCA, respect ively) . 
 
Overall survival in ANCA-associated glom erulonephrit is 
I n all 72 pat ients with eligible biopsies, follow-up data were available. 
Est im ated survival at  5 years and 10 years was 54%  and 34% , 
respect ively ( figure 2) . Causes of death are presented in table 2. 
Est im ated m edian surv ival was significant ly shorter in pat ients > 65 
years at  biopsy (3.1 years)  when com pared to those < 50 years 
(undefined)  and those between 50 and 65 years of age (7.0 years;  P =  
0.05) . The est im ated m edian survival in pat ients who were dialysis 
dependent  at  diagnosis was also significant ly shorter than survival in 
Table 1 . Renal biopsy findings in PR3 -  and MPO- ANCA 
associated glom erulonephrit is 
 PR3-ANCA MPO-ANCA P value 
%  normal glomeruli 36.4 ±  28.5 29.7 ±  24.4 0.28 
%  glomerular necrosis 9.5 ±  11.7 3.8 ±  5.5 0.005 
%  cellular  crescents 26.6 ±  23.0 18.4 ±  20.9 0.04 
%  fibrous crescents 15.2 ±  19.1 27.1 ±  24.6 0.02 
%  glomerular sclerosis 8.1 ±  13.8 13.9 ±  17.1 0.05 
I nterst it ial inflammat iona 1.4 ±  0.9 1.4 ±  0.9 0.68 
I nterst it ial f ibrosisa 0.7 ±  0.8 1.3 ±  0.7 0.0004 
Tubular at rophya 0.9 ±  0.9 1.6 ±  0.9 0.003 
Act iv ity scoreb 3.5 ±  1.7 2.9 ±  1.5 0.07 
Chronicity scorec 3.0 ±  2.7 5.1 ±  2.6 0.001 
PR3, proteinase 3;  MPO, myeloperoxidase;  ANCA, ant ineutrophil cytoplasm ic 
ant ibodies 
a Scored sem iquant itat ively on a scale of 0 to 3 (absent , m ild, moderate, and 
severe, respect ively)  
b
 Act iv ity score consists of the grade of f ibr inoid necrosis, cellular  crescents, 
and interst it ial inflammat ion 
c
 Chronicity score consists of the grade of f ibrous crescents, glomerular 
sclerosis, interst it ial f ibrosis and tubular atrophy 
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pat ients who were not  on dialysis (0.46 vs. 8.7 years, respect ively, P =  
0.002) . Survival with independent  renal funct ion was 47%  at  5 years 
and 26%  at  10 years ( figure 2) . 
 
Mortalit y within one year 
Of the 72 pat ients, 21 pat ients (29% )  died within one year. I n 
univariate analysis, severe renal involvem ent  was associated with early 
death (dialysis dependency at  the t im e of biopsy:  relat ive r isk (RR)  3.1, 
95%  confidence interval (CI )  1.4 – 12.6) ;  serum  creat inine > 500 
m ol/ L:  RR 4.8 (0.84 – 9.1)  when com pared to pat ients with serum  
creat inine <  120 m ol/ L) . I n m ult ivariate analysis, serum  creat inine 
was associated with m ortalit y within 12 m onths (Table 3) . 
Figure 1 . Renal biopsy findings in proteinase 3 (PR3)-  and myeloperoxidase (MPO)-ANCA 
associated glomerulonephr it is (AAGN). I n all f igures, 0 indicates no glomeruli involved;  1, 
less than 25%  of glomeruli involved;  2, 25 to 50%  of glomeruli involved;  3, 50%  or more 
of glomeruli involved. A. Glomeruli with fibr inoid necrosis. Necrosis is more common in 
PR3-AAGN (P =  0.005) . B. Glomeruli with cellular  crescents. Cellular  crescents are more 
common in PR3-AAGN (P =  0.04) . C. Glomeruli with fibrous crescents. Fibrous crescents 
are more common in MPO-AAGN (P =  0.02) . D. Sclerosed glomeruli. Glomeruli with 
global sclerosis are more common in MPO-AAGN (P =  0.05) . 
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I ndependence of renal replacem ent  therapy within one year 
Of the 17 pat ients who were dialysis dependent  at  diagnosis, five did 
not  regain renal funct ion (29% )  but  survived at  one year and four 
pat ients (24% )  died within one year without  regaining independent  
renal funct ion. Of five pat ients who regained independent  renal 
funct ion, three died within one year. I n three pat ients, who died within 
Figure 2 . Pat ient  survival ( & )  and pat ient  survival without  need for renal replacement 
therapy ( ' )  in 80 pat ients diagnosed with ANCA-associated glomerulonephr it is. Numbers 
indicate number of pat ients at r isk at  5 and 10 years after  diagnosis. 
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Table 2 . Causes of death 
 N (% )  Within one year Beyond one year 
Vasculit is 1 (3)  1 0 
I nfect ion 12 (30)  8 4 
Cardiovascular 7 (18)  4 3 
Renal insufficiency 3 (8)  0 3 
Malignancy 2 (5)  1 1 
Other 4 (10)  2  2 
Unknown 11 (28)  5 6 
Total 40 21 19 
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one year, it  was unknown whether they had regained independent  
renal funct ion. Of 51 pat ients dialysis independent  at  biopsy, seven 
pat ients (14% )  required dialysis within one year. I n 4 pat ients, dialysis 
requirem ent  at  the t im e of biopsy was unknown. With univariate 
analysis, serum  creat inine (P for t rend 0.04)  and the degree of 
interst it ial fibrosis (absent  or m ild versus m oderate or severe:  RR 4.2, 
1.1 to 34.9)  were associated with the developm ent  of renal failure 
within one year. Addit ionally, the absence of glom eruli with necrosis 
(RR 5.3, 0.84 to 16.5)  and the chronicity score (0 – 3 versus > 3:  RR 
5.3, 0.84 to 16.6)  t ended to be associated with reduced renal survival. 
I n m ult ivariate analysis, only serum  creat inine was associated with 
persistent  or renewed dialysis dependency within one year after biopsy 
(Table 4) . 
 
Long- term  pat ient  survival 
Of 46 pat ients with a follow-up of m ore than one year, 17 pat ients 
(37% )  died m ore than one year after  diagnosis. Est im ated m edian 
survival was significant ly shorter in pat ients > 65 years at  biopsy (8.3 
years)  when com pared to those < 50 years (undefined)  and those 
between 50 and 65 years of age (18.6 years;  P for t rend =  0.05) .  
Dialysis dependency at  biopsy tended to be associated with reduced 
pat ient  survival during long- term  follow-up (RR 2.7, 0.86 to 20.3) . I n 
m ult ivariate analysis, only age was associated with death (Table 3) . 
Table 4 . Predictors of renal fa ilure in m ult ivariate analysis 
Predictor RR 95%  CI  P value 
Renal fa ilure (  1  year ( N =  7 2 )     
Serum creat inine 1 µmol/ L increase 1.005 (1.001 – 1.009)  0.006 
Renal fa ilure >  1  year ( N =  4 5 )     
Not  performed    
 
Table 3 . Predictors of pat ient  m ortality in m ult ivariate analysis 
Predictor RR 95%  CI  P value 
Pat ient  m orta lity )  1  year ( N  =  7 2 )     
Serum creat inine 1 µmol/ L increase 1.002 (1.001 – 1.003)  0.001 
Pat ient  m orta lity >  1  year ( N  =  4 5 )     
Age at  biopsy 1 yr increase 1.05 (1.007 – 1.099)  0.006 
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Long- term  renal survival 
Of 46 pat ients with a follow-up of m ore than one year, 36 pat ients 
(78% )  were dialysis independent  at  one year. During long- term  follow-
up, seven pat ients (19% )  progressed to ESRD;  the m edian t im e to 
ESRD in these pat ients was 3.1 years ( range, 1.3 to 7.8 years) . I n 
univariate analysis, fem ale gender was the only factor associated with 
renal failure during follow-up (RR 6.6, 2.8 to 163) ;  serum  creat inine or 
dialysis dependency at  biopsy, and renal biopsy findings, were not  
associated with reduced renal survival in long- term  follow-up. 
Mult ivariate analysis was not  perform ed due to the low am ount  of 
events in this group. 
 
PR3-  versus MPO-ANCA during follow-up 
Eighteen of 34 pat ients (53% )  with PR3-ANCA died versus 23 of 46 
pat ients (50% )  with MPO-ANCA (P =  NS)  ( figure 3) . ANCA specificity  
was not  a r isk factor for death within or beyond one year of follow-up. 
Com paring survival without  need for renal replacem ent  therapy, 8 of 
34 pat ients (24% )  with PR3-ANCA needed RRT during follow-up versus 
17 of 46 pat ients (37% )  with MPO-ANCA (P =  NS) . ANCA specificit y 
was not  a r isk factor for  developing need for RRT within or beyond one 
Figure 3 . Survival in ANCA-associated vasculit is according to ANCA specificity. Pat ient  
survival was comparable between pat ients with proteinase 3 (PR3)-ant ineutrophil 
cytoplasm ic ant ibodies (ANCA) ( ' )  and pat ients with myeloperoxidase (MPO)-ANCA ( & ) . 
0 4 8 12 16 20
0
20
40
60
80
100
Follow - up since biopsy ( years)
P
a
ti
e
n
t 
s
u
rv
iv
a
l 
(%
)
 112   Chapter 7 
year of follow-up.  
 
Discussion 
I n the present  study, we evaluated pat ient  and renal survival in 
pat ients with ANCA-associated glom erulonephrit is during long- term 
follow-up and related these to histological findings in renal biopsies. I n 
the pat ient  populat ion we studied, the prognosis of AAV was poor;  both 
pat ient  and renal survival were low in long- term  follow-up. We found 
serum  creat inine and dialysis dependency at  t he t im e of biopsy, the 
percentage of norm al glom eruli, and the presence of m oderate or 
severe interst it ial inflam m at ion were indicat ive of developing ESRD 
within one year.  I n pat ients who developed dialysis dependency later 
on, the percentage of norm al glom eruli and the cum ulat ive chronicity 
score were predictors for reduced renal survival. We found m ore acute 
lesions in pat ients with PR3-ANCA and m ore chronic lesions in pat ients 
with MPO-ANCA. However, there was no difference in renal outcom e 
between pat ients with PR3-ANCA and pat ients with MPO-ANCA. 
The pat ient  survival in our study is lower than in previous studies 
considering pat ients with sm all- vessel vasculit is with renal involvem ent  
where it  varied from  44 to 95%  in various pat ient  groups during 
various follow-up periods5,8,10,11,14,16-18,23-26 ( table 5) . This m ay be due 
to pat ients being t reated in regional hospitals, instead of in a 
specialized center. The low am ount  of pat ients being t reated with 
plasm a exchange seem s to st rengthen this point . To analyze this 
hypothesis, we com pared pat ient  and renal survival in our previous 
study in Groningen18,  a specialized center, to survival in the Lim burg 
area. Overall pat ient  survival was significant ly lower in the Lim burg 
area (P =  0.04) , support ing our hypothesis. Survival without  need for  
renal replacem ent  therapy did not  differ between Groningen and the 
Lim burg area (data not  shown) . Addit ionally, although ANCA test ing 
becam e locally available in 1994, pat ients biopsied before that  year did 
not  have a worse pat ient  or  renal survival than pat ients biopsied since 
1994 (data not  shown) , ruling year of biopsy out  as a cause of our high 
10-year m ortalit y rate. 
Several studies have com pared renal histology of PR3-ANCA with MPO-
ANCA12,22,27- 30.  Results have varied from  com parable renal disease 
between PR3-  and MPO-ANCA12,28,29 t o m ore act ive lesions in PR3-ANCA 
and m ore chronic lesions in MPO-ANCA22 in addit ion to m ore diffuse 
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glom erulonephrit is in MPO-ANCA30.  Furtherm ore, a m ixture of both 
m ore chronic and m ore act ive lesions in pat ients with MPO-ANCA has 
also been described27.  Our study confirm s the presence of m ore act ive 
lesions in PR3-  and m ore chronic lesions in MPO-ANCA, result ing in a 
higher act ivit y score in pat ients with PR3-ANCA and a higher chronicity 
score in pat ients with MPO-ANCA. Interest ingly, the serum  creat inine 
level was com parable between PR3-  and MPO-ANCA, which has been 
described before17,22,24,30.  I n spite of this, our results support  the 
hypothesis that  already at  diagnosis m ore irreversible kidney dam age 
exists in MPO-ANCA com pared to PR3-ANCA. 
During long- term  follow-up, we could not  detect  a difference in pat ient  
or  renal survival between pat ients with PR3-  and MPO-ANCA. Pat ients 
with cytoplasm ic ANCA9 or PR3-ANCA31 have previously been described 
to have a higher r isk of pat ient  death, but  this has been disputed by 
others22,32,33.  A high PR3-ANCA level in capture ELISA is a r isk factor for 
both poor pat ient  and renal survival8,  and a consistent ly elevated MPO-
ANCA level is a r isk factor for poor renal survival as well16.  Vizjak et  al 
reported a higher rate of renal failure in MPO-  when com pared to PR3-
Table 5 . Pat ient  survival in ANCA- associated vasculit is 
Study study per iod (years)  Pat ient  survival at the 
end of study per iod 
Hedger (5)  1.8 59%  
Westman (8)  10 52%  
Wilkowski (10)  10 44%  
Andrassy (11)  3 96%  
Lit t le (14)  5 63%  
Franssen (16)  2 95%  
Cohen (17)  2.7 87%  
Slot  (18)  10 62%  
Aasarød (23)  5 74%  
Booth (24)  5 76%  
Lane (25)  5 66%  
Rihova (26)  10 62%  
Present  study 10 36%  
 
 114   Chapter 7 
ANCA30,  in cont rast  to previous studies that  reported no 
difference22,32,33,  and one study even reported a higher rate of ESRD in 
pat ients with PR3-ANCA31.  I n the present  study, 24%  of pat ients with 
PR3-ANCA developed renal failure com pared to 37%  of pat ients with 
MPO-ANCA, a difference that  was not  stat ist ically significant . 
Furtherm ore, we found no associat ion between high PR3-ANCA level 
(both direct  and capture ELISA)  at  renal biopsy and pat ient  or renal 
survival. 
To our knowledge, this is the first  study invest igat ing differences in 
renal biopsies between pat ients with PR3-  and MPO-ANCA and 
determ ining the effect  of these differences in long- term  follow-up. We 
found that  although differences existed in renal lesions, this did not  
lead to a difference in renal outcom e in pat ients with AAV. This m ay, 
however, be due to the overall poor outcom e in pat ients with AAV in 
our study m aking us unable to detect  an exist ing difference. Another 
explanat ion m ay be the different  r isk factors for developing renal 
failure in PR3-  and MPO-ANCA. In pat ients with PR3-ANCA, m ore acute 
lesions are found, which are expected to respond to t reatm ent  leading 
to a large im provem ent  in renal funct ion. However, a creat inine 
clearance above 60 m L/ m in is a r isk factor for  relapse34,  and renal 
relapse is an im portant  r isk factor for developing renal failure in 
pat ients with PR3-AAV18.  I n pat ients with MPO-ANCA, m ore chronic 
lesions are present , which are expected to result  in glom erulosclerosis.  
Glom erulosclerosis m ay lead to persistent  proteinuria, and proteinuria 
is the m ost  im portant  r isk factor for developing renal failure in pat ients 
with MPO-AAV16.    
I n conclusion, pat ient  and renal survival in ANCA-associated vasculit is 
is associated with both clinical variables and renal biopsy findings. 
There is, however, a large overlap in renal biopsy findings between 
pat ients who do and do not  develop renal failure;  therefore, renal 
biopsy alone should not  guide the intensity of t reatm ent . Furtherm ore,  
even though ANCA specificit y results in different  m orphology in renal 
biopsy;  outcom e is com parable between PR3-  and MPO-ANCA. 
 Renal biopsies and outcom e in ANCA vasculit is  115 
Acknow ledgem ents 
We would like to thank H. van Rie and P. Heerings, Clinical and 
Experim ental Im m unology, university hospital Maast r icht , for the 
excellent  collect ion of study m aterial and all part icipat ing physicians 
and pat ients for their generous cont r ibut ions to this paper ( including 
the following physicians Dr. F. de Heer and Dr. G.H. Verseput ,  
Maasland Ziekenhuis, Sit tard;  Dr.  W. Grave, Dr.  J. Wirtz, and Dr. S. 
Boorsm a, St .Laurent ius Ziekenhuis, Roerm ond;  Dr. J. Wolters and Dr. 
L.A.M. Frenken, At r ium  Medisch Cent rum , Heerlen;  Dr. E. Zeppenfelt , 
Landgraaf;  Prof. Dr. K.M.L. Leunissen, University hospital Maast r icht , 
Maast r icht ) . 
Ms. Marjan Slot  is supported by a grant  of ZonMW. 
 116   Chapter 7 
References 
1. Cohen Tervaert  JW, Goldschm eding R, Elem a JD, van der Giessen M, 
Huitem a MG, Van der Hem  GK, et  al. Autoant ibodies against  m yeloid 
lysosom al enzym es in crescent ic glom erulonephrit is. Kidney I nt  
1990; 37: 799-806. 
2. Jennet te JC, Falk RJ. Sm all-vessel vasculit is. N Engl J Med 
1997; 337: 1512-1523. 
3. Velosa JA, Hom burger HA, Holley KE. Prospect ive study of ant i-neut rophil 
cytoplasm ic autoant ibody tests in the diagnosis of idiopathic necrot izing-
crescent ic glom erulonephrit is and renal vasculit is. Mayo Clin Proc 
1993; 68: 561-565. 
4. Walton EW. Giant -cell granulom a of the respiratory t ract  (Wegener’s 
granulom atosis) . Br Med J 1958; 2: 265-270. 
5. Hedger N, Stevens J, Drey N, Walker S, Roderick P. I ncidence and 
outcom e of pauci- im m une rapidly progressive glom erulonephrit is in 
Wessex, UK:  a 10-year ret rospect ive study. Nephrol Dial Transplant  
2000; 15: 1593-1599. 
6. Hoffm an GS, Kerr GS, Leavit t  RY, Hallahan CW, Lebovics RS, Travis WD, 
et  al. Wegener’s granulomatosis:  an analysis of 158 pat ients. Ann I ntern 
Med 1992; 116: 488-498. 
7. Reinhold-Keller E, Beuge N, Latza U, Groot  de K, Rudert  H, Nolle B, et  al. 
An interdisciplinary approach to the care of pat ients with Wegener’s 
granulom atosis. Arthr it is Rheum  2000; 43: 1021-1032. 
8. Westm an KWA, Selga D, I sberg P-E, Bladst rom  A, Olsson H. High 
proteinase 3-ant i-neut rophil cytoplasmic ant ibody (ANCA)  level m easured 
by the capture enzym e- linked im m unosorbent  assay m ethod is 
associated with decreased pat ient  survival in ANCA-associated vasculit is 
with renal involvem ent . J Am  Soc Nephrol 2003; 14: 2926-2933. 
9. Hogan SL, Nachm an PH, Wilkm an AS, Jennet te JC, Falk RJ. Prognost ic 
m arkers in pat ients with ant ineut rophil cytoplasm ic autoant ibody-
associated m icroscopic polyangiit is and glomerulonephrit is. J Am  Soc 
Nephrol 1996; 7: 23-32. 
10. Wilkowski MJ, Velosa J, Holley KE, Offord KP, Chu C-P, Torres VE, et  al. 
Risk factors in idiopathic renal vasculit is and glom erulonephrit is. Kidney 
I nt  1989; 36: 1133-1141. 
11. Andrassy K, Erb A, Koderisch J, Waldherr R, Ritz E. Wegener’s 
granulom atosis with renal involvem ent :  pat ient  survival and correlat ions 
between init ial renal funct ion, renal histology, therapy and renal 
outcom e. Clin Nephrol 1991; 35: 139-147. 
12. Bajem a IM, Hagen EC, Herm ans J, Noel LH, Waldherr R, Ferrar io F, et  al. 
Kidney biopsy as a predictor for renal outcome in ANCA-associated 
necrot izing glom erulonephrit is. Kidney I nt  1999; 56: 1751-8. 
 Renal biopsies and outcom e in ANCA vasculit is  117 
13. Gans ROB, Kuizinga MC, Goldschm eding R, Assm ann K, Huysm ans FTM, 
Gerlag PGG, et  al. Clinical features and outcome in pat ients with 
glomerulonephrit is and ant ineut rophil cytoplasm ic autoant ibodies. 
Nephron 1993; 64: 182-8. 
14. Lit t le MA, Nazar L, Farr ington K. Outcom e in glomerulonephrit is due to 
system ic sm all-vessel vasculit is:  effect  of funct ional status and non-
vasculit ic co-m orbidit y. Nephrol Dial Transplant  2004; 19: 356-64. 
15. Neum ann I , Kain R, Regele H, Soleim an A, Kandusch S, Meisl FT. 
Histological and clinical predictors of early and late renal outcom e in 
ANCA-associated vasculit is. Nephrol Dial Transplant  2005; 20: 96-104. 
16. Franssen CFM, Stegem an CA, Oost -Kort  WW, Kallenberg CGM, Lim burg 
PC, Tiebosch ATMG, et  al. Determ inants of renal outcom e in ant i-
m yeloperoxidase-associated necrot izing crescent ic glom erulonephrit is. J 
Am  Soc Nephrol 1998; 9: 1915-1923. 
17. Cohen BA, Clark WF. Pauci- im m une renal vasculit is:  Natural history, 
prognost ic factors, and impact  of therapy. Am  J Kidney Dis 2000; 36: 914-
924. 
18. Slot  MC, Cohen Tervaert  JW, Franssen CFM, Stegeman CA. Renal survival 
and prognost ic factors in pat ients with PR3-ANCA associated vasculit is 
with renal involvem ent . Kidney I nt  2003; 63: 670-7. 
19. Franssen CFM, Stegem an CA, Kallenberg CGM, Gans ROB, de Jong PE, 
Hoornt je SJ, et  al. Ant iproteinase 3-  and ant im yeloperoxidase-associated 
vasculit is. Kidney I nt  2000; 57: 2195-2206. 
20. Tiebosch ATMG, Wolters J, Frederik PFM, van der Wiel TWM, Zeppenfeldt  
E, van Breda Vriesm an PJC. Epidem iology of idiopathic glom erular 
disease:  a prospect ive study. Kidney I nt  1987; 32: 112-6. 
21. van Paassen P, van Breda Vriesm an PJ, van Rie H, Tervaert  JW. Signs 
and sym ptom s of thin basem ent  m em brane nephropathy:  a prospect ive 
regional study on primary glom erular disease-The Lim burg Renal 
Regist ry. Kidney I nt  2004; 66: 909-13. 
22. Franssen CFM, Gans RO, Arends B, Hageluken C, ter Wee PM, Gerlag PG, 
et  al. Differences between ant i-m yeloperoxidase-  and ant i-proteinase 3-
associated renal disease. Kidney I nt  1995; 47: 193-9. 
23. Aasarød K, I versen BM, Ham m erst røm  J, Bostad L, Vat ten L, Jørstad S. 
Wegener's granulom atosis:  clinical course in 108 pat ients with renal 
involvem ent . Nephrol Dial Transplant  2000; 15: 611-618. 
24. Booth AD, Alm ond MK, Burns A, Ellis P, Gaskin G, Neild GH, et  al.  
Outcom e of ANCA-associated renal vasculit is:  a 5-year ret rospect ive 
study. Am  J Kidney Dis 2003; 41: 776-84. 
25. Lane SE, Wat ts RA, Shepstone L, Scot t  DG. Prim ary system ic vasculit is:  
clinical features and m ortalit y. QJM 2005; 98: 97-111. 
 118   Chapter 7 
26. Rihova Z, Jancova E, Merta M, Rysava R, Reiterova J, Zabka J, et  al. 
Long- term  outcom e of pat ients with ant ineut rophil cytoplasm ic 
autoant ibody-associated vasculit is with renal involvem ent . Kidney Blood 
Press Res 2005; 28: 144-52. 
27. Hauer HA, Bajem a IM, van Houwelingen HC, Ferrar io F, Noël L, Waldherr 
R, et  al. Renal histology in ANCA-associated vasculit is:  Differences 
between diagnost ic and serologic subgroups. Kidney I nt  2002; 61: 80-89. 
28. Jennet te JC, Wilkm an AS, Falk RJ. Ant i-neut rophil cytoplasm ic 
autoant ibody-associated glom erulonephrit is and vasculit is. Am  J Pathol 
1989; 135: 921-930. 
29. Vergunst  CE, van Gurp E, Hagen EC, van Houwelingen HC, Hauer HA, 
Noël L-H, et  al. An index for renal outcome in ANCA-associated 
glomerulonephrit is. Am  J Kidney Dis 2003; 41: 532-8. 
30. Vizjak A, Rot t  T, Koselj -Kaj tna M, Rozm an B, Kaplan-Pavlovcic S, Ferluga 
D. Histologic and im m unohistologic study and clinical presentat ion of 
ANCA-associated glomerulonephrit is with correlat ion to ANCA ant igen 
specificit y. Am  J Kidney Dis 2003; 41: 539-49. 
31. Weidner S, Geuss S, Hafezi-Racht i S, Wonka A, Rupprecht  HD. ANCA-
associated vasculit is with renal involvem ent :  an outcom e analysis. 
Nephrol Dial Transplant  2004; 19: 1403-11. 
32. Falk RJ, Hogan S, Carey TS, Jennet te JC. Clinical course of ant i-
neut rophil cytoplasm ic autoant ibody-associated glom erulonephrit is and 
system ic vasculit is. The Glom erular Disease Collaborat ive Network. Ann 
I ntern Med 1990; 113: 656-63. 
33. Geffr iaud-Ricouard C, Noel LH, Chauveau D, Houhou S, Grunfeld JP, 
Lesavre P. Clinical spect rum  associated with ANCA of defined ant igen 
specificit ies in 98 selected pat ients. Clin Nephrol 1993; 39: 125-136. 
34. Stegem an CA, Cohen Tervaert  JW, Sluiter WJ, Manson WL, de Jong PE, 
Kallenberg CGM. Associat ion of chronic nasal carr iage of Staphylococcus 
aureus and higher relapse rates in Wegener granulom atosis. Ann I ntern 
Med 1994; 120: 12-17. 
  
 
Chapter 8 
A posit ive C-ANCA t iter at  switch to 
azathioprine therapy is associated with 
a disquiet ing relapse rate in PR3-ANCA-
related vasculit is  
Slot  MC, Cohen Tervaert  JW, Boom sm a MM, Stegem an CA 
 
Arthrit is Rheum  2004; 51: 269-73 
 120   Chapter 8 
Object ive.  To analyze disease- free survival in pat ients with ANCA-
associated sm all- vessel vasculit is (AAV)  t reated with cyclophospham ide 
only or switched to azathioprine after 3 m onths of full rem ission with 
cyclophospham ide. 
Methods. Analysis of disease- free survival in all consecut ive pat ients 
diagnosed with ANCA-related sm all- vessel vasculit is between 1990 and 
2000 at  our center,  who were followed at  least  12 m onths, and t reated 
with cyclophospham ide only (1990-1996)  or switched to azathioprine 
after  3 m onths of rem ission on cyclophospham ide (1997-2000) . 
Results.  I ncluded were 128 pat ients of whom  44 (34% )  switched to 
azathioprine. Fift y- three pat ients (41% )  relapsed. Actuarial disease-
free survival at  2 and 4 years was 76%  and 65%  in the 
cyclophospham ide group com pared to 76%  and 51%  in the 
azathioprine group (RR 1.4, 95%  CI  0.8-2.7;  p= 0.20) . I n pat ients with 
PR3-ANCA associated vasculit is switched to azathioprine (n= 33)  a 
posit ive C-ANCA t iter at  the m om ent  of t reatm ent  switch (n= 13)  was 
significant ly associated with the occurrence of relapse (RR 2.6, 95%  CI  
1.1 -  8.0;  p= 0.04) . I n pat ients with a negat ive ANCA t iter at  the t ime 
of switch to azathioprine, disease- free survival at  2 and 4 years was 
80%  and 62% , which was ident ical to pat ients t reated with 
cyclophospham ide only. I n pat ients who were ANCA posit ive at  the 
t im e of t reatm ent  switch disease- free survival at  2 and 4 years was 
only 58%  and 17% . 
Conclusion. Switching cyclophospham ide to azathioprine after  
induct ion of rem ission in pat ients with PR3-ANCA associated vasculit is 
who are st ill ANCA posit ive at  the t im e of t reatm ent  switch is 
associated with a high r isk of developing relapses. 
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Sm all vessel vasculit ides, such as Wegener’s Granulom atosis (WG)  and 
m icroscopic polyangiit is (MPA) , are st rongly associated with 
ant ineut rophil cytoplasm ic ant ibodies (ANCA) , which are either directed 
to m yeloperoxidase (MPO)  or proteinase 3 (PR3) 1-3.  ANCA-associated 
vasculit is (AAV)  can occur in any organ system ;  the respiratory t ract  
and the kidney are m ost  frequent ly involved. Unt reated, these diseases 
have a dism al prognosis. Since the int roduct ion of cyclophospham ide 
and prednisolone as t reatm ent  regim en, survival has im proved 
dram at ically from  less than 20%  at  1 year4 to 60 – 90%  at  10 years5-7.   
Although life-saving in m any pat ients, t reatm ent  with 
cyclophospham ide is associated with severe m orbidity and m ortality,  
both at  short - term  and during long- term  follow-up. Alternat ive 
m aintenance regim ens have been proposed to reduce 
cyclophospham ide exposure8.  The European m ult icent re CYCAZAREM 
study showed that  switching cyclophospham ide to azathioprine after 
induct ion of rem ission does not  lead to m ore relapses within 18 m onths 
after  diagnosis com pared to m ore prolonged cyclophospham ide therapy 
(12 m onths)  in pat ients with AAV9.  Although the long- term  safety has 
not  been established, this switching is widely adopted in the t reatm ent  
of pat ients with AAV. In our center,  we adopted this switching regim en 
in 1996. We had the impression, however, that  relapses occurred m ore 
frequent ly after  \HDUV RI IROORZ-up when pat ients with AAV were 
switched to azathioprine. To address this issue, we analyzed pat ients 
diagnosed with AAV, t reated at  our center with cyclophospham ide and 
switched to azathioprine after induct ion of rem ission, and com pared 
long- term  outcom e with a historical cont rol group that  was t reated with 
cyclophospham ide only.  
 
Pat ients and Methods 
Pat ients 
All pat ients, diagnosed between 1990 and 2000 with AAV, followed at  
our center with \HDUIROORZ-up, and t reated with cyclophospham ide 
only (1990 – 1996)  or switched to azathioprine after induct ion of 
rem ission (1997 – 2000)  were included. All pat ients fulfilled the Chapel 
Hill definit ions of WG, MPA, Churg-St rauss syndrom e or renal lim ited 
vasculit is10,  in addit ion to the presence of PR3-  or MPO-ANCA. Pat ients 
were prospect ively followed unt il Decem ber 2001. 
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Treatm ent  
The t reatm ent  consisted of oral cyclophospham ide (2 m g/ kg)  and 
prednisolone (1 m g/ kg body weight )  daily with a m axim al oral 
prednisolone dose of 60 m g/ day11.  Doses of cyclophospham ide were 
adjusted to m aintain the leukocyte count  above 4 x 109/ L. After  4 to 6 
weeks, the daily prednisolone dose was tapered by 10 m g every 2 
weeks unt il the dose reached 30 m g, and thereafter by 5 m g every 2 to 
4 weeks. Once rem ission was achieved the daily dose of oral 
cyclophospham ide was tapered by 25 m g every 3 m onths (1990-
1996) , result ing in a t reatm ent  durat ion of approxim ately 18 m onths. 
From  1997 onwards, pat ients were switched to azathioprine (2 m g/ kg 
body weight  daily)  after  at  least  three m onths of therapy and induct ion 
of rem ission with cyclophospham ide. Azathioprine was then tapered by 
25 m g every 3 m onths, result ing in a t reatm ent  durat ion of 
approxim ately 21 m onths. Actual durat ion of t reatm ent  was calculated 
unt il m edicat ion was stopped, or unt il pat ients were diagnosed with a 
relapse, whichever cam e first .   
 
Detect ion of ANCA 
ANCA were detected by indirect  im m unofluorescence ( I IF)  as described 
previously12.  ANCA t iters were analyzed by serial dilut ions of sera 
start ing at  1: 20. Sera were considered posit ive for ANCA when staining 
was present  in at  least  a 1: 40 dilut ion and a cytoplasm ic pat tern (C-
ANCA)  in pat ients diagnosed with PR3-ANCA associated vasculit is, or  
an atypical or perinuclear pat tern (P-ANCA)  in pat ients diagnosed with 
MPO-ANCA associated vasculit is. I n all pat ients, the presence of PR3-  
or MPO-ANCA was confirm ed by ant igen-specific enzym e- linked 
im m unosorbent  assay (ELISA) 2.  ANCA t iters were recorded every 4 to 6 
weeks. 
 
Definit ions 
Rem ission was defined as the absence of clinical signs and sym ptom s 
of act ive vasculit is (Birm ingham  Vasculit is Act ivit y Score (BVAS) 13 =  0) , 
and a norm al C- react ive protein11.  A relapse was defined as clinical 
signs of vasculit ic act ivit y in com binat ion with biopsy proven vasculit ic 
disease act ivit y, or the occurrence of nodular pulm onary lesions after  
exclusion of infect ious or m alignant  diseases. Renal vasculit ic disease 
was defined as biopsy proven necrot izing glom erulonephrit is or a 
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com binat ion of m icroscopic glom erular erythrocyturia, erythrocyte cell 
casts, proteinuria and a decrease in creat inine clearance14.   
 
Stat ist ical analyses 
Data are presented as m ean ±  standard deviat ion unless stated 
otherwise. Cont inuous data between groups were com pared using 
Student ’s t - test  and the Wilcoxon signed rank test  when appropriate. 
Survival curves were calculated using Kaplan-Meier est im ates for  
survival dist r ibut ion. Differences between groups in survival were 
analyzed with log- rank test  with disease- free survival as dependent  
variable. End point  for survival analysis was the occurrence of relapse. 
Pat ients without  a relapse were censored at  31 Decem ber 2001, or 
death, whichever cam e first . 
The prim ary planned analyses were the associat ion of t reatm ent  with 
cyclophospham ide only or cyclophospham ide switched to azathioprine 
and relapse- free survival in the whole group of pat ients with AAV, and 
the PR3-  and MPO-ANCA groups separately. Secondary analyses 
included the influence of ANCA posit ivit y at  6 and 12 m onths, and at  
the m om ent  of t reatm ent  switch from  cyclophospham ide to 
azathioprine on relapse- free survival. Analyses were perform ed with 
GraphPad Prism  version 3.00 (GraphPad Software Inc., San Diego, CA) . 
A two-sided p-value < 0.05 was considered to indicate stat ist ical 
significance. 
 
Results 
Between January 1990 and January 2000, 128 consecut ive pat ients 
were eligible for entering the study. Median follow-up was 5.3 years 
( range 1.0 – 11.5 years) . Ninety- three pat ients (73% )  were posit ive for  
PR3-ANCA, whereas 35 pat ients (27% )  were posit ive for MPO-ANCA. 
Forty- four pat ients (34% )  were switched to azathioprine after a m edian 
follow-up of 0.48 years ( range 0.23 – 1.43 years)  after diagnosis. Ten 
pat ients, who switched to azathioprine, had also been included in the 
CYCAZAREM t r ial. Pat ients who switched to azathioprine were 
significant ly younger than pat ients who rem ained on cyclophospham ide 
(n =  84)  ( table 1) . As expected, durat ion of t reatm ent  was significant ly 
longer in pat ients who were switched to azathioprine. Otherwise, the 
two groups did not  differ with respect  to clinical characterist ics ( table 
1) . 
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Fift y- three pat ients (41% )  experienced at  least  one non- renal or renal 
relapse. Actuarial disease- free survival at  2 and 4 years was 76%  and 
65% , respect ively, in the cyclophospham ide group com pared to 76%  
and 51%  in the group switched to azathioprine ( relat ive r isk (RR) for 
relapse 1.4, 95%  CI  0.8 – 2.7;  p =  0.20)  ( figure 1) . I n pat ients with 
PR3-ANCA (n =  93)  and MPO-ANCA associated vasculit is (n =  35)  no 
significant  difference in disease- free survival between the t reatm ent  
lim bs was observed ( figure 2) . However, relapses were m ore frequent ly 
observed in pat ients with PR3-ANCA as com pared to MPO-ANCA 
specificit y (RR 3.2, 95%  CI  1.4 – 4.4;  p =  0.002) .  
 
A posit ive ANCA t iter  at  6 or 12 m onths after diagnosis was not  
significant ly associated with the occurrence of a relapse (data not  
shown) . However, when analyzed according to ANCA specificit y, a 
posit ive C-ANCA t iter in I IF at  12 m onths tended to be associated with 
the occurrence of a relapse with RR 1.7 (95%  CI  0.9 – 3.0, p =  0.11)  
when com pared to a negat ive C-ANCA t iter at  12 m onths in pat ients 
with PR3-ANCA associated vasculit is.  
Table 1 . Pat ient  characterist ics in t reatm ent  groups 
Variable Cyclophosphamide only 
(n =  84)  
Treatment  switch to 
azathiopr ine 
(n =  44)  
PR3-ANCA specificity 60 (73% ) 33 (75% ) 
Age at  diagnosis*  57 ±  13 48 ±  18† 
Male gender 54 (64% ) 26 (59% ) 
BVAS at  diagnosis*  22 ±  8 24 ±  10 
Pulmonary involvement  48 (57% ) 23 (52% ) 
Renal involvement  62 (74% ) 37 (84% ) 
ENT involvement  64 (76% ) 34 (77% ) 
Durat ion of t reatment  (years)   
Cyclophosphamide /  azathioprine*  1.38 ±  0.53 1.82 ±  0.54‡ 
Prednisolone*  1.20 ±  0.46 1.20 ±  0.46 
*  Values are mean ±  SD.  PR3, proteinase 3;  ANCA, ant ineutrophil cytoplasm ic 
ant ibodies;  BVAS, Birm ingham vasculit is act iv ity score;  ENT, ear nose throat . 
†
 p =  0.002 when compared to pat ients who were t reated with cyclophosphamide only 
‡
 p < 0.0001 when compared to pat ients t reated with cyclophosphamide only 
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Figure 1 . Disease- free survival in 128 pat ients diagnosed with ANCA-associated 
vasculit is, according to t reatment  limb. There is no significant  difference in disease-free 
survival between pat ients t reated with cyclophosphamide only ( & ) , and pat ients switched 
to azathiopr ine ( * ) . 
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Figure 2 . Disease- free survival in 128 pat ients diagnosed with ANCA-associated 
vasculit is, according to ANCA specificity and t reatment  switch. There is no significant 
difference in disease- free survival in MPO-ANCA associated vasculit is between pat ients 
t reated with cyclophosphamide only ( & ) , or  switched to azathiopr ine ( * ) . Sim ilar ly, there 
is no difference in PR3-ANCA associated vasculit is between pat ients treated with 
cyclophosphamide only ( + ) , or  switched to azathiopr ine ( ' ) . Disease- free survival in 
MPO- and PR3-ANCA associated vasculit is however is significant ly different . 
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Thirty- three pat ients with PR3-ANCA associated vasculit is switched 
from  cyclophospham ide to azathioprine following at  least  3 m onths of 
com plete rem ission. Nineteen pat ients of these 33 (58% )  relapsed, of 
which 10 pat ients were st ill t reated with azathioprine at  the occurrence 
of a relapse. Thirteen pat ients (39% )  of the 33 pat ients switched to 
azathioprine had a posit ive C-ANCA t iter in I IF at  the m om ent  of 
t reatm ent  switch. I n baseline clinical characterist ics, these pat ients did 
not  differ from  pat ients who were C-ANCA negat ive at  t reatm ent  switch 
( table 2) . Ten of 13 pat ients, C-ANCA-posit ive at  t reatm ent  switch, 
relapsed. Mean BVAS at  relapse was 11 ±  3 ( range 7 – 18) ;  in 3 
pat ients (30% ) , the relapse was renal. Eight  pat ients (80% )  were 
t reated with cyclophospham ide and steroids again. A posit ive C-ANCA 
t iter at  t reatm ent  switch was significant ly associated with the 
Table 2 . Pat ient  characterist ics in PR3 - ANCA associated vasculit is. 
Variable Cyclophosphamide 
only 
(n =  60)  
Azathiopr ine 
ANCA negat ive 
at  switch 
(n=  20)  
Azathiopr ine 
ANCA posit ive 
at  switch 
(n= 13)  
Age at  diagnosis* † 57 ±  11 47 ±  19 43 ±  16 
Male gender 42 (70% ) 13 (65% ) 8 (62% ) 
BVAS at  diagnosis*  23 ±  8 25 ±  10 27 ±  10 
Pulmonary involvement  33 (55% ) 11 (55% ) 8 (62% ) 
Renal involvement  43 (72% ) 16 (80% ) 11 (85% ) 
ENT involvement  55 (92% ) 16 (80% ) 12 (92% ) 
Durat ion of t reatm ent  ( years)  
Cyclophosphamide pr ior  
to switch*  
N/ A 0.49 ±  0.21 0.55 ±  0.32 
Cyclophosphamide /  
azathiopr ine* ‡ 
1.5 ±  0.8 1.9 ±  0.6 1.8 ±  0.5 
Prednisolone*  1.2 ±  0.4 1.0 ±  0.3 1.3 ±  0.4 
*  Values are mean ±  SD. PR3, proteinase 3;  ANCA, ant ineutrophil cytoplasm ic 
ant ibodies;  BVAS, Birm ingham Vasculit is Act iv ity Score;  ENT, ear nose throat ;  N/ A, 
not  applicable. 
†
 Age was significant ly higher in pat ients t reated with cyclophosphamide only but  
not  significant ly different  in pat ients who were ANCA posit ive versus pat ients who 
were ANCA negat ive. 
‡
 p =  0.004 for the overall comparison 
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occurrence of a relapse (RR 2.6, 95%  CI  1.1 – 8.0;  p =  0.04) . I n 
pat ients who were t reated with cyclophospham ide only, there was no 
associat ion between a posit ive C-ANCA t iter at  6 m onths and the 
occurrence of a relapse (data not  shown) . Disease- free survival at  2 
and 4 years after diagnosis was 58%  and 17% , respect ively, in 
pat ients who were posit ive for C-ANCA at  t reatm ent  switch ( figure 3) . 
I n cont rast , pat ients who switched to azathioprine and were negat ive 
at  the m om ent  of t reatm ent  switch had a disease- free survival of 80%  
and 62%  at  2 and 4 years, respect ively, which was nearly ident ical to 
pat ients t reated with cyclophospham ide only ( figure 3) . 
 
Discussion 
After the CYCAZAREM t r ial, switching to azathioprine after  induct ion of 
rem ission is widely adopted as t reatm ent  regim en, since the 
CYCAZAREM t r ial showed that  switching cyclophospham ide to 
azathioprine in AAV does not  result  in m ore relapses within 18 m onths 
after  diagnosis com pared to cont inued cyclophospham ide therapy9.  
I ndeed, in our study, the relapse rate is sim ilar between the two 
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Figure 3 . Disease- free survival in 93 pat ients diagnosed with PR3-ANCA associated 
vasculit is, according to t reatment  limb. ( * )  indicates pat ients posit ive for ANCA at  
t reatment  switch to azathiopr ine, ( , )  pat ients negat ive for ANCA at  switch. ( - )  indicates 
pat ients t reated with cyclophosphamide only.  
 128   Chapter 8 
t reatm ent  lim bs unt il 18 m onths ( figure 3) . Our results are com parable 
with the CYCAZAREM study:  at  18 m onths, 10%  of our pat ients 
switched to azathioprine had relapses versus 16%  in the CYCAZAREM 
study;  in pat ients t reated with cyclophospham ide only relapse rate at  
18 m onths was 10%  and 17%  in our study and the CYCAZAREM study, 
respect ively.  
Differences between our study and the CYCAZAREM t r ial do, however, 
exist . Our study is a non- random ized ret rospect ive study com paring 
groups that  have been t reated according to two t reatm ent  regim ens 
that  have been consequent ly used in two sequent ial t im e periods. 
Despite this pat ients switched or not  switched from  cyclophospham ide 
to azathioprine were com parable with respect  to clinical and disease 
characterist ics. Our study has the advantage of longer follow-up after 
diagnosis and thus is able to show that  the excess in relapse rate in 
pat ients t reated with azathioprine does not  occur unt il after 2 years. 
Several surveys on outcom e in ANCA-associated vasculit is have been 
perform ed in which pat ients are usually t reated with cort icosteroids 
and cyclophospham ide ( in som e pat ients switched to azathioprine) 11,15-
17
.  I n these studies, reported m ean disease- free survival varies from  
9.8 to 27 m onths after  rem ission (m edian 21.8 m onths) . Follow-up in 
the CYCAZAREM study did not  exceed 18 m onths and therefore m ay 
have been too short  for detect ion of a difference in relapse rates. 
Second, in the CYCAZAREM t r ial, no dist inct ion has been m ade 
between PR3-  and MPO-ANCA related vasculit is. We have analyzed 
relapse rate in relat ion to ANCA specificit y and we found that  this is 
relevant , because in pat ients with PR3-ANCA associated vasculit is the 
relapse rate is significant ly higher than pat ients with MPO-ANCA 
associated vasculit is. Third, cont inuat ion of cyclophospham ide therapy 
differed between our study and the cyclophospham ide limb of the 
CYCAZAREM t r ial. We t reated pat ients with AAV with cyclophospham ide 
for 15 – 18 m onths, whereas in the CYCAZAREM t r ial pat ients were 
t reated with cyclophospham ide for 12 m onths. 
I n our study, there was a significant ly higher relapse rate in pat ients 
switching to azathioprine who had a posit ive C-ANCA t iter at  t reatm ent  
switch. However, if pat ients were to rem ain on t reatm ent  with 
cyclophospham ide, ser ious drug toxicity may occur. Besides, 3 
pat ients, posit ive for  C-ANCA when t reatm ent  switch is considered, 
need to rem ain on cyclophospham ide to avoid one relapse. On the 
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other hand, our data show that  pat ients, who are C-ANCA negat ive by 
I IF after 3 m onths of com plete rem ission on cyclophospham ide, can 
safely be switched to azathioprine without  an increased rate of relapses 
during long- term  follow-up. 
As m ost  relapses occur during or short ly after t apering of azathioprine, 
prolonged therapy with azathioprine m ay also be an opt ion. I n the 
present  study, m ean durat ion of t reatm ent  with azathioprine was 
within two years. I n REMAIN, a second-wave t r ial by the European 
Vasculit is Study Group (EUVAS) , long- term  (4 years)  low dose 
im m unosuppressive therapy will be com pared to the standard of two 
years of t reatm ent 18.  Although this study is mainly designed to study 
pat ients in whom  a second episode of renal vasculit is would seriously 
threaten their renal survival, results m ight  be ext rapolated to all 
pat ients with ANCA-associated vasculit is. 
Other t reatm ent  regim ens for m aintenance therapy have been 
proposed, for instance, switching of cyclophospham ide to m ethot rexate 
(MTX) . I n an open- labeled study by Langford et  al.19 in 31 pat ients with 
Wegener’s granulom atosis, this led to a disease- free survival rate of 
84%  at  a m edian follow-up of 16 m onths (m axim um  disease- free 
survival was 49 m onths) . On the other hand, a study by Reinhold-
Keller et  al. showed that  pat ients who were switched to MTX had a high 
rate of renal relapse20.  However, these studies have not  considered the 
influence of ANCA t iters at  t reatm ent  switch on the occurrence of a 
relapse. 
A fourth opt ion in the t reatm ent  of pat ients with PR3-ANCA associated 
vasculit is m ay be intensificat ion of induct ion therapy with the at tem pt  
to deplete circulat ing ANCA, for instance, with plasm a exchange (PE) 21,  
or ant i-CD20 therapy22.  PE has been shown to increase survival in 
pat ients with renal failure at  diagnosis21.  To our knowledge, benefit  of 
PE on relapse rate has not  been reported. Ant i-CD20 therapy as 
induct ion therapy for a relapse led to the disappearance of C-ANCA and 
com plete rem ission in a pat ient  with WG22.  Another opt ion to intensify 
induct ion therapy m ay be ant i-TNF targeted therapy;  a random ized, 
placebo-cont rolled t rial of etanercept  plus standard therapy in WG has 
recent ly started23.  
I n conclusion, our data challenge the safety of switching 
cyclophospham ide to azathioprine in pat ients with PR3-ANCA 
associated vasculit is who are st ill posit ive for  ANCA. Whether 
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alternat ive t reatm ent  regim ens can prevent  relapses in this subgroup 
of pat ients is unclear. Based on our findings, we postulate that  C-ANCA 
response during rem ission induct ion and early follow-up m ay provide a 
powerful tool for r isk-adjusted t reatm ent  regim ens. 
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Aim  of the study. Many pat ients surviving vasculit is are prone to 
accelerated atherosclerosis and often have enhanced levels of ant ibodies 
to oxidized low-density lipoprotein (oxLDL) . To m easure ant i-oxLDL 
ant ibodies, oxidat ion of LDL is achieved with copper (Cu)  or 
malondialdehyde (MDA). Since in vivo,  LDL may be oxidized with 
myeloperoxidase (MPO)  or its product  hypochlorite, we measured ant i-
hypochlorite LDL ant ibodies in pat ients with vasculit is, hem odialysis 
pat ients, and healthy controls.  
Methods. A newly developed ELISA-m ethod was used to detect  
ant ibodies to oxLDL as modified by hypochlorite. Results are compared 
with data obtained by standard LDL oxidat ion using MDA-LDL or Cu-LDL 
as subst rate. Results were compared between ant ineutrophil cytoplasmic 
ant ibodies (ANCA)-associated vasculit is (AAV) pat ients (n= 93) , 
hem odialysis (HD) pat ients (n= 59)  and healthy controls (HC;  n= 43) . 
Furtherm ore, pat ients with MPO-ANCA associated vasculit is (n= 47)  were 
compared with pat ients with PR3-ANCA associated vasculit is (n= 46) . 
Opt imal cut -off points were determ ined by ROC-curve analysis. 
Results. Ant i-oxLDL ant ibodies are enhanced in AAV pat ients (MDA-LDL 
and hypochlorite-LDL)  and in HD pat ients (hypochlorite-LDL) , when 
compared to HC. Furthermore, pat ients with MPO-ANCA associated 
vasculit is had higher levels of ant ibodies to hypochlorite-LDL than 
pat ients with PR3-ANCA associated vasculit is. 
Conclusion . Our newly developed assay, in which hypochlorite-LDL is 
used as subst rate, seem s a m ore sensit ive assay than t radit ional assays 
to m easure oxLDL ant ibodies. Furtherm ore, our results suggest  that  
enhanced MPO-m ediated LDL oxidat ion occurs in pat ients with MPO-
ANCA reflect ing the idea that  circulat ing MPO-ANCA prevents inact ivat ion 
of circulat ing MPO act ivity by its natural inhibitor ceruloplasmin. 
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Sm all vessel vasculit is, such as Wegener ’s granulom atosis (WG)  and 
m icroscopic polyangiit is (MPA)  are st rongly associated with ant i-
neut rophil cytoplasm ic ant ibodies (ANCA)  which are either directed to 
proteinase 3 (PR3)  or to m yeloperoxidase (MPO) 1-3.  ANCA associated 
vasculit is (AAV)  pat ients have an increased risk to develop accelerated 
atherosclerosis4,5 and to experience subsequent  cardiovascular 
events6,7.  Atherosclerosis is generally considered an inflam m atory 
disease8,  and chronic inflam m at ion is a prom ot ing factor for  
progression of atherosclerosis toward cardiovascular events9.  
Ant ibodies to oxidized low density lipoproteins (oxLDL)  are useful 
m arkers for atherosclerosis10,  and levels of these ant ibodies are 
increased in AAV at  diagnosis11.  Detect ion of ant ibodies to oxLDL can 
be accom plished by oxidat ion of LDL in vit ro by exposing LDL to 
m alondialdehyde (MDA) , a react ive aldehyde generated during lipid 
oxidat ion and result ing in adduct  form at ion on apoB10010.  
Alternat ively, LDL can be oxidized in vit ro by copper10,12.  An interest ing 
in vivo pathway for  LDL oxidat ion is catalyzed by MPO, a hem e enzym e 
present  in neut rophilic granulocytes. MPO catalyses the generat ion of 
several react ive oxidants, leading to products which have been found in 
atherosclerot ic lesions13,14.  I t  is the only known enzym e capable of 
producing the highly toxic hypochlorite in vivo in the presence of 
chloride and hydrogen peroxide (H2O2) . 
MPO is not  only int racellularly act ive. MPO is also released into the 
ext racellular space after act ivat ion of granulocytes. Here, enzym e 
act ivit y is inhibited by ceruloplasmin, a copper binding protein which 
at taches to the act ive site of MPO and hence regulates MPO enzym e 
act ivit y in the circulat ion15.  MPO-ANCA, isolated from  AAV pat ients, is 
capable of part ially reversing this MPO- inact ivat ion16.   
We hypothesize that  pat ients who are prone to accelerated 
atherosclerosis have ant ibodies to hypochlorite-m odified LDL. 
Furtherm ore, we hypothesize that  in MPO-AAV pat ients, but  not  in PR3-
AAV pat ients, increased circulat ing MPO act ivit y m ay result  in enhanced 
LDL m odificat ion by hypochlorite and subsequent  generat ion of 
ant ibodies specific for hypochlorite-m odified LDL epitopes. 
To test  these hypotheses, we analyzed ant i-oxLDL ant ibody levels in 93 
consecut ive AAV pat ients with pauci- im m une crescent ic 
glom erulonephrit is, 59 hem odialysis pat ients and 43 healthy cont rols. 
Forty-seven of the AAV pat ients had MPO-ANCA and 46 had PR3-ANCA. 
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Ant i-oxLDL ant ibody levels were m easured using hypochlorite-m odified 
LDL as well as MDA-  and copper-m odified LDL. 
 
Methods 
Pat ients 
Pat ients included in this study had biopsy-proven pauci- immune 
crescent ic glomerulonephrit is without  evidence of system ic lupus 
erythematosus (SLE) , IgA nephropathy, Henoch Schönlein purpura, 
post- infect ious glomerulonephrit is (GN) , cryoglobulinaemia, or ant i-
glomerular basem ent  m embrane (GBM) nephrit is17.  Only pat ients whose 
biopsy showed act ive lesions (either at  the first  disease episode or at  
relapse)  were included. Serum samples, taken at  the t ime of biopsy, 
were tested for the presence of ANCA. Ninety- three pat ients with ANCA 
associated glom erulonephrit is (AAGN) were included in this study, 46 of 
which had PR3-ANCA and 47 had MPO-ANCA;  pat ients with both PR3-  
and MPO-ANCA and those with both MPO-ANCA and ant i-GBM ant ibodies 
were excluded. As disease controls we used sera from all pat ients who 
are rout inely dialyzed at  the hem odialysis (HD) unit  in the university 
hospital Maast richt  (n= 59) . Pat ients with renal failure due to AAV were 
excluded from this lat ter group. Addit ionally, 43 healthy controls (HC;  
laboratory personnel)  were tested. This study was perform ed in 
accordance with the 1997 Declarat ion of Helsinki of the World Medical 
Associat ion. 
 
LDL isolat ion and preparat ion of oxidized LDL 
LDL was isolated from plasma of a healthy subject  by ult racentrifugat ion 
in a KBr discont inuous gradient  according to Redgrave et  al18. KBr and 
EDTA were rem oved by rapid filt rat ion through disposable desalt ing 
columns (Econo-Pac 10 DG, Bio-Rad, Hercules, USA). The LDL protein 
content  was determ ined according to Lowry et  al19. Nat ive LDL was 
either freshly used for preparat ion of oxLDL or stored at  4°C in PBS 
under N2,  with 1 mg/ m l EDTA as a preservat ive. 
MDA-LDL was prepared as described by Palinski et  al10;  in brief, 0.5 M 
MDA (Merck, Darm stadt , FRG)  was added to LDL in a rat io of 100 l 
per m g LDL and incubated for 3 hours at  37°C. After rem oval of 
unbound MDA by exclusion chrom atography, MDA-LDL was stored at  
4°C in PBS/ EDTA under N2 after  sterile filt rat ion. 
Copper oxidat ion (Cu-LDL)  was perform ed by incubat ing a 0.2 m g/ m l 
 Preferent ial recognit ion of hypochlorite-LDL in AAV  137 
solut ion of LDL in PBS with 20 µM CuCl2 for 20 hours at  37°C;  react ion 
was stopped by adding 100 µM EDTA.  
Hypochlorite m odificat ion (hypochlorite-LDL)  was done by coat ing 100 l 
of nat ive LDL, diluted to 100 g/ m l in PBS, in m icrot iter plates (Nunc 
MaxiSorp™, Nalge Nunc, Rochester, NY)  overnight  at  4°C and, after 
washing three t im es with PBS, incubat ing half of each plate for two 
hours at  4°C in a solut ion of 36 M sodium hypochlorite (Sigma, 
St .Louis, MO) in PBS;  the other half of the plate was incubated in PBS. 
Incubat ion was followed by a threefold wash with PBS to stop the 
react ion, and plates were stored in PBS at  4°C for m aximal 2 hours 
before start ing the ELISA. Opt imal concent rat ion of hypochlorite was 
determ ined using a serial dilut ion and subsequent  test ing of ant ibody 
react ivity (data not  shown) .  
 
ELI SA for the detect ion of ant ibodies against  MDA-LDL, Cu-LDL and 
hypochlorite-LDL 
Nat ive LDL and MDA-LDL or Cu-LDL were diluted to 100 g / m l in PBS, 
and 100 l/ well was incubated in m icrot iter plates (Nunc)  overnight  at  
4°C;  for detect ion of ant ibodies to hypochlorite-LDL, nat ive LDL was 
coated before hypochlorite modificat ion as described above. Wells were 
then washed 5 t imes with a buffer containing 0.01 M Tris, 0.15 M NaCl 
and 0.05 %  Tween 20 (pH 8.0)  followed by incubat ion in t riplicate with 
pat ient  serum  in a 1: 100 dilut ion, 100 µl/ well, in buffer containing 0.1 M 
Tris, 0.3 M NaCl and 0.05 %  Tween 20 (pH 8.0)  and kept  overnight  at  
4°C;  a posit ive cont rol was used on each plate to test  for int ra assay 
variat ion. The next  day, plates were washed 5 t imes with washing buffer 
and incubated with alkaline phosphatase conjugated goat  F(ab’) 2 ant i-
human IgG ( specific conjugate (American Qualex, San Clem ente, CA) , 
diluted 1: 3000 in incubat ion buffer, for 1 hour at  37°C. After washing 5 
t imes with washing buffer, 100 l of freshly made subst rate containing 1 
mg/ m l of nit rophenyl phosphate (Sigma)  in diethanolamine buffer at  pH 
9.8 was added to each well. After 30 m inutes on a shaking plat form at  
room  temperature, plates were read at  405 nm. Results are expressed 
as m ean ant i-oxLDL levels in opt ical density (OD) from  t riplicate 
determ inat ions and were calculated by subt ract ing binding to nat ive LDL 
from binding to oxLDL. All results were obtained with nat ive and oxLDL 
preparat ions that  were stored for less than two weeks. 
 
 138   Chapter 9 
Stat ist ical analyses 
All data are presented as m edian [ range]  unless stated otherwise. 
Kruskal-Wallis test  was used for comparing values of healthy controls 
and ANCA pat ients, and Dunn’s post- test  was used for test ing 
differences between MPO-ANCA and PR3-ANCA groups. Receiver 
operator characterist ic (ROC) curves were used to calculate appropriate 
cut-off values. Analyses were perform ed with SPSS version 11.0.1 (SPSS 
Inc., Chicago, I L) . A two-sided p-value ≤0.05 was considered to indicate 
stat ist ical significance. 
 
Results  
Ant i-oxLDL ant ibody detect ion in pat ients with AAV, hem odialysis 
pat ients, and healthy cont rols. 
We first  confirm ed previous findings that  ant ibody levels to oxLDL are 
increased in AAV pat ients by using MDA-oxidized LDL as ant igen11. Ant i-  
MDA-LDL ant ibody levels are higher in AAV pat ients than in healthy 
cont rols (0.250 vs. 0.131;  P< 0.001)  and/ or HD pat ients (0.250 vs. 
0.164;  P= 0.001;  Figure 1A) . Ant ibody levels in HD pat ients were not  
significant ly higher than in HC. 
Next , we evaluated a second comm only used LDL oxidat ion procedure, 
i.e. copper oxidat ion. This did not  reveal a significant  difference in ant i-
Cu-LDL ant ibody levels between AAV pat ients (0.035) , HD pat ients 
(0.021)  or HC (0.032;  Figure 1B) . 
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Figure 1 A. Ant i-MDA-LDL react ivity is significant ly higher in pat ients with ANCA-associated 
vasculit is (AAV) compared to healthy controls (HC) and chronic hemodialysis pat ients (HD). 
HD pat ients are comparable to HC. Lines represent median values. 
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Third, we evaluated a new m ethod for oxidat ion of LDL by using 
hypochlorite. The difference in ant i-hypochlorite-LDL ant ibody levels 
between AAV pat ients (0.598)  and healthy controls (0.389)  was 
stat ist ically highly significant  (P< 0.001;  Figure 1C) . As for MDA-LDL, 
ant ibody levels against  hypochlorite-LDL were significant ly higher in AAV 
pat ients compared to HD pat ients (0.598, and 0.468, respect ively, 
P< 0.001) . I nterest ingly, detect ion of ant ibody levels against  
hypochlorite-LDL also enabled discrim inat ion between HD pat ients and 
HC (0.468 and 0.389, respect ively, P= 0.03) . 
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Figure 1 B. Ant i-Cu-LDL react ivity is comparable between HC, pat ients with AAV, and HD 
pat ients. Lines represent median values. 
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Figure 1 C. Ant i-hypochlorite-LDL react ivity is significant ly higher in pat ients with AAV 
compared to HD pat ients and HC. React ivity is also slight ly higher in HD pat ients compared 
to HC. Lines represent median values. 
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Finally, we determ ined the discrim inat ing performance of the respect ive 
assays for AAV pat ients, HD pat ients, and HC using ROC curve analysis 
(Figure 2) . The ROC curves of hypochlorite-  and MDA-LDL were almost  
ident ical and revealed, in contrast  to the ROC curve of Cu-LDL, the 
ability to discrim inate between the different  study populat ions. For 
comparison we analyzed the number of posit ive samples (sensit ivity)  
from  AAV pat ients and HD pat ients at  a cut-off linked to an arbit rarily 
chosen specificity of 88.4%  (5 HC posit ive for ant i-oxLDL;  Table 1) . With 
this given specificity, sensit ivity is highest  using hypochlorite-LDL (53 of 
93 AAV pat ients posit ive (57.0% ;  OR 10.1, 95%  CI  3.6 – 27.9, 
P< 0.001) . Addit ionally, 21 of 59 HD pat ients were posit ive (35.6% ;  OR 
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Figure 2 . ROC curves of ANCA pat ients vs. healthy controls. Assay sensit iv ity in 
comparing AAV pat ients to healthy controls is higher using hypochlor ite-modified LDL or 
MDA-modified LDL than using copper-modified LDL.  
Table 1 . Sensit ivity of the three ant i oxLDL assays at  a  given 
specificity 
ant igen cut -off OD value %  specificity %  sensit iv ity 
ANCA vs. HC    
MDA-LDL 0.242 88.4 54.8 
Cu-LDL 0.108 88.4 18.3 
Hypochlor ite-LDL 0.559 88.4 57.0 
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4.2, 95%  CI  1.4 – 12.3, P= 0.006) . With MDA-LDL, 51 AAV pat ients were 
posit ive (54.8% ;  OR 9.2, 95%  CI  3.3 – 25.5, P< 0.001)  and 9 HD 
pat ients were posit ive (15.3% ;  NS) . Finally, while using Cu-LDL we 
found only 17 AAV pat ients (18.3% ) and 9 HD pat ients (15.3% )  posit ive 
(Table 1) . 
 
AAV pat ients with MPO -ANCA have higher ant ibody levels to 
hypochlorite m odified LDL than pat ients with PR3-ANCA 
Ant ibody levels to the different  oxLDL ant igens were com pared 
between pat ients with MPO-ANCA and PR3-ANCA. Ant i-MDA-LDL 
ant ibody levels were not  different  in MPO-AAV pat ients (0.250)  in 
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Figure 3 A. Ant i-MDA-LDL react ivity is comparable between pat ients with MPO-ANCA and 
pat ients with PR3-ANCA. Lines represent median values. 
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Figure 3 B. Ant i-Cu-LDL react ivity in pat ients with MPO-ANCA is significant ly higher 
compared to pat ients with PR3-ANCA. Lines represent median values. 
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com parison with PR3-AAV pat ients (0.256;  Figure 3A) . Using cut-off 
values as presented in Table 1, twenty- five of 46 PR3-AAV pat ients 
(54% ) were posit ive compared to 26 of 47 MPO-AAV pat ients (55% ;  
NS) . Using Cu-LDL as an ant igen, a significant  difference was found 
between MPO-AAV pat ients (0.052)  and PR3-AAV pat ients (0.025;  
P= 0.03;  Figure 3B) . Thirteen of 47 MPO-AAV pat ients (28% ) were 
posit ive compared to 4 of 46 PR3-AAV pat ients (8.7% , OR 4.0, 95%  CI  
1.2 – 13.5, P= 0.03) . The use of hypochlorite- t reated LDL resulted in 
significant ly increased ant ibody levels in MPO-AAV pat ients (0.697)  
versus PR3-AAV pat ients (0.507;  P< 0.001;  Figure 3C) . MPO-AAV 
pat ients more often had ant i-hypochlorite-LDL ant ibodies (34 of 47, 
72% ) compared to PR3-AAV pat ients (19 of 46, 41% ;  OR 3.7, 95%  CI  
1.6 – 8.8, P= 0.003) . 
In conclusion, modificat ion of LDL with hypochlorite perform s best  when 
different iat ing between both groups of AAV pat ients. 
 
Discussion 
Our results show that  ant ibody levels to hypochlorite m odified LDL are 
significant ly increased when com paring AAV pat ients and HD pat ients 
to healthy cont rols and that  these ant ibodies are m ore increased in 
pat ients with MPO-AAV than in pat ients with PR3-AAV. When 
com paring our new m ethod for  oxidat ion of LDL with previously 
established m ethods, we found that  hypochlorite-LDL and MDA-LDL are 
equally sensit ive for detect ion of ant i-oxLDL ant ibodies in AAV pat ients, 
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Figure 3 C. Ant i-hypochlorite-LDL react ivity is significant ly higher in pat ients with MPO-
ANCA compared to pat ients with PR3-ANCA. Lines represent median values. 
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while hypochlorite-LDL, but  not  MDA-LDL, enabled detect ion of ant i-
oxLDL ant ibodies in HD pat ients. Cu-LDL lacked sensit ivit y in both 
pat ient  populat ions. The increase in ant i-oxLDL ant ibodies, as detected 
by hypochlorite-LDL, in MPO-AAV pat ients in com parison to PR3-AAV 
pat ients was also observed by using Cu-LDL. However, the results 
obtained with Cu-LDL were stat ist ically less significant . 
These results are in accordance with our hypothesis that  the MPO-
catalyzed pathway of LDL oxidat ion is increased in pat ients with 
accelerated atherosclerosis. Several pathways for  MPO-catalyzed 
m odificat ion of LDL have been described indicat ing that  both the 
protein and lipid part  are affected, which processes seem  to interact .  
Oxidat ion of the apoB100 part  of LDL act ivates lipid peroxidat ion20,21 
while the lat ter can lead to protein alterat ions20,22.  I n the presence of 
NO, MPO generates react ive nit rogen species init iat ing lipid 
peroxidat ion23,24,  and in the presence of chloride and H2O2,  MPO 
catalyses chlorinat ion of unsaturated fat ty acids and phospholipids25,26 
and conversion of LDL-cholesterol into chlorinated sterols13.  However, 
protein m odificat ion seem s to play a m ore pronounced role. Podrez24 
reported tyrosine nit rat ion, while tyrosine chlorinat ion was described by 
Hazen13 in turn causing form at ion of dityrosyl in the apoB100 part  of 
LDL27-29.  Cysteine, m ethionine, lysine and t ryptophan are also targets 
of MPO-catalyzed m odificat ion30-32.  Another effect  of tyrosyl radical 
form at ion is the prom ot ion of peroxidat ion of the lipid part  of LDL21.  
MPO-derived epitopes on LDL are at  least  in part  different  from  those 
generated by copper-  and MDA- t reatm ent ;  this is reflected in the 
above study where we showed that  the use of hypochlorite- t reated LDL 
to detect  autoant ibodies results in a m ore sensit ive assay to 
different iate between different  groups of pat ients. I n atherosclerosis 
pat ients, ant i-oxLDL ant ibody levels are com m only tested using 
copper-  or MDA- t reated LDL as the ant igen of choice. I ndeed, in HD 
pat ients, ant ibodies against  both ant igens are increased33,34 and these 
ant ibodies are thought  to m irror the presence of atherosclerosis34,  a 
well- known com plicat ion in these pat ients35,36.  I n our study, ant i-
hypochlorite-LDL levels were increased in HD pat ients, whereas ant i-
MDA-LDL and ant i-Cu-LDL levels were not , indicat ing that  our 
hypochlorite-LDL m ethod m ay be a m ore sensit ive test  for  
atherosclerosis. Further studies are needed to see whether the use of 
hypochlorite- t reated LDL is a useful tool for  this purpose. 
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Previously, we dem onst rated enhanced levels of ant ibodies to MDA-
m odified LDL in vasculit is pat ients com pared to healthy cont rols11.  I n 
the present  study, we confirm  these findings in a m uch larger cohort  of 
pat ients. Furtherm ore, we found that  pat ients with MPO-ANCA have 
higher levels of ant i-oxLDL ant ibodies than pat ients with PR3-ANCA, 
when using hypochlorite-m odified LDL as an ant igen. The presence of 
MPO-ANCA seem s to influence the form at ion of ant ibodies to 
hypochlorite-m odified LDL. These ant i-MPO ant ibodies are thought  to 
reverse inact ivat ion of MPO by ceruloplasm in result ing in persistent  
MPO act ivit y in the circulat ion which m ight  result  in oxidat ion of LDL in 
blood vessels16,37.  I n HD pat ients, MPO act ivit y increases during dialysis 
t reatm ent  as we have shown previously38;  this m ay have sim ilar 
consequences as the presence of MPO-ANCA. 
In conclusion, the use of hypochlorite m odified LDL has advantage over 
other m odificat ions of LDL when detect ing ant ibodies to oxLDL. Overall, 
our newly developed assay proved to be a m ore sensit ive assay to 
m easure these ant ibodies than the t radit ional assays in which LDL is 
m odified by MDA or copper. By using our new assay, we found 
enhanced levels of autoant ibodies to oxLDL in MPO-AAV pat ients when 
com pared to PR3-AAV pat ients, suggest ing that  MPO-ANCA m ay 
interfere with MPO inhibit ion by ceruloplasm in. Our study also suggests 
that  m easuring ant ibodies to hypochlorite-modified LDL m ay be a 
useful addit ion for test ing ant i-oxLDL ant ibodies in pat ients who are 
suspected of accelerated atherosclerosis. 
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Object ive .  Previous studies have suggested accelerated 
atherosclerosis in ant ineut rophil cytoplasmic ant ibodies (ANCA)-
associated vasculit is (AAV) . I n this study, we analyzed the num ber of 
circulat ing CD4+ CD28null T cells in relat ion to the presence of 
atherosclerot ic dam age in pat ients with AAV. Furtherm ore, we 
determ ined whether ant ibodies against  cytom egalovirus (CMV)  and 
hum an Heat  Shock Protein 60 (hHSP60)  were related to the presence 
of CD4+ CD28null T cells in AAV. 
Methods.  Forty pat ients with inact ive AAV were included in this study. 
Pat ients’ spouses were recruited as healthy cont rols (HC, N= 38) . 
I nt im a-m edia thickness ( IMT)  and pulse wave velocity (PWV)  were 
m easured. Addit ionally, CD4+ CD28null T cells, ant i-CMV and ant i-
hHSP60 levels were determ ined. 
Results.   CD4+ CD28null T cells are present  in pat ients with AAV in a 
higher percentage (m edian 3.1, range 0.01 – 85)  than in HC (0.28, 0 – 
36, P< 0.0001) . There was a st rong correlat ion between a previous CMV 
infect ion and the presence and percentage of CD4+ CD28null T cells 
(Spearm an r =  0.76, P < 0.0001) . No significant  difference in IMT 
between pat ients and cont rols was detected (m ean 0.77 ±  standard 
deviat ion 0.15 and 0.73 ±  0.11, respect ively, P= 0.20) . PWV 
standardized for MAP, however, was increased in AAV pat ients (9.80 ±  
2.50, com pared to 8.72 ±  1.68 in HC, P= 0.04) . We could not  detect  a 
direct  relat ionship between CD4+ CD28null T cells and/ or a previous CMV 
infect ion and higher IMT or PWV values. There was no relat ion between 
ant i-hHSP60 and CD4+ CD28null T cells. 
Conclusions.  There is evidence of atherosclerot ic dam age in pat ients 
with AAV. Plaque size, however, did not  seem  to differ.  CD4+ CD28null T 
cells are relat ively increased in AAV and related to previous CMV 
infect ion.  
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Sm all vessel vasculit ides, such as Wegener’s granulom atosis (WG)  and 
m icroscopic polyangiit is (MPA) , are st rongly associated with ANCA, 
which are either directed to m yeloperoxidase (MPO)  or proteinase 3 
(PR3) 1-3.  These diseases can occur in any organ system  but  the 
respiratory t ract  and the kidneys are m ost  frequent ly involved. 
Unt reated, WG results in death within weeks to m onths. Since the 
int roduct ion of cyclophospham ide and prednisolone as standard 
t reatm ent , survival has im proved dram at ically from  less than 20%  at  1 
year reported in 19584 to at  least  60%  5-years survival reported in the 
past  ten years5- 8.  
With prolonged survival, pat ients m ay experience long- term  sequelae 
as a result  of their vasculit is or it s t reatm ent 6,7,9.  Several studies have 
shown that  in long- term  follow-up, cardiovascular disease is a m ajor 
cause of m ortalit y in pat ients with AAV5,8,10-16.  Furtherm ore, the annual 
incidence of m yocardial infarct ion in pat ients with AAV is m uch higher 
than in the background populat ion17.   
Atherosclerosis is now widely regarded as an inflam m atory disease18,  
and chronic inflam m at ion seem s to be im portant  in the progression of 
atherosclerosis19.  Several studies dem onst rated that  signs of 
atherosclerosis are apparent  in pat ients with ANCA-associated 
vasculit is (AAV) . Endothelial dysfunct ion, the earliest  stage of 
atherosclerosis18,  is present  during act ive disease in pat ients with 
prim ary system ic vasculit is20.  Furtherm ore, ant ibodies against  oxidized 
low-density lipoprotein (oxLDL) , a m arker for progression of 
atherosclerosis21,  are also present  in act ive vasculit is22.  Ant ibodies 
against  hum an Heat  Shock Protein 60 (hHSP60)  are another m arker 
elevated in both atherosclerosis and vasculit is23-25.  
I n pat ients with unstable angina and m yocardial infarct ion, the 
expansion of an unusual subset  of CD4+  T cells has been described26,27.  
I nterest ingly, these cells have been found in WG as well28.  The lack of 
the CD28 m olecule on these cells suggests repeated ant igenic 
exposure, with cytom egalovirus (CMV)  and hHSP60 as candidate 
ant igens29,30.  CD4+ CD28null T cells have acquired a cytotoxic phenotype, 
with expression of perforin and granzym e B, and have been shown to 
be cytotoxic to endothelial cells. These T cells m ay have a role in 
accelerat ing the atherosclerot ic process in pat ients with WG. In this 
study, we analyzed the num ber of circulat ing CD4+ CD28null T cells in 
relat ion to the presence of atherosclerot ic dam age in pat ients with 
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AAV. Furtherm ore, we determ ined whether ant ibodies against  CMV and 
hHSP60 were related to the presence of CD4+ CD28null T cells in AAV. 
 
Methods 
Subjects 
Pat ients with AAV, who visited the outpat ient  clinic of our hospital, 
were included in this study. All pat ients fulfilled the disease definit ions 
for  WG, MPA, and Churg St rauss syndrom e as proposed by the Chapel 
Hill Consensus Conference31.  Only pat ients with inact ive disease, as 
evaluated by the Birm ingham  Vasculit is Act ivit y score (BVAS) 32,  were 
included. Pat ients’ spouses were recruited as cont rol subjects. The local 
m edical ethics com m it tee approved of the study. Writ ten inform ed 
consent  was obtained from  each subject . 
The t radit ional r isk factors for atherosclerosis assessed were the 
presence or absence of a fam ily history of prem ature cardiovascular 
disease (cardiovascular event  before the age of 60 years) , sm oking 
status (pack years) , t he presence of hypertension (as defined by a 
blood pressure of at  least  140 m m Hg systolic or 90 m m Hg diastolic, or  
the use of ant ihypertensive m edicat ions, at  the study visit ) , the 
presence of diabetes m ellitus, and cholesterol and t r iglyceride levels. 
All subjects were interviewed using a standardized data-collect ion 
form . Previous and current  m edicat ion use was assessed through 
pat ient  interviews and chart  review.  
 
Laboratory analyses 
Ant i-CD3, ant i-CD4 and ant i-perforin m onoclonal ant ibodies were 
purchased from  Becton Dickinson (Franklin Lakes, NJ) . Ant i-CD28 
m onoclonal ant ibodies were purchased from  Beckm an Coulter  
(Fullerton, CA) . The sim ultaneous presence of CD3, CD4, CD28 and 
perforin was evaluated on peripheral blood m ononuclear cells using 4-
color flow cytom et ry (FACSCalibur, BD)  and analyzed using CellQuest  
software (BD) . Addit ionally, we tested the presence of CD25, HLA-Dr, 
and killer cell im m unoglobulin- like receptors (KIR2DS1 and KIR2DS2)  
(BD) . 
Ant ibodies against  hHSP60 were determ ined as described previously33.  
I n short , ELISA plates were coated with recom binant  hHSP60 
(St ressgen, Victoria, Canada)  overnight  at  4°C. For blocking of 
nonspecific binding, wells were incubated the next  day with coat ing 
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buffer and again left  overnight  at  4°C. The third day, plates were 
preincubated with preincubat ion buffer for one hour, washed, incubated 
with pat ient  serum  in 1: 50 dilut ion, and kept  overnight  at  4°C. The 
fourth day, plates were incubated with goat  F(ab’) 2 ant i-hum an IgG 
(Fc) -horseradish peroxidase conjugate (Cappel- ICN Im m unobiologicals, 
Costa Mesa, CA) , for 2 hours at  room  tem perature. Then 100 L of 
freshly m ade subst rate (containing o-Phenylenediamine (Sigm a) )  was 
added to each well. After 10 m inutes, the react ion was stopped with 
H2SO4 and absorbances were read at  490 nm . Results are expressed as 
ant i-hHSP60 levels in arbit rary units (AU)  / mL. The cut -off value for 
this test  was previously established at  80 AU/ m L. 
Ant i-CMV ant ibodies were determ ined using the axSYM m icropart icle 
enzym e im m unoassay (Abbot t  Laboratories, Abbot t  Park, I L) . Results 
are expressed as ant i-CMV levels in AU/ m L. The cut -off value for this 
test  is 15 AU/ m L. 
 
Measurem ent  of the int im a-m edia thickness 
The carot id int im a-m edia thickness ( I MT)  was determ ined in the 
com m on carot id artery (CCA)  segm ent  10 m m  to 20 m m  proxim al to 
the t ip of the flow divider. B-m ode im ages of t he CIMT were acquired 
for  the predefined 10 m m  segm ent  of the r ight  and left  CCA at  defined 
interrogat ion angles using Meijers Arc. Standard im ages were obtained 
from  4 angles at  each side. The m ean IMT of the far walls was 
determ ined from  a single enddiastolic B-m ode im age at  each 
interrogat ion angle for both the r ight  and left  CCA with an autom ated 
edge- t racking m ethod (M’Ath version 2.0.1.0, METRIS, Paris, France) .  
Addit ionally, the largest  IMT value in the predefined segm ent  was 
noted for  both the left  and the r ight  CCA. 
 
Measurem ent  of the pulse wave velocity 
Pulse pressure waveform s were recorded from  the radial and fem oral 
artery using the Com plior® SP (Colson, France) . Pulse wave velocity 
was then calculated between the carot id and fem oral artery, and the 
carot id and radial artery. The average of ten m easurem ents was used. 
As PWV is related to blood pressure, and blood pressure was 
significant ly higher in the HC, we did not  only com pare PWV between 
pat ients and cont rols, but  also PWV corrected for the m ean arterial 
pressure (MAP) , standardized at  a MAP of 94 (PWV@94) , as this was 
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the m ean MAP in AAV pat ients. Ant ihypertensive m edicat ion was 
cont inued in all subjects. 
 
Stat ist ical analyses 
All data are presented as m ean ±  standard deviat ion unless stated 
otherwise. Cont inuous data between groups were com pared using 
Student ’s t  t est  and Wilcoxon signed rank test , ANOVA and Kruskal-
Wallis test  with Dunn’s post - test  when appropriate. Due to the 
perceived relevance of the results, we did not  only perform  Dunn’s 
post - test  for subgroup analysis, but  we also com pared subgroups using 
Wilcoxon signed rank test . Correlat ions between data were derived 
using Spearm an correlat ion. Odds rat ios (OR)  and 95%  confidence 
intervals (CI )  were obtained using Fisher’s exact  test . Analyses were 
perform ed with GraphPad Prism  version 4.00 and GraphPad Instat  
software package version 2.04a (both GraphPad Software Inc., San 
Diego, CA) . A two-sided p-value < 0.05 was considered to indicate 
stat ist ical significance. 
 
Results 
Pat ient  characterist ics 
Forty pat ients with AAV and 38 healthy cont rols were included. Mean 
age was 56.4 ±  10.5 in pat ients and 54.4 ±  9.7 in HC. Fifty- five 
percent  of the pat ients were m ale com pared to 45%  of HC. The 
t radit ional risk factors for atherosclerosis are presented in table 1. 
These risk factors for atherosclerosis differed between pat ients and 
cont rols as pat ients had a higher body m ass index, m ore often had 
hypertension (as defined by a blood pressure of at  least  140 m m Hg 
systolic or 90 m m Hg diastolic, or the use of ant ihypertensive 
m edicat ions, at  the study visit ) , higher t r iglyceride levels, and a lower 
blood pressure. Addit ionally, pat ients had significant ly higher CRP 
levels than HC (8.0 and 2.2, respect ively, P =  0.0002)  even though 
only pat ients in clinical rem ission had been selected. 
Median disease durat ion was 2.6 years ( range, 0.6 to 16.3 years, table 
2) . Twenty-one pat ients had had one or m ore relapses. All but  one 
pat ient  had used prednisolone;  34 pat ients had used cyclophospham ide 
and 36 pat ients had used azathioprine. 
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Higher percentage of circulat ing CD4+ CD28null T cells in ANCA-
associated vasculit is 
I n pat ients with AAV, the percentage of circulat ing CD4+ CD28null T cells 
was significant ly higher (m edian 3.1, range 0.01 – 85)  than in HC 
(m edian 0.28, range 0 – 36, table 3) . I nterest ingly, the absolute 
num ber of CD4+ CD28null T cells did not  differ  between pat ients and 
cont rols (m edian 9.8, range 0.02 – 377 per m L in pat ients and 1.5 (0 – 
321)  in cont rols) . CD8+ CD28null T cells did not  differ between pat ients 
and cont rols, both as percentage and as absolute cell count  ( table 3) .  
Table 1 . Clinical characterist ics and r isk factors in pat ients and 
healthy cont rols*  
 Pat ients (N =  40)  Controls (N =  38)  P-value 
Age, years 56.4 ±  10.5 54.4 ±  9.7 0.38 
Male 22 (55)  17 (45)  0.50 
Risk factors    
Smoking    
ever 24 (60)  18 (47)  0.36 
pack years 13.5 ±  18.1 12.0 ±  18.2 0.53 
BMI  27.8 ±  5.1 25.7 ±  3.6 0.04 
DM 5 (13)  1 (2.6)  0.20 
Current  hypertension 23 (58)  8 (21)  0.001 
systolic 130 ±  18 138 ±  18 0.04 
diastolic 76 ±  10 82 ±  10 0.01 
MAP 94 ±  11 101 ±  11 0.01 
Total cholesterol 5.85 ±  0.97 5.86 ±  0.99 0.96 
HDL 1.49 ±  0.33 1.55 ±  0.40 0.48 
LDL 3.61 ±  1.01 3.57 ±  0.91 0.85 
Tr iglycer ides 2.09 ±  1.23 1.63 ±  0.87 0.06 
Fam ily history 10 (25)  14 (37)  0.22 
CRP level 8.0 ±  10.4 2.2 ±  2.5 0.0002 
* Values are given as mean ±  standard deviat ion or N (% )  
BMI , Body Mass I ndex;  DM, diabetes mellitus;  MAP, mean arter ial pressure;  
HDL, high-density lipoprotein;  LDL;  low-density lipoprotein;  CRP, C-react ive 
protein 
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Addit ional FACS analysis showed that  CD4+ CD28null T cells were CD25 
negat ive, perforin posit ive, and to som e extent  posit ive for  HLA-Dr and 
KIR2DS1 and KIR2DS2 ( figure 1) . 
 
CD4+ CD28null T cells in AAV are related to ant i-CMV but  not  to ant i-
hHSP60 ant ibodies 
As ant igenic specificit y of CD4+ CD28null T cells has been described to be 
for  hHSP60 and CMV, we determ ined the relat ionship between 
ant ibodies against  these ant igens and the presence of CD4+ CD28null T 
cells. Prevalence of ant ibodies against  hHSP60 was com parable 
between pat ients and cont rols ( table 3) . The prevalence of CMV 
Table 2 . Disease characterist ics in ANCA- associated vasculit is*  
Character ist ic AAV (N =  40)  
Disease durat ion, years 2.6 (0.6 – 16.3)  
ANCA specificity  
PR3 23 (58)  
MPO 10 (25)  
both 1 (3)  
none 6 (15)  
Disease subtype  
Wegener ’s granulomatosis 25 (63)  
MPA 7 (18)  
Churg-Strauss syndrome 4 (10)  
Renal- lim ited vasculit is 4 (10)  
Renal involvement  18 (45)  
Cumulat ive medicat ion  
Prednisolone (g)  7.6 (0 – 80.2)  
Cyclophosphamide (g)  18.0 (0 – 302)  
Azathiopr ine (g)  34.2 (0 – 303)  
Number of relapses 1 (0 – 5)  
Number of pat ients with relapses 21 (53)  
* Values are given as median (range)  or N (% )  
AAV, ANCA-associated vasculit is;  ANCA, Ant ineutrophil cytoplasm ic ant ibodies;  
PR3, proteinase 3;  MPO, myeloperoxidase;  MPA, m icroscopic polyangiit is 
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infect ion was com parable between pat ients and cont rols as well ( table 
3) . We could not  detect  a correlat ion between ant ibodies against 
hHSP60 and the presence or percentage of CD4+ CD28null T cells. 
However, there was a st rong correlat ion between a previous CMV 
infect ion and the presence and percentage of CD4+ CD28null T cells 
(Spearm an r =  0.76, P < 0.0001) . I nterest ingly, AAV pat ients with a 
previous CMV infect ion had a significant ly higher percentage of 
CD4+ CD28null T cells than HC with a previous CMV infect ion (P =  0.006,  
figure 2) . 
 
Carot id int im a-m edia thickness is not  increased in pat ients with ANCA-
associated vasculit is 
Both the left  and the r ight  com m on carot id artery were evaluated for 
the presence of early atherosclerot ic dam age. Results of the IMT 
m easurem ents are presented in table 4. Pat ients with AAV did not  have 
a significant ly higher I MT com pared to HC (0.77 ±  0.15 and 0.73 ±  
0.11 in the r ight  CCA, respect ively, P =  0.20) . As the I MT was not  
always hom ogenous in pat ients with AAV, the m axim um  IMT value was 
addit ionally determ ined;  these also did not  differ between pat ients and 
Table 3 . Laboratory evaluat ion  
Test  AAV pat ients 
(N =  40)  
HC 
(N =  38)  
P 
Flow  cytom etry    
%  CD4+ CD28null T cells 3.1 (0.01 – 85)  0.3 (0 – 36)  0.003 
CD4+ CD28null cells/ µL 9.8 (0.02 – 377)  1.5 (0 – 321)  0.68 
%  CD8+ CD28null T cells 28 (0.91 – 92)  21 (4.5 – 71)  0.19 
CD8+ CD28null cells/ µL 36 (1.1 – 539)  63 (14 – 547)  0.08 
ELI SA    
Ant i-hHSP60 19 (0 – 256)  18 (0 – 491)  0.98 
Posit ive (% )  6 (15)  5 (13)  1.0 
Ant i-CMV 176 (0 – 250)  5 (0 – 250)  0.20 
Posit ive (% )  24 (60)  18 (47)  0.36 
AAV, Ant ineutrophil cytoplasmic ant ibody-associated vasculit is;  HC, healthy 
controls;  ELI SA, enzyme- linked immunosorbent  assay;  ant i-hHSP60, ant ibodies 
against  human Heat  Shock Protein 60;  ant i-CMV, ant ibodies against  
cytomegalovirus 
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cont rols ( table 4) . 
 
Pulse-wave velocity is increased in pat ients with ANCA-associated 
vasculit is 
To determ ine vascular elast icit y, pulse-wave velocity was m easured 
over the carot id- fem oral and carot id- radial arterial segm ents. Since 
PWV is related to the blood pressure, and blood pressure was 
significant ly higher in our HC, we standardized the PWV in both groups 
 
Figure 1 . FACS analysis of CD4+ CD28null T cells. CD4+ CD28null T cells lack expression of 
CD25 (upper left ) . On the other hand, they are posit ive for perfor in ( lower left ) . Subsets 
of CD4+ CD28null T cells express HLA-Dr (upper r ight )  and CD158b (a marker for killer  cell 
immunoglobulin- like receptors, lower r ight ) . 
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Figure 2 . CD4+ CD28null T cells in healthy controls and vasculit is pat ients. CD4+ CD28null T 
cells are relat ively more often present  in pat ients with ANCA-associated vasculit is (AAV)  
who have had a cytomegalovirus (CMV) infect ion (ACMV+ ) . However, they are also 
present  in healthy controls with a previous CMV infect ion (HCMV+ ). I n AAV pat ients and 
controls without  a previous CMV infect ion, CD4+ CD28null T cells are scarcely detected 
(ACMV- and HCMV-, respect ively) . 
at  a MAP of 94 and com pared both PWV and PWV@94. Fem oral PWV 
was com parable between AAV pat ients and controls, as was radial PWV 
( table 4) . However, when PWV values were corrected for MAP, fem oral 
Table 4 . Vascular tests in pat ients and healthy controls*  
 Pat ients Controls P-value 
I MT    
Right , mean 0.77 ±  0.15 0.73 ±  0.11 0.20 
Right , max 1.027 ±  0.20 0.98 ±  0.13 0.22 
Left , mean 0.73 ±  0.12 0.72 ±  0.11 0.59 
Left , max 0.96 ±  0.18 0.96 ±  0.14 0.99 
PW V    
Femoral 9.73 ±  2.76 9.27 ±  2.18 0.44 
Femoral@94 9.80 ±  2.50 8.72 ±  1.68 0.04 
Radial 8.86 ±  1.40 8.47 ±  1.91 0.32 
Radial@94 8.88 ±  1.42 8.07 ±  1.89 0.02 
* All values are mean ±  standard deviat ion 
I MT, int ima media thickness;  PWV, pulse-wave velocity;  Femoral@94, 
Femoral PWV standardized at a MAP of 94;  Radial@94, Radial PWV 
standardized at  a MAP of 94. 
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PWV was higher in AAV pat ients (9.80 ±  2.50, com pared to 8.72 ±  
1.68 in HC, P =  0.04) . Addit ionally, radial PWV@94 was higher in 
pat ients with AAV (8.88 ±  1.42)  than in HC (8.07 ±  1.89, P =  0.01) . 
 
CD4+ CD28null cells and previous CMV infect ion not  associated with 
increase in I MT or PWV 
Previously, an increase in I MT was described in pat ients with 
rheum atoid arthrit is who had an increased percentage of CD4+ CD28null 
T cells33.  However, we could not  detect  a difference in IMT between 
subjects with > 5%  CD4+ CD28null T cells and subjects with < 5% . 
Furtherm ore, PWV m easurem ents also did not  differ between pat ients 
with a high or low percentage of CD4+ CD28null T cells. Addit ionally, we 
could not  detect  a difference between pat ients and cont rols with or 
without  a previous CMV infect ion. 
 
Discussion 
I n the present  study, we determ ined the presence of early 
atherosclerot ic dam age, com paring carot id IMT and fem oral and radial 
PWV between AAV pat ients and healthy age-  and sex-m atched 
volunteers. No difference in IMT between pat ients and cont rols was 
detected. PWV standardized for MAP, however, was increased in AAV 
pat ients, suggest ing accelerat ion of atherosclerosis com pared to 
healthy cont rols. Furtherm ore, CD4+ CD28null T cells were found to be 
present  in pat ients with AAV in a higher percentage com pared to 
cont rols and were found to be related to a previous CMV infect ion. No 
direct  relat ionship, however, between CD4+ CD28null T cells and IMT 
and/ or PWV was found. 
Pat ients with AAV who survive the acute phase of their vasculit is often 
die of cardiovascular disease in long- term  follow-up5,8,10-16.  I n addit ion, 
pat ients with AAV have a higher incidence of m yocardial infarct ion than 
their background populat ion17.  During act ive vasculit is endothelial 
dysfunct ion can be dem onst rated20.  Furtherm ore, Booth et  al recent ly 
described a higher PWV in pat ients with AAV during act ive disease but  
not  during rem ission34.  I n our study, we found higher PWV in pat ients 
with quiescent  disease corrected for MAP. The num ber of pat ients with 
AAV in rem ission (N =  16) , as studied by Booth et  al34,  was relat ively 
sm all com pared to our study group, and as PWV was slight ly higher in 
their pat ients in rem ission group com pared to t heir HC, this difference 
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m ay not  have reached stat ist ical significance due to the sam ple size. 
Recent ly, de Leeuw et  al studied IMT in pat ients with WG (N =  29)  and 
com pared findings to m atched cont rols35.  With B-m ode evaluat ion, no 
differences were found in m ean IMT levels between pat ients and 
cont rols. When evaluat ing m axim um  IMT levels, they did detect  higher 
IMT values in WG pat ients. I n the present  study, however, we did not  
find differences in m ean or m axim um  IMT levels in our larger cohort  of 
AAV pat ients when com pared to healthy cont rols. The finding that  IMT 
and/ or PWV between pat ients and their spouses did show only m inor 
differences is surprising. Risk factors for  cardiovascular disease 
between the two groups differed largely and pat ients with AAV did have 
prolonged periods of inflam m at ion, which are supposed to accelerate 
the atherosclerot ic process. We hypothesize that  cytostat ic therapy 
with cyclophospham ide and/ or azathioprine m ay have protected our 
pat ients with AAV since these drugs m ay influence the developm ent  of 
atherosclerot ic lesions20,34 as has been found in pat ients with SLE36.  On 
the other hand, increase in body weight , hypertension and diabetes 
m ellitus are well- known side-effects of the use of cort icosteroids and 
also r isk factors for developing atherosclerosis. I n fact , a recent  study 
by Wei and colleagues showed that  taking glucocort icoids by 
prescript ion is associated with an increase of cardiovascular events37.  
The increased incidence of m yocardial infarct ion in AAV without  an 
increase in IMT and only m arginal differences in PWV raises the 
possibilit y that  it  is not  plaque size but  plaque stabilit y that  m ay be 
different  between AAV pat ients and healthy subjects. Liuzzo and 
colleagues reported the presence of CD4+ CD28null T cells in pat ients 
with unstable angina or m yocardial infarct ion. CD4+ CD28null T cells are 
resistant  to apoptosis and the percentage of these cells rem ains 
rem arkably stable during follow-up38.  Furtherm ore, these cells are 
cytotoxic for endothelial cells39 and produce large am ounts of interferon 
40
,  both factors that  are relevant  for  plaque instabilit y. I nterest ingly, 
these cells had only invaded the “culprit  plaques” ,  i.e., plaques that  
have ruptured and seem ed to have caused m yocardial infarct ion. 
Pat ients with AAV have an increased percentage of circulat ing 
CD4+ CD28null T cells. So, we postulate that  although plaque size is 
com parable between pat ients and cont rols, the increase in 
CD4+ CD28null T cells in AAV pat ients m ay result  in an increased 
propensity for m yocardial infarct ion. I t  m ay therefore be interest ing to 
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look at  the presence of rupture-prone plaques in pat ients and 
cont rols41.  
The reason why CD4+ CD28null T cells are relat ively increased in AAV is 
not  yet  clear.  Previous studies suggested that  hHSP60 and/ or CMV m ay 
be candidate ant igens that  are recognized by these T cells29,30.  I n our 
study, we could not  detect  an associat ion between CD4+ CD28null T cells 
and the presence of ant i-hHSP60 ant ibodies. A previous CMV infect ion, 
however, was highly associated with the presence of CD4+ CD28null T 
cells. The percentage of CD4+ CD28null T cells was even higher in AAV 
pat ients with a previous CMV infect ion com pared to the percentage of 
these cells in healthy cont rols with a previous CMV infect ion. This m ay 
be due to (subclinical)  CMV react ivat ion in AAV pat ients with a previous 
CMV infect ion, caused by the im m unosuppressive therapy that  is 
needed to cont rol act ive vasculit is. The lack of the CD28 m olecule on 
CD4+ CD28null T cells suggests repeated ant igenic exposure30,  
support ing this hypothesis. I nterest ingly, CMV infect ion has been 
associated with the presence of atherosclerosis as well42.  I n m ice, CMV 
infect ion increases atherosclerosis43.  Perhaps CMV is causing plaque 
instabilit y in AAV, act ing both direct ly and through the em ergence of 
CD4+ CD28null T cells. We are current ly perform ing a long- term  follow-
up study in these pat ients to evaluate whether pat ients with increased 
CD4+ CD28null T cells indeed have m ore cardiovascular events than 
pat ients without  these cells. 
I n conclusion, we found only m inor evidence of accelerated 
atherosclerosis in pat ients with ANCA-associated vasculit is when 
studying IMT and PWV. CD4+ CD28null T cells, however, are relat ively 
increased in AAV and found to be related to previous CMV infect ion. 
The occurrence of these cells m ay be relevant  for plaque instabilit y and 
responsible for  the observed increased incidence of m yocardial 
infarct ion in these pat ients. 
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Atherosclerosis and vasculit is associated with ant ineut rophil 
cytoplasm ic ant ibodies (ANCA)  are both considered to be inflam m atory 
diseases of the blood vessels. Whereas in atherosclerosis, prim arily the 
large-  and m edium -sized vessels are involved1,  ANCA-associated 
vasculit is (AAV)  is a disease of the sm aller blood vessels2,  including 
arterioles, capillaries and venules. 
Atherosclerosis is the m ost  com m on vascular disease of the western 
world. Atherosclerot ic lesions m ay be present  throughout  a person’s 
lifet im e;  indeed, the earliest  lesion in atherosclerosis, the so-called 
fat ty st reak, m ay often be found in children. The progression of the 
fat ty st reak to an advanced, com plicated lesion m ainly occurs later  in 
life;  eventually leading to com plicat ions of atherosclerosis including 
m yocardial and cerebral infarct ion.  
The spect rum  of AAV includes Wegener ’s granulom atosis (WG) , 
m icroscopic polyangiit is (MPA) , Churg-St rauss syndrom e (CSS)  and 
idiopathic necrot izing and crescent ic glom erulonephrit is ( iNCGN) . These 
vasculit ides are rare diseases;  their prevalence has been est im ated at  
144.5/ m illion (0.01% ) 3.  AAV, like atherosclerosis, t ypically becom es 
m anifest  later in life, with a m edian age at  diagnosis between 50 and 
653-5.  Although vasculit is can lead to injury to the vascular wall and 
ischem ic dam age to organs supplied by these vessels, cerebral or  
m yocardial infarct ion due to act ive vasculit is is only rarely observed. 
While it  seem s that  AAV and atherosclerosis are different  disease 
processes evolving in different  types of blood vessels, several recent  
discoveries have led to believe that  pat ients with AAV do have an 
increased risk of developing atherosclerot ic com plicat ions, and that  
developm ent  of atherosclerosis m ay be accelerated in pat ients with 
AAV. This review will focus on the role of im m unity in atherosclerosis 
and whether there are im m unological m echanism s in AAV that  m ay 
lead to accelerated atherosclerosis in pat ients with AAV.  
 
ANCA- associated vasculit is 
Sm all vessel vasculit ides, such as Wegener’s granulom atosis (WG)  and 
m icroscopic polyangiit is (MPA) , are st rongly associated with ANCA, 
which are either directed to m yeloperoxidase (MPO)  or proteinase 3 
(PR3) 2,6,7.  These diseases can occur in any organ system  but  the 
respiratory t ract  and the kidneys are m ost  frequent ly involved. 
Unt reated, WG results in death within weeks to m onths. Since the 
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int roduct ion of cyclophospham ide and prednisolone as standard 
t reatm ent , survival has im proved dram at ically from  less than 20%  at  1 
year reported in 19588 to at  least  60%  5-years survival reported in the 
past  ten years9- 12.  
With prolonged survival, pat ients m ay experience long- term  sequelae 
as a result  of their vasculit is or it s t reatm ent 10,11,13.  Several studies 
have shown that  in long- term  follow-up, cardiovascular disease is a 
m ajor cause of m ortality in pat ients with AAV9,12,14-20.  Furtherm ore, the 
annual incidence of m yocardial infarct ion in pat ients with AAV is 
m arkedly increased com pared to the background populat ion21.   
 
Atherosclerosis 
Generally, atherosclerosis is believed to be a response to injury, with 
endothelial dysfunct ion as the first  step in the disease process22.  
Endothelial dysfunct ion increases both the adhesiveness of the 
endothelium and it s perm eabilit y. I ncreased perm eabilit y of the 
endothelium m ay lead to t rapping of lipoproteins, including low-density 
lipoprotein (LDL) . LDL can be oxidized upon ent rapm ent  in the vessel 
wall and subsequent ly taken up by m acrophages. The accum ulat ion of 
oxidized LDL in m acrophages leads to the form at ion of foam  cells. The 
presence of foam  cells is characterist ic for the second step in 
atherosclerosis, the fat ty st reak22.  As fat t y st reaks progress to 
interm ediate and advanced lesions, they form  a fibrous cap to separate 
the lesion from  the lum en of the blood vessel. I nside, a necrot ic core 
m ay be form ed, consist ing of leukocytes, lipid and debris. Ult im ately, 
the fibrous cap becom es thin which results in rupture of the cap or 
ulcerat ion of the plaque. This is the final stage of atherosclerosis 
result ing in com plicat ions like m yocardial or cerebral infarct ion. 
I nflam m at ion seem s to be an im portant  part  of the developm ent  and 
progression of atherosclerosis22.  Although the nature of the 
inflam m atory response in the atherosclerot ic lesion is not  yet  clear, 
im m unological m echanism s seem  to play an essent ial role. The 
im m une response in atherosclerosis m ay be the result  of ant igenic 
st im ulat ion. Several ant igens have been im plicated in the pathogenesis 
of atherosclerosis;  in part icular hum an cytom egalovirus (CMV) , 
Chlam ydia pneum oniae,  oxidized LDL and hum an Heat  Shock Protein 
60 (hHSP60) . We will next  discuss evidence that  has arisen from  
im m unological studies involving these ant igens in the pathogenesis of 
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atherosclerosis. 
 
T lym phocytes 
T lym phocytes are present  in all stages of developm ent  of the 
atherosclerot ic plaque22.  I ndeed, the earliest  lesions of atherosclerosis 
consist  only of m onocyte-derived m acrophages and T cells23.  De Boer 
and colleagues showed that  these T cells express cost im ulatory 
m olecules indicat ive of recent  local contact  with a specific ant igen24.  
Several groups have t r ied to determ ine the ant igenic specificit y of T 
cells in the atherom atous lesion. Stem m e et  al showed that  a subset  of 
these T cells respond to oxidized LDL25.  Addit ionally, Mosorin and 
colleagues ident ified Chlam ydia pneum oniae as a specific m icrobial 
ant igen recognized by in vivo act ivated plaque T cells26.  
A role for T cells in the developm ent  m ay thus be suspected;  evidence 
for this suspicion com es from  anim al m odels in which atherosclerosis-
prone m ice (apolipoprotein E-deficient  or LDL- receptor-deficient  m ice)  
are crossed into m ice with severe com bined im m unodeficiency, 
generat ing hypercholesterolem ic m ice lacking both T and B cells. When 
these m ice are analyzed for the presence of atherosclerosis, it  was 
shown that  under certain circum stances, t he effect  of im m une 
deficiency results in a decrease in the extent  of lesions form ed27-29.  
Addit ionally, when CD4+  T cells were t ransferred into these m ice, they 
developed atherosclerosis sim ilar to that  of im m unocom petent  
cont rols30.  
Of part icular interest  is a subgroup of CD4+  T cells, i.e., CD4+ CD28null T 
cells. These T cells are clonally expanded31,  autoreact ive31,  and have 
acquired a cytotoxic phenotype32.  Originally described in severe 
rheum atoid arthrit is (RA)  and rheum atoid vasculit is33,  this unusual 
subset  of T cells has also been reported in pat ients with unstable 
angina (UA) 34.  Liuzzo et  al showed that  unstable plaques are invaded 
by clonally expanded CD4+ CD28null T cells but  stable plaques are not 35.  
These cells m ay cont r ibute direct ly to plaque instabilit y by st im ulat ing 
t issue- infilt rat ing m acrophages through product ion of interferon- 
Addit ionally, CD4+ CD28null T cells m ay m ediate plaque instability 
through lysis of local endothelial cells36.  Two recent  studies have 
gained som e insight  in the t r iggers of act ivat ion and expansion of 
CD4+ CD28null T cells. Zal et  al reported that  hHSP60 is an ant igen 
recognized by CD4+ CD28null T cells of pat ients with an acute coronary 
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syndrom e37.  I n renal t ransplant  pat ients, however, CD4+ CD28null T cells 
are to a large extent  CMV-specific38.  I nterest ingly, CMV is one of the 
ant igens that  has also been repeatedly associated with 
atherosclerosis39-42.  Nevertheless, since the pat ients in this 
invest igat ion were renal t ransplant  recipients and not  studied for the 
presence of atherosclerosis38,  no correlat ion between these cells and 
atherosclerot ic com plicat ions could be m ade. 
 
Auto-ant ibodies 
Although B lym phocytes are not  found in atherosclerot ic plaques24,43,  or  
only in sm all percentages44,  they do seem  to be involved in the 
developm ent  of atherosclerosis. I n two studies, the protect ive effect  of 
B cells has been dem onst rated45,46.  I n both studies, atherosclerosis-
prone m ice were m ade deficient  in B cells, result ing in increased 
atherom atous plaque form at ion in these m ice. These findings were 
suggested to be related to a deficiency in ant ibody product ion. I ndeed, 
the disease-aggravat ing effect  was associated with a significant  
reduct ion of ant ibody t iters against  m alondialdehyde (MDA) -m odified 
LDL46.  I n hum ans, the presence of ant ibodies against  oxidized LDL or 
MDA-LDL has repeatedly been associated with the presence and 
severity of atherosclerosis47,48,  although the role of these ant ibodies is 
st ill largely unknown. Recent  data suggest  that  im m unoglobulin M 
( IgM)  against  oxidized LDL m ay be protect ive against  atherosclerosis, 
as high ant i-oxidized LDL ant ibody levels were negat ively related to 
int im a-m edia thickness, a m arker for the presence of atherosclerosis49.  
A protect ive role for ant ibodies is also suggested by im m unizat ion 
studies with oxidized LDL. Im m unizat ion with oxidized LDL has been 
found to inhibit  the progression of atherosclerosis in several anim al 
m odels50-53.  The protect ive effect  of these ant ibodies m ay result  from  
the abilit y to block the binding and degradat ion of oxidized LDL by 
m acrophages, although this has only been dem onst rated in vit ro54.  
Ant ibodies against  other ant igens have also been determ ined in 
pat ients with atherosclerosis, to dem onst rate involvem ent  of these 
ant igens and /  or the ant ibodies against  them  in the developm ent  of 
atherosclerosis. Much research has been devoted to the heat  shock 
proteins (HSP) , either from  bacterial or hum an origin. Xu and 
colleagues reported an associat ion between ant ibodies against  
m ycobacterial HSP65 and the presence of carot id atherosclerosis55.  
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They found that  sustained existence of these ant ibodies in pat ients with 
severe atherosclerosis was predict ive for m ortalit y in these pat ients56.  
These ant i-HSP65 ant ibodies were found to cross- react  with it s hum an 
hom ologue, hHSP6057.  HSP60 is present  on the surface of st ressed 
endothelial cells, including cells in atherosclerot ic lesions58.  Schet t  et  al 
reported that  react ion of ant i-HSP65 ant ibodies with hHSP60 on 
st ressed endothelial cells m ay result  in endothelial cytotoxicity59.  These 
findings suggest  an im portant  role for ant ibodies against  hHSP60 in the 
pathogenesis of atherosclerosis. The associat ion between ant ibodies 
against  hHSP60 and coronary atherosclerosis has been dem onst rated 
by som e60,61,  but  has been disputed by others62.  
I nterest ingly, increased serum  levels of HSP70 are associated with low 
risk of coronary artery disease (present  on coronary angiography) , 
possibly through its m ult iple protect ive effect s on a cell’s response to 
st ress63.  Furtherm ore, pat ients with high serum  levels of HSP70 had a 
lesser increase in IMT over a period of 4 years64.  I n both studies, 
ant ibodies against  HSP70 were not  related to the presence or 
developm ent  of atherosclerosis63,64.  
 
Atherosclerosis in ANCA- associated vasculit is 
Cardiovascular r isk factors 
Prevalence of cardiovascular r isk factors has been studied in pat ients 
with AAV21.  Diabetes and hypertension were m uch m ore com m on in 
pat ients than in the background populat ion;  however, the incidence of 
sm oking was lower in pat ients with AAV. Obesity and hyperlipidem ia 
did not  differ between pat ients and background populat ion.  
 
I ndirect  m easurem ents of atherosclerosis 
Several indirect  m arkers for atherosclerosis have been studied in 
pat ients with AAV. Raza et  al assessed endothelial funct ion in pat ients 
with act ive AAV by m easuring flow-m ediated, endothelium -dependent  
brachial artery vasodilatat ion (EDV) 65.  They found that  EDV was 
significant ly im paired in pat ients with act ive vasculit is com pared to 
healthy cont rols. I nterest ingly, after rem ission induct ion, EDV was 
com parable between pat ients and healthy cont rols65.  
A second indicator for atherosclerosis, int im a-m edia thickness of the 
carot id artery ( figure 1) , has also been described in WG66,67.  I n both 
studies, it  was found that  pat ients had an increased I MT in com parison 
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to age-  and sex-m atched healthy cont rols. De Leeuw and colleagues 
hypothesized that  IMT increase m ay be very focal in WG, and therefore 
studied both m ean and m axim um  IMT value in the carot id artery. They 
found a difference in m axim um  IMT, but  not  m ean I MT, between 
pat ients and cont rols67.  I n cont rast , Zaenker et  al found a difference in 
m ean I MT between pat ients and cont rols;  furtherm ore, atherom atous 
plaques were seen m ore frequent ly in WG66.  Tradit ional cardiovascular 
r isk factors were com parable in the groups studied66,67.  
Recent ly, Booth et  al described a third m arker in pat ients with AAV, 
pulse wave velocity (PWV)  and it s augm entat ion index (AI x) 68.They 
found that  AAV is associated with increased arterial st iffness, and that  
st iffness correlates with the degree of act ive inflam m at ion. I n this 
study, pat ients in rem ission also were com parable to healthy cont rols.  
These data support  the hypothesis that  during act ive disease, AAV 
pat ients experience accelerat ion of the atherosclerot ic process in 
com parison with cont rols m atched for age, sex and cardiovascular r isk 
factors. However, when inflam m at ion is cont rolled in these pat ients, 
endothelial funct ion and arterial st iffness return to values com parable 
to healthy subjects. Of course, dam age that  has occurred in the blood 
vessels m ay st ill be present  possibly result ing in higher IMT values in 
pat ients with AAV. Furtherm ore, with every disease react ivat ion, a 
state of endothelial dysfunct ion and arterial st iffness m ay again be 
reached result ing in a faster increase in IMT com pared to healthy age-
m atched persons.  
Figure 1 . I nt ima-media thickness ( I MT, arrow)  in a vasculit is pat ient . 
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T cells 
Pat ients with vasculit is often have a disturbed peripheral blood T cell 
com partm ent 69.  Several studies found increased serum  m arkers of T 
cell act ivat ion70,71,  and percentages of act ivated CD4+  and CD8+  T cells 
in peripheral blood were higher in pat ients with WG than in healthy 
subjects, both during act ive disease and in rem ission72,73.  Circulat ing T 
cells have been further characterized by Moosig and colleagues74.  They 
found a lack of expression of CD28 on T cells in pat ients with WG, but  
the significance of this finding is not  yet  clear.  We recent ly discovered a 
st rong associat ion between previous CMV infect ion and circulat ing 
CD4+ CD28null T cells in pat ients with AAV75 ( figure 2) . Whether these 
CD4+ CD28null T cells, like those in m yocardial infarct ion, are causing 
plaque instabilit y in AAV is yet  unknown. 
 
Auto-ant ibodies 
Ant ibodies, associated with atherosclerosis have also been studied in 
AAV. We have previously described the presence of ant i-MDA-LDL in 
pat ients with act ive vasculit is, decreasing during im m unosuppressive 
t reatm ent 76.  Recent ly, we also observed higher levels of ant ibodies 
against  hypochlorite-m odified LDL in pat ients with AAV77.  These 
ant ibodies m ay arise due to the disease process, especially in pat ients 
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Figure 2 . CD4+ CD28null T cells in healthy controls and vasculit is pat ients. CD4+ CD28null T 
cells are relat ively more often present  in pat ients with ANCA-associated vasculit is (AAV)  
who have had a cytomegalovirus (CMV) infect ion (ACMV+ ) . However, they are also 
present  in healthy controls with a previous CMV infect ion (HCMV+ ). I n AAV pat ients and 
controls without  a previous CMV infect ion, CD4+ CD28null T cells are scarcely detected 
(ACMV- and HCMV-, respect ively) . 
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with MPO-ANCA. In MPO-AAV, the presence of MPO-ANCA m ay hinder 
the binding of MPO to it s natural inhibitor, ceruloplasm in78.  Current  
evidence suggests that  MPO has an im portant  role in the oxidat ive 
conversion of LDL79.  Pat ients with MPO-ANCA m ay have prolonged 
oxidat ion of LDL result ing in higher levels of ant ibodies against  
hypochlorite-m odified LDL. However, this oxidat ive process m ay be a 
result  of the disease process per se, leading to a different  m ode of 
oxidat ion of LDL com pared to the oxidat ion of LDL in atherosclerosis. 
Thus, pat ients with MPO-AAV m ay have ant ibodies against  oxLDL 
regardless of the presence or absence of atherosclerosis. 
Recent ly, we described the presence of another autoant ibody 
associated with atherosclerosis in pat ients with AAV80.  Ant i-hHSP60 
levels were elevated in pat ients with MPO-ANCA com pared to pat ients 
with PR3-ANCA and healthy cont rols. Whether this is due to chronic 
inflam m at ion in pat ients with MPO-ANCA, or cross- react ivit y between 
m yeloperoxidase and ant i-hHSP60, is yet  unknown. 
 
Accelerated atherosclerosis in SLE and rheum atoid arthrit is 
I n recent  years, several studies have described the presence of 
accelerated atherosclerosis in pat ients with rheum atoid arthrit is or  
system ic lupus erythem atosus (SLE) . I n pat ients with SLE, the 
incidence of m yocardial infarct ion seem s to be at  least  5 t im es as high 
as in the general populat ion81.  Svenungsson et  al com pared carot id IMT 
in SLE pat ients with a history of cardiovascular events with SLE 
pat ients without  such a history. They found a significant  increase in the 
form er pat ient  group82.  On the other hand, IMT values were 
com parable between the lat ter group without  cardiovascular events, 
and the healthy cont rol group studied. Asanum a and colleagues studied 
coronary-artery atherosclerosis using elect ron-beam  com puted 
tom ography and found that  the prevalence of coronary-artery 
atherosclerosis is increased in pat ients with SLE, and the age of onset  
is reduced. Furtherm ore, a third study showed that  pat ients with SLE 
have lower endothelium  dependent  vasodilatat ion than sex and age-
m atched cont rols, even in pat ients without  t radit ional cardiovascular 
r isk factors83.  The presence of CD4+ CD28null T cells has been 
dem onst rated in pat ients with SLE84.  
Over the past  several decades, pat ients with RA were found to have an 
increased m ortalit y85,86,  m ost ly due to cardiovascular disease87.  I n 
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pat ients with RA, PWV88 and carot id IMT89,90 were found to be elevated, 
and EDV was found to be decreased89,91 indicat ing accelerated 
atherosclerosis in these pat ients. Furtherm ore, circulat ing CD4+ CD28null 
T cells are increased in pat ients with RA31 and have been shown to be 
associated with increased I MT values in these pat ients89.  
 
Conclusions and recom m endat ions for future studies 
Recent  evidence indicates that  several m arkers of atherosclerosis are 
m ore pronounced in pat ients with ANCA-associated vasculit is (AAV)  
com pared to healthy cont rols. Endothelial dysfunct ion, the earliest  
stage of atherosclerosis, is present  during act ive disease in pat ients 
with prim ary system ic vasculit is. Furtherm ore, ant ibodies against  
oxidized LDL and hum an HSP60, m arkers for progression of 
atherosclerosis, are also elevated during act ive vasculit is. Subt le 
increases of the int im a-m edia thickness m ay be present  in pat ients 
with AAV, possibly as a result  of periods of act ive disease.  
We believe that  these findings call for a search for t reatm ent  of 
accelerated atherosclerosis in pat ients with AAV. Angiotensin 
convert ing enzym e (ACE)  inhibitors, 3-hydroxy-3-m ethylglutaryl 
coenzym e A reductase inhibitors (stat ins)  and aspir in are widely used 
agents in pat ients with coronary artery disease. ACE inhibitors 
t radit ionally elicit  their effect s by inhibit ing conversion of angiotensin I  
to angiotensin I I 92.  Angiotensin I I  m ay direct ly enhance synthesis and 
release of proinflam m atory cytokines, for instance, interleukin-693,  and 
ACE inhibit ion can blunt  this94.  Because interleukin-6 m ediates B cell 
m aturat ion, com plem ent  act ivat ion, cytokine release, and release of C-
react ive protein94,  ACE inhibit ion m ay act  im m unom odulatory and ant i-
inflam m atory. I n addit ion, ACE inhibitors decrease the breakdown of 
bradykinin. Bradykinin causes vasodilatat ion, enhanced endogenous 
fibrinolysis, and im proved endothelial funct ion95.  Thus, ACE inhibit ion 
m ay im prove endothelial funct ion in pat ients with AAV in addit ion to 
im m unom odulatory and ant i- inflam m atory effects. 
Stat ins are the m ost  powerful class of lipid- lowering drugs available. 
I nterest ingly, addit ional act ions of stat ins unrelated to cholesterol 
reduct ion have been ident ified, including ant i- inflam m atory and 
im m unom odulatory propert ies. For instance, stat ins act  as direct  
inhibitors of induct ion of m ajor histocom pat ibilit y com plex (MHC)  class 
I I  expression and thus suppress T lym phocyte act ivat ion. Furtherm ore, 
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stat ins prevent  downregulat ion of nit r ic oxide synthase induced by 
oxidized lipoproteins96,  im proving endothelial funct ion and reducing 
oxidat ive st ress, two factors im portant  for the developm ent  of 
atherosclerosis and present  in AAV. 
The use of acetylsalicylic acid, or aspirin, results in decreased 
product ion of prostaglandins and throm boxane A2,  likely account ing for 
the ant iaggregatory and ant i- inflam m atory effects of aspir in. Aspir in 
m ay help to decrease the progression of atherosclerosis by protect ing 
LDL from  oxidat ive modificat ion and also by im proving endothelial 
funct ion in atherosclerot ic vessels97.  
Treatm ent  of exist ing risk factors for atherosclerosis seem s logical, but  
addit ional t reatm ent  m ay be necessary. Raza and colleagues suggested 
that  suppression of inflam m at ion m ay be the m ost  im portant  factor in 
pat ients with AAV, as endothelial funct ion restores to values found in 
norm al subjects after  im m unosuppressive t reatm ent 65.  Addit ionally, 
im m unosuppressive t reatm ent  results in lowering of ant i-oxLDL 
ant ibody levels76.  I ndeed, in system ic lupus erythem atosus, pat ients 
with atherosclerot ic lesions in the carot id artery were less likely to have 
been t reated with cyclophospham ide or prednisone98.  However, 
increase in body weight , hypertension and diabetes m ellitus are well-
known side-effects of the use of cort icosteroids and also r isk factors for  
developing atherosclerosis. Cyclophospham ide use can have serious 
side effects, both in short -  and long- term  follow-up. Other m edicat ions, 
for instance biologicals m ay be an alternat ive t reatm ent  opt ion. Booth 
et  al reported that  t reatm ent  with inflixim ab in pat ients with AAV m ay 
result  in im proved endothelium -dependent  vasom otor responses99.  
Addit ionally, therapy with inflixim ab m ay decrease the CD4+ CD28null T 
cell com partm ent  in AAV, as was described in pat ients with rheum atoid 
arthrit is100.  
I n conclusion, there is increasing evidence that  im m unological 
m echanism s in atherosclerosis are also present  in pat ients with AAV. 
These m echanism s could be responsible for the observed accelerat ion 
of atherosclerosis in AAV. Clinicians should be alerted to the increased 
risk of cardiovascular disease in pat ients with AAV and reduce the 
presence of inflam m at ion and t radit ional r isk factors for atherosclerosis 
in these pat ients as m uch as possible. 
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Vasculit is associated with ant ineut rophil cytoplasm ic ant ibodies 
(ANCA) , including Wegener ’s granulom atosis (WG) , m icroscopic 
polyangiit is (MPA) , Churg-St rauss syndrom e (CSS) , predom inant ly 
affects sm all-  and m edium-sized blood vessels. These ANCA-related 
syndrom es form  a dist inct  subset  with overlapping features within the 
spect rum  of prim ary vasculit ic diseases;  the respiratory t ract  and 
kidney are organ system s frequent ly involved. 
The ANCA-associated vasculit ides can be dist inguished in two ways. 
First , a dist inct ion based on diagnosis;  subcategories then include WG, 
MPA, CSS, and idiopathic necrot izing and crescent ic glom erulonephrit is 
( iNCGN) . A drawback of this m ethod is that  a disease pat tern first  
being diagnosed as MPA can evolve into WG several years after  
diagnosis. A second drawback is that  a diagnosis of WG can alm ost  
never be excluded, as granulom as m ust  be present  in a biopsy for this 
diagnosis to be m ade, and they m ay not  be present  in a part icular 
biopsy, even though the pat ient  has WG. 
A second dist inct ion is based on ANCA specificit ies. Proteinase 3 (PR3)  
and m yeloperoxidase (MPO)  are the m ajor autoant igens in ANCA-
associated vasculit is (AAV) , although other ANCA specificit ies 
occasionally are seen. However, pat ients with a biopsy-proven “ANCA-
related”  vasculit ic syndrom e m ay very well be ANCA negat ive, 
especially when the vasculit is is lim ited or locoregional ( for instance, 
pat ients with vasculit is of the upper respiratory t ract  with 
granulom atous inflam mat ion in a nasal biopsy) . Especially pat ients with 
CSS are often ANCA-negat ive (up to 70%  of the cases) . 
As an int roduct ion to the diseases studied in the subsequent  chapters, 
Chapter 1  gives a general overview of the ANCA-associated vasculit ides 
and the current  role of ANCA in the diagnosis and prognosis of pat ients 
with this disease. 
 
Several drugs have been associated with the onset  of AAV, including 
ant irheum at ic and ant ithyroid drugs. I n Chapter 2 we evaluate the 
potent ial of the ant irheum at ic drugs m inocycline, sulfasalazine and 
penicillam ine to induce ANCA. We tested 248 pat ients who had 
part icipated in clinical t r ials, providing us with pre-  and post -exposure 
blood sam ples. From  our study results, there was no suggest ion of 
ANCA seroconversion due to these drugs. 
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Chapter 3 describes a related study in which we invest igated the 
presence of ANCA after  the use of ant ithyroid drugs. We hypothesized 
that  ANCA and AAV m ay not  only be induced during t reatm ent  with 
ant ithyroid drugs, but  can also becom e m anifest  when m edicat ion has 
been ceased, possibly after years. To test  this hypothesis, we 
evaluated pat ients with hyperthyroidism , on various ant ithyroid 
t reatm ent  m odalit ies, for the presence of ANCA. We found that  of 209 
pat ients with hyperthyroidism , 12 pat ients (6% )  were posit ive for  
m yeloperoxidase-  (MPO-) , proteinase 3-  (PR3- )  and/ or hum an 
leukocyte elastase-  (HLE- )  ANCA, and that  the presence of ANCA was 
highly associated with (previous)  t reatm ent  with ant ithyroid drugs. 
 
Hum an Heat  Shock Protein 60 (hHSP60)  has been im plicated in 
autoim m unity through m olecular m im icry, based on the high degree of 
hom ology with HSP65 of m icro-organism s leading to autoim m une 
recognit ion of the hum an protein. Addit ionally, sequence hom ology 
between hHSP60 and m yeloperoxidase (MPO)  has been described. MPO 
is a m ajor autoant igen in vasculit is associated with ant ineut rophil 
cytoplasm ic ant ibodies (ANCA) . I n Chapter 4,  we hypothesized that  
infect ions m ay t rigger the ANCA response against  MPO through 
hHSP60. 
I n 86 consecut ive pat ients with ANCA-associated vasculit is (AAV) , ant i-
hHSP60 and ant i-m ycobacterial HSP65 were m easured by ELISA. 
Pat ients were com pared with 69 healthy cont rols (HC) . We found that  
ant ibodies against  m HSP65 are higher in AAV com pared to HC, and 
ant i-hHSP60 ant ibodies are higher in pat ients with MPO-ANCA than in 
pat ients with PR3-ANCA and HC. Although this finding m ay be 
indicat ive for cross- react ivit y between MPO-ANCA and hHSP60, 
addit ional assays did not  support  our hypothesis. 
 
I n Chapter 5 we invest igated whether genet ic factors, regulat ing T cell 
act ivat ion, are involved in the onset  of AAV. T cell act ivat ion is 
regulated by inhibitory m olecules such as PD-1 and CTLA-4, whose 
expression in turn may be affected by gene polym orphism s. We 
invest igated the relat ionship between polym orphism s in PDCD1 and 
CTLA4 and the presence of AAV, and found that  AAV is associated with 
the presence of a G allele at  the + 49 posit ion of CTLA4;  this associat ion 
is even st ronger if also the PD-1.5 T allele is absent  in the genom e. 
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This led us to hypothesize that  for autoim m une disease, a m utat ion in 
m ore than one inhibitory receptor predisposes to the developm ent  of 
disease, for instance, AAV. Furtherm ore, disease subsets are 
associated with different  genet ic polym orphism s in CTLA4.  
 
Chapter 6 presents a long- term  follow-up study in pat ients with PR3-
ANCA associated vasculit is with renal involvem ent . Eighty- five pat ients 
that  were diagnosed between 1982 and 1996 were followed for at  least  
5 years, to invest igate prognost ic factors for pat ient  and renal survival. 
We discovered that  early death and failure to recover renal funct ion in 
PR3-ANCA associated vasculit is is associated with age above 65 years 
and dialysis dependency at  diagnosis. Furtherm ore, long- term  renal 
survival is determ ined by renal relapses during follow-up only. Slow, 
progressive renal failure without  relapses, not  infrequent ly found in 
pat ients with MPO-ANCA associated vasculit is, is rarely observed in 
pat ients with PR3-ANCA associated vasculit is with glom erulonephrit is. 
 
I n pat ients with PR3-ANCA, renal funct ion is stable during rem ission, 
but  declines with every renal relapse. I n pat ients with MPO-ANCA a 
slowly progressive course with pat ients developing dialysis dependency 
during follow-up without  signs of clinically act ive disease is oft en 
observed. I n Chapter 7 we studied the clinical and histological 
differences at  diagnosis between pat ients with PR3-ANCA and pat ients 
with MPO-ANCA, and we invest igated whether these differences explain 
the dist inct ive outcom es in AAV. Eighty pat ients (46 with MPO-  and 34 
with PR3-ANCA)  were included. Renal lesions differed between pat ients 
with PR3-  and MPO-ANCA, being m ore acute in PR3-ANCA, and m ore 
chronic in MPO-ANCA. However, despite the overt  differences in renal 
biopsies, ANCA specificit y was not  a r isk factor for pat ient  death or the 
developm ent  of renal failure during long- term  follow-up. Risk factors 
for  death were fem ale gender, age 65 years or higher at  diagnosis and 
serum  creat inine level at  biopsy. The developm ent  of renal failure 
during follow-up was associated with fem ale gender, a lower 
percentage of norm al glom eruli, and the chronicity score in renal 
biopsy. 
 
Next  to pat ient  and renal survival, we invest igated factors that  are 
associated with disease- free survival. I n Chapter 8,  we analyzed 
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disease- free survival in pat ients with AAV t reated with 
cyclophospham ide only or switched to azathioprine after 3 m onths of 
full rem ission with cyclophospham ide. I ncluded were 128 pat ients of 
whom  44 (34% )  switched to azathioprine. I n pat ients with PR3-ANCA 
associated vasculit is switched to azathioprine (n= 33)  a posit ive C-
ANCA t iter at  the m om ent  of t reatm ent  switch (n= 13)  was significant ly 
associated with the occurrence of relapse. I n pat ients with a negat ive 
ANCA t iter at  the t im e of switch to azathioprine (n= 20) , disease- free 
survival at  2 and 4 years was 80%  and 62% , which was ident ical to 
pat ients t reated with cyclophospham ide only. I n pat ients who were 
ANCA posit ive at  the t im e of t reatm ent  switch disease- free survival at  2 
and 4 years was only 58%  and 17% . Thus, switching 
cyclophospham ide to azathioprine after induct ion of rem ission in 
pat ients with PR3-ANCA associated vasculit is who are st ill ANCA 
posit ive at  the t im e of t reatm ent  switch is associated with a high r isk of 
developing relapses. 
 
A serological m arker for the extent  and progression of atherosclerosis, 
ant i-oxidized low-density lipoprotein (oxLDL) , is studied in AAV in 
Chapter 9.  Three m ethods for detect ion of ant i-oxLDL are com pared 
between pat ients with MPO-ANCA and pat ients with PR3-ANCA. We 
m easured ant ibody levels to LDL after t reatm ent  with hypochlorite, 
MDA or copper in sera of ANCA-posit ive vasculit is pat ients, and 
com pared them  to ant ibody levels in sera of hem odialysis pat ients and 
healthy cont rols. We found that  ant i-oxLDL ant ibodies are enhanced in 
AAV pat ients (MDA-LDL and hypochlorite-LDL)  and in dialysis pat ients 
(hypochlorite-LDL) , when com pared to cont rols.   Furtherm ore, pat ients 
with MPO-ANCA associated vasculit is had higher levels of ant ibodies to 
hypochlorite-LDL than pat ients with PR3-ANCA associated vasculit is. 
We concluded that  our newly developed assay to m easure ant ibodies to 
ox-LDL, in which hypochlorite-LDL is used as subst rate, seem s a m ore 
sensit ive assay than t radit ional assays to m easure these ant ibodies. 
Furtherm ore, our results suggest  that  enhanced MPO-m ediated LDL 
oxidat ion in pat ients with MPO-ANCA reflects t he idea that  circulat ing 
MPO-ANCA prevents inact ivat ion of circulat ing MPO act ivit y by 
ceruloplasmin in these pat ients. 
 
I n Chapter 10,  we analyzed the num ber of circulat ing CD4+ CD28 -  T 
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cells in relat ion to the presence of atherosclerot ic dam age in pat ients 
with AAV. Furtherm ore, we determ ined whether ant ibodies against  
cytom egalovirus (CMV)  and hum an Heat  Shock Protein 60 (hHSP60)  
were related to the presence of CD4+ CD28null T cells in AAV. Forty 
pat ients with inact ive AAV were included in this study. Pat ients’ 
spouses were recruited as healthy cont rols (HC, n= 38) . I nt im a-m edia 
thickness ( IMT)  and pulse wave velocity (PWV)  were m easured. Our 
results showed that  there is evidence of atherosclerot ic dam age in 
pat ients with AAV, as m easured by PWV, although carot id plaque size 
did not  seem  to differ. CD4+ CD28null T cells are relat ively increased in 
AAV and related to previous CMV infect ion. However, there was no 
correlat ion between CD4+ CD28null T cells and increased IMT or PWV. 
 
Finally, in Chapter 11,  we sum m arize the current  percept ions on 
involvem ent  of the im m une system  in atherosclerosis, with part icular  
at tent ion to possible im m unological causes of accelerated 
atherosclerosis in AAV. 
 
General conclusions 
The work described in this thesis is focused on ANCA-associated 
vasculit is. I t s subjects are factors involved in disease onset  (Chapters 
2, 3, 4, 5) , factors involved in pat ient  and renal survival (Chapters 6, 
7)  and disease- free survival (Chapter 8) , and the presence and 
developm ent  of atherosclerosis at  diagnosis and during follow-up of 
AAV (Chapters 9, 10) . Although we are st ill a long way from  curing this 
disease, som e issues have becom e clear. 
First  of all,  if the factors involved in disease onset  are known, therapies 
or st rategies m ay evolve that  m ight  be able to prevent  vasculit is, or 
cure this disease at  an early stage. We studied several drugs that  have 
been associated with the induct ion of ANCA, and possibly of AAV. A 
relat ionship between the use of ant ithyroid drugs and the presence of 
AAV was established (Chapter 3) ;  on the other hand, a connect ion 
between certain ant irheum at ic drugs and vasculit is is st ill quest ionable 
(Chapter 2) . 
Although m edicat ion use has som et im es been associated with 
vasculit is, infect ions (and especially infect ion with Staphylococcus 
aureus)  have often been linked to vasculit is. Ant ibodies against  
bacterial and hum an Heat  Shock Proteins (HSPs)  are elevated in AAV, 
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especially in MPO-AAV (Chapter 4) .  Nevertheless, we could not  
establish a correlat ion between the presence of ant ibodies against  HSPs 
and the presence of ANCA. 
Next  t o the possible induct ion of ANCA by infect ion or m edicat ion use, 
we studied a possible cause for the involvem ent  of T cells in the onset  
of AAV. We found that  certain gene polym orphism s that  lead to a 
reduced expression or funct ion of the T cell inhibitory m olecule CTLA-4, 
in com binat ion with a gene polym orphism  in a second inhibitory 
m olecule (PD-1) , are associated with the presence of AAV (Chapter 5) .  
This m ay indicate that  reduced inhibit ion of T cells influences the 
occurrence of AAV. 
Second, we invest igated whether we could ident ify factors that  are 
involved in pat ient , renal and disease- free survival, possibly leading to 
a m ore tailored approach of pat ients with AAV. We observed that  age 
and reduced renal funct ion are prim arily associated with abridged 
short - term  pat ient  and renal survival (Chapter 6, 7) , whereas long-
term  renal survival is st rongly dependent  on the occurrence of renal 
relapses (Chapter 6) . I n our long- term  survival analysis, we found that  
atherosclerosis and m alignancy are the m ost  com m on causes of death 
in pat ients with AAV (Chapter 6) . Am ong other reasons, the high 
chance of m alignancy with the use of the standard therapy against  AAV 
(cyclophospham ide and prednisolone) , has led invest igators to propose 
a less aggressive t reatm ent  for rem ission m aintenance, giving pat ients 
azathioprine instead of cyclophospham ide. The use of azathioprine, 
however, m ay not  be as successful as cyclophospham ide in prevent ing 
the occurrence of relapses of disease act ivity during follow-up. I n 
pat ients that  rem ain posit ive for ANCA, the use of azathioprine m ay 
lead to a st rongly reduced disease- free survival (Chapter 8) . 
Third, we invest igated the presence of atherosclerosis as a 
consequence of ANCA-associated vasculit is, at  diagnosis and during 
follow-up. One serological m arker of atherosclerosis, ant ibodies against  
oxidized LDL, was found to be already present  at  diagnosis of AAV, 
part icularly in pat ients with MPO-ANCA (Chapter 9) .  During long- term  
follow-up, we also found evidence for the presence of accelerated 
atherosclerosis in pat ients with AAV (Chapter 10) . Furtherm ore, 
im m unological abnorm alit ies were found in pat ients with AAV that  are 
also com m on in pat ients with atherosclerosis (Chapter 10) . 
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Future perspect ives 
Pathophysiology of ANCA-associated vasculit is 
I n the last  years, m ore insight  has been gained regarding the 
pathophysiological role of ANCA in ANCA-associated vasculit is, leading 
som e invest igators to propose the term  “ANCA vasculit is”  instead1.  
These invest igators have dem onst rated in a m ouse m odel that  ANCA 
alone are sufficient  for disease induct ion1.  The MPO knockout  m ice they 
used were im m unized with m urine MPO, leading to the developm ent  of 
MPO-ANCA in these m ice. I nject ing these ant ibodies in m ice with MPO 
led to the developm ent  of vasculit is and glom erulonephrit is. Of course, 
the quest ion st ill rem ains how a person can suddenly develop an 
autoim m une response against  MPO or, for that  m at ter, PR3. Many 
theories have been developed, with m olecular m im icry between 
bacterial and hum an proteins as a favored one;  one that  has also been 
studied by us (Chapter 4) . Recent ly, a second theory has gained m uch 
at tent ion after proving it s pathogenecity in a m ouse m odel. Pendergraft  
and colleagues described an autoim m une response induced by the 
presence of a pept ide that  is ant isense or com plem entary to PR32.  After  
im m unizing m ice with ant isense PR3, they found an autoim m une 
react ion to blood vessels in these m ice. The m ice had not  only 
developed ant ibodies against  ant isense PR3, but  also to the sense 
pept ide PR3. Furtherm ore, ant ibodies in sera from  pat ients with 
Wegener’s granulom atosis reacted not  only with PR3, but  also with 
ant isense hum an PR3. An explanat ion for this rem arkable finding is 
that  when the sense and ant isense m olecules of a pept ide are 
com plem entary to each other, an im m une response against  the 
ant isense pept ide m ay induce ant i- idiotypic ant ibodies (autoant ibodies)  
that  cross- react  with the autoant igen. The ant isense im m une response 
m ay, in turn, be a result  of m olecular m im icry with bacterial proteins – 
the ant isense PR3 protein, for instance, shares sequence hom ology 
with a protein of Staphylococcus aureus2,  a pathogen that  has been 
repeatedly linked to WG. 
The role of T cells in the pathogenesis of AAV is st ill m uch less clear.  
Obviously, T cells are necessary for  the product ion of I gG ANCA3,  and T 
cells are present  in inflam m atory lesions in AAV4,5.  On the other hand, 
in the m ouse m odel previously described, infusion of only T cells does 
not  lead to inflam m at ion in m ice, in cont rast  to infusion of only MPO-
ANCA. Nevertheless, infusion of both T cells and MPO-ANCA leads to 
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m uch m ore inflam m at ion in the m ouse m odel than infusion of MPO-
ANCA alone1.  
Since the T cell response is necessary for the product ion of ANCA, it  is 
interest ing to invest igate why a T cell would react  with autoant igens. 
We have invest igated one hypothesis for hyperreact ivit y of T cells;  
im pairm ent  of counterregulat ion due to polym orphism s in genes coding 
for  the im m unoregulatory m olecules CTLA-4 and PD-1 (Chapter 5) . Of 
course, these m olecules are not  the only ones involved in the 
regulat ion of the imm une response. Besides, since these gene 
polym orphism s are also found in m any healthy persons, and various 
other autoim m une diseases, it  seem s that  m ore than a gene 
polym orphism  is necessary for the developm ent  of AAV. I t  could be 
interest ing to look whether a com binat ion of factors that  are thought  to 
be at  least  part ially responsible for the induct ion of AAV coincide in 
pat ients with AAV. For instance, are pat ients with im munoregulatory 
polym orphism s m ore suscept ible to drug- induced vasculit is?  
 
Treatm ent  and follow-up of ANCA-associated vasculit is 
Many studies have described potent ial prognost ic factors for pat ient  
and renal survival ( sum m arized in Chapters 6 and 7) . Unfortunately,  
m ost  of these prognost ic factors can not  readily be influenced by 
therapy. An except ion to this is renal failure at  diagnosis, defined as 
serum  creat inine above 500 m ol/ L or dialysis dependency. Renal 
failure at  diagnosis is highly associated with early death and failure to 
recover renal funct ion (Chapters 6 and 7) .  A recent  study has shown 
that  plasm a exchange m ay be beneficial to these pat ients, drast ically 
im proving their survival without  need for renal replacem ent  therapy 
within one year6.  
I nduct ion therapy with cyclophospham ide and prednisolone is st ill the 
golden standard for generalized ANCA-associated vasculit is. Long- term  
use of cyclophospham ide, however, leads to serious m orbidity, even 
m ortalit y, m ost ly due to m alignancies several years after diagnosis7.  To 
decrease the chance on developing these long- term  side effects, other 
drugs have been tested for rem ission m aintenance and rem ission 
induct ion. Azathioprine at  first  seem ed equally able to suppress disease 
act ivit y8;  however, during long term  observat ion, we showed that  
azathioprine use does lead to m ore relapses of disease act ivit y, 
especially when pat ients were C-ANCA posit ive at  the t im e of t reatm ent  
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switch from  cyclophospham ide to azathioprine (Chapter 8) . Two t r ials 
are current ly on their way;  one test ing the effect  of longer use of 
azathioprine in pat ients that  rem ain C-ANCA posit ive;  the other t est ing 
m ycophenolate m ofet il (MMF)  as t reatm ent  for  rem ission m aintenance. 
On the other hand, perhaps induct ion should be m ade m ore aggressive 
and aim ing at  an absent  ANCA t iter when t reatm ent  switch is 
considered. Adding ant i-CD20 or ant i-TNFa to induct ion t reatm ent  can 
be interest ing in this perspect ive. 
 
Atherosclerosis and ANCA-associated vasculit is 
Since the int roduct ion of cyclophospham ide and prednisolone as 
standard t reatm ent , AAV has evolved from  an alm ost  uniform ly fatal 
disease to a chronic disorder. Long- term  follow-up, however, has 
shown that  late consequences of the disease and /  or it s t reatm ent  can 
result  in serious m orbidity. Cardiovascular events occur in a substant ial 
percentage of pat ients with AAV9,  leading us to invest igate the 
presence of accelerated atherosclerosis in these pat ients. Although we 
did not  find m arked differences between pat ients and healthy, age-
m atched cont rols, subt le dist inct ions were there. I t  would be very 
interest ing to know how these differences progress. 
Of course, the m ethods we used to detect  atherosclerosis in AAV 
pat ients m ay not  have been sensit ive enough for us to detect  large 
differences between pat ients and cont rols. With a recent  m ethod 
described by Kooi et  al10 it  would be possible to specifically look at  
rupture-prone atherosclerot ic plaques, which m ay m ore adequately 
assess the increased risk of cardiovascular events for pat ients with AAV 
than int im a-m edia thickness m easurem ents or pulse-wave velocity. 
Assessm ent  of m yocardial perfusion could also be a way to detect  
atherosclerot ic lesions11.  
Since the presence of CD4+ CD28null T cells was clearly related to 
m yocardial infarct ion in the studies by Liuzzo et  al12,13,  one point  for 
follow-up could be the occurrence of cardiovascular events, though the 
num ber of pat ients we studied is sm all. Anim al studies could perhaps 
give us m ore insight  in the role of CD4+ CD28null T cells in 
atherosclerosis. Furtherm ore, the natural course of atherosclerosis in 
vasculit is could be studied in the m ouse m odel for AAV. 
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Vasculit is geassocieerd m et  ant ineut rofiele cytoplasm at ische ant istoffen 
(ANCA) , zoals Wegener’s granulom atose, m icroscopische polyangiit is 
(MPA) , en het  syndroom  van Churg-St rauss (CSS) , kom t  m et  nam e 
voor in de kleine en m iddelgrote bloedvaten. Deze ANCA-gerelateerde 
aandoeningen vorm en een speciale categorie m et  overlappende 
sym ptom en binnen het  spect rum  van de vasculit iden van de kleine 
vaten;  de luchtwegen en de nieren zij n daarbij  vaak aangedaan. 
Er kan op 2 m anieren onderscheid gem aakt  worden binnen de ANCA-
geassocieerde vasculit iden. De eerste m anier is gebaseerd op de 
verschillende diagnoses;  subcategorieën zij n dan WG, MPA, CSS en 
idiopathische necrot iserende en crescent ische glom erulonefr it is 
( iNCGN) . Een nadeel van deze m ethode is dat  een syndroom  dat  eerst  
gediagnost iceerd wordt  als MPA, jaren na de daignose kan evoluëren 
naar een WG. Een tweede nadeel is dat  de diagnose WG bijna nooit  
geëxcludeerd kan worden, aangezien de aanwezigheid van granulom en 
in m inim aal een biopt  voorwaarde is voor deze diagnose. Deze kunnen 
echter bij  het  m aken van het  biopt  gemist  worden, waardoor de 
diagnose WG niet  gesteld kan worden zelfs als deze wel de 
onderliggende oorzaak is. 
Een tweede onderscheid tussen de aandoeningen is gebaseerd op 
ANCA specificiteiten. Proteinase 3 (PR3)  en m yeloperoxidase (MPO)  zijn 
veruit  de belangrij kste autoant igenen in ANCA-geassocieerde vasculit is 
(AAV) , hoewel sporadisch andere specificiteiten gevonden worden. 
Echter, pat iënten m et  een biopt  bewezen “ANCA-gerelateerd”  
syndroom  kunnen ANCA negat ief zij n, vooral wanneer de ziekte 
gelim iteerd of locoregionaal is (bij voorbeeld pat iënten m et  vasculit is 
van de bovenste luchtwegen en granulom ateuse ontsteking in een 
neusbiopt ) . Met  nam e pat iënten m et  CSS zij n vaak ANCA negat ief ( t ot  
70%  van de pat iënten) .  
Hoofdstuk 1 geeft  als int roduct ie tot  het  ziektebeeld een overzicht  van 
de ANCA-geassocieerde vasculit iden en de huidige rol van ANCA in de 
diagnose en prognose van pat iënten m et  deze ziekte. 
 
Verscheidene m edicam enten zijn geassocieerd m et  het  ontstaan van 
AAV, onder andere ant i- reum at ische m edicijnen en thyreostat ica. I n 
Hoofdstuk 2 onderzoeken we of de ant i- reum at ische m edicij nen 
m inocycline, sulfasalazine en penicillam ine ANCA kunnen induceren. 
We test ten hiervoor 248 pat iënten die hadden gepart icipeerd in clinical 
 Sam envat t ing  201 
t r ials, waardoor wij  serum  van voor en na de blootstelling tot  onze 
beschikking hadden. Onze resultaten lieten geen aanwij zingen zien 
voor het  ontstaan van ANCA door het  gebruik van deze m edicij nen. 
 
Hoofdstuk 3 beschrij ft  een gerelateerde studie waarin wij  de 
aanwezigheid van ANCA na het  gebruik van thyreostat ica 
onderzochten. We hypothet iseerden dat  ANCA niet  alleen kan ontstaan 
t ij dens het  gebruik van thyreostat ica, m aar ook jaren later, wanneer de 
thyreostat ica gestopt  zij n. Om  deze hypothese te testen onderzochten 
wij  pat iënten m et  hyperthyreoïdie, m et  verschillende vorm en van 
behandeling, op de aanwezigheid van ANCA. Van de 209 pat iënten m et  
hyperthyreoïdie hadden 12 pat iënten (6% )  MPO- , PR3-  of hum an 
leukocyte elastase (HLE) -ANCA;  de aanwezigheid van ANCA was sterk 
geassocieerd m et  thyreostat ische behandeling. 
 
Hum aan heat  shock protein 60 (hHSP60)  wordt  een rol toegedicht  bij  
het  ontstaan van autoim m uniteit  door m olecular m im icry, veroorzaakt  
door een sterke overeenkom st  m et  HSP65 dat  gevonden wordt  bij  
m icro-organism en. Daarnaast  is overeenkom st  tussen hHSP60 en MPO 
beschreven. MPO is een van de belangrij kste autoant igenen in ANCA-
geassocieerde vasculit is. I n Hoofdstuk 4 hypothet iseerden we dat  
infect ies het  ontstaan van ANCA gericht  tegen MPO kunnen induceren 
via kruisreact iviteit  m et  hHSP60. I n 86 pat iënten m et  AAV werden 
ant istoffen tegen hHSP60 en m ycobacterieel HSP65 gem eten m et  
behulp van ELISAs. Deze pat iënten werden vergeleken m et  69 gezonde 
cont roles (HC) . We zagen dat  ant istoffen tegen m HSP65 hoger waren 
in AAV pat iënten in vergelij king m et  HC, en ant i-hHSP60 ant istoffen 
waren hoger in pat iënten m et  MPO-ANCA dan in pat iënten m et  PR3-
ANCA en HC. Dit  zou kunnen wij zen op kruisreact iviteit , m aar in 
aanvullende onderzoeken bleef bewij s van kruisreact iviteit  uit . 
 
I n Hoofdstuk 5 onderzochten we of genet ische factoren, van invloed op 
de T-cel regulat ie, bet rokken zij n bij  het  ontstaan van AAV. T-cel 
act ivat ie wordt  gereguleerd door inhibitoire m oleculen zoals PD-1 en 
CTLA-4. De expressie van deze m oleculen wordt  beïnvloedt  door 
genet ische polym orfism en. We onderzochten de relat ie tussen 
polym orfism en in PDCD1 en CTLA4 en de aanwezigheid van AAV, en we 
zagen dat  AAV geassocieerd is m et  de aanwezigheid van het  G allel op 
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de posit ie + 49 van CTLA4;  deze relat ie wordt  sterker als ook het  PD-
1.5 T allel niet  aanwezig is in het  genoom .  Dit  resultaat  leidde naar 
onze huidige hypothese;  voor het  ontstaan autoim m uunziekten zoals 
AAV is waarschijnlij k m eer dan één m utat ie nodig in inhibitoire 
receptoren. Daarnaast  zij n verschillende subgroepen binnen AAV 
geassocieerd m et  verschillende CTLA4 polym orfism en. 
 
Hoofdstuk 6 presenteert  een lange term ijn follow-up studie van 
pat iënten m et  PR3-ANCA geassocieerde vasculit is m et  
nierbet rokkenheid. Vij fentacht ig pat iënten, gediagnost iceerd tussen 
1982 en 1996 werden m inim aal 5 j aar gevolgd om  te onderzoeken 
welke factoren van invloed zij n op overleving van pat iënten en 
nierfunct ie. We zagen dat  snel overlij den en blij vend verlies van 
nierfunct ie in PR3-ANCA vasculit is geassocieerd is m et  leeft ij d boven 65 
jaar en dialyse-afhankelij kheid ten t ij de van diagnose. Verder vonden 
wij  dat  alleen het  opt reden van renale recidieven voorspellend is voor 
overleving van de nierfunct ie op lange term ijn. Langzam e 
achteruitgang van de nierfunct ie zonder act iviteit  van de vasculit is, 
zoals regelm at ig gezien wordt  bij  MPO-ANCA vasculit is, kom t  zelden 
voor bij  PR3-ANCA vasculit is. 
 
I n pat iënten m et  PR3-ANCA is de nierfunct ie stabiel t ij dens rem issie, 
m aar gaat  achteruit  met  elk renaal recidief. I n pat iënten m et  MPO-
ANCA wordt  j uist  vaak gezien dat  de nierfunct ie versneld achteruit  
gaat , zonder dat  er act iviteit  van de ziekte te herkennen is. I n 
Hoofdstuk 7 bestudeerden we welke klinische en histologische 
verschillen aanwezig zijn tussen pat iënten m et  PR3-ANCA en pat iënten 
m et  MPO-ANCA, en we onderzochten of deze verschillen de verschillen 
in outcom e kunnen verklaren. Tacht ig pat iënten (46 m et  MPO-ANCA en 
34 m et  PR3-ANCA)  werden geïncludeerd in de studie. De afwij kingen in 
het  nierbiopt  verschilden tussen pat iënten m et  PR3-  en MPO-ANCA;  in 
PR3-ANCA zij n de laesies m eer acuut , t erwij l in MPO-ANCA m eer 
chronische schade wordt  gezien. Desondanks was ANCA specificiteit  
geen risicofactor voor overlijden van de pat iënt  of nierfalen t ijdens 
follow-up. De risicofactoren voor overlij den die wij  wel zagen waren 
vrouwelij k geslacht , leeft ij d boven 65 jaar, en serum  creat inine ten 
t ij de van het  biopt . Het  ontstaan van nier falen was geassocieerd m et  
het  vrouwelij k geslacht , een lager percentage van norm ale glom eruli, 
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en de chroniciteitsscore van het  nierbiopt . 
 
Naast  pat iënten-  en renale overleving hebben we ook factoren 
onderzocht  die van invloed kunnen zij n op ziektevrij e overleving. I n 
Hoofdstuk 8 analyseerden we ziektevrij e overleving in pat iënten m et  
AAV die ofwel m et  cyclofosfam ide werden behandeld, danwel na 3 
m aanden volledige rem issie van cyclofosfam ide naar azathioprine 
overschakelden. Er werden 128 pat iënten geïncludeerd;  44 hiervan 
(34% )  gingen over op azathioprine. I n pat iënten m et  PR3-ANCA 
(n= 33) , die een posit ieve ANCA t iter hadden op het  m om ent  van swith 
(n= 13) , was de kans op een recidief significant  hoger. I n pat iënten m et  
een negat ieve ANCA t iter ten t ij de van switch (n= 20)  was de 
ziektevrij e overleving op 2 en 4 jaar respect ievelij k 80%  en 62% ;  dit  
was gelij k aan de ziektevrij e overleving van pat iënten die 
cyclofosfam ide bleven gebruiken. I n pat iënten die ANCA posit ief waren, 
was de ziektevrij e overleving op 2 en 4 jaar slechts 58%  en 17% . Wij  
concludeerden dan ook dat  de overstap van cyclofosfam ide naar 
azathioprine bij  pat iënten m et  PR3-ANCA geassocieerde vasculit is, die 
ANCA posit ief zij n ten t ij de van de overstap, het  r isico op recidieven 
sterk verhoogd is. 
 
Een serologische m arker voor de uitgebreidheid en progressie van 
atherosclerose, ant ilicham en tegen geoxideerd low-density lipoprotein 
(oxLDL) , werd bestudeerd in AAV in Hoofdstuk 9.  Drie m anieren om  
ant i-oxLDL te detecteren werden vergeleken tussen pat iënten m et  
MPO-ANCA en pat iënten m et  PR3-ANCA. We bepaalden de hoeveelheid 
ant ilicham en tegen LDL, nadat  dit  behandeld werd m et  hypochloriet , 
MDA of koper, in ANCA-posit ieve pat iënten, en vergeleken deze m et  de 
hoeveelheid ant ilicham en in sera van hem odialysepat iënten en gezonde 
cont roles. We zagen dat  de hoeveelheid ant i-oxLDL ant ilicham en waren 
toegenom en in AAV pat iënten (MDA-LDL en hypochloriet -LDL)  en in 
dialysepat iënten (hypochloriet -LDL)  in vergelij king m et  gezonde 
cont roles. Daarnaast  zagen we dat  pat iënten m et  MPO-ANCA m eer 
ant ilicham en tegen hypochloriet -LDL hadden dan pat iënten m et  PR3-
ANCA. We concludeerden dat  onze nieuw ontwikkelde test  voor het  
m eten van ant i-oxLDL, m et  hypochloriet -LDL als subst raat , gevoeliger 
is voor het  detecteren van deze ant ilicham en dan t radit ionele testen. 
Daarnaast  lij kt  het  zo te zij n dat  oxidat ie van LDL m et  behulp van MPO 
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in pat iënten m et  MPO-ANCA voorkom t  en veroorzaakt  wordt  door de 
circulerende MPO-ANCA ant ilicham en, die door hun binding m et  MPO 
de binding van MPO aan zij n natuurlij ke rem m er, ceruloplasmine, 
voorkom en. 
 
I n Hoofdstuk 10 analyseerden we de hoeveelheid circulerende 
CD4+ CD28 -  T cellen in relat ie tot  de aanwezigheid van 
atherosclerot ische schade in pat iënten m et  AAV. Daarnaast  bepaalden 
we of ant ilicham en tegen cytom egalovirus (CMV)  en hum aan heat  
shock protein 60 (hHSP60)  geassocieerd waren m et  de aanwezigheid 
van CD4+ CD28null T cellen in AAV. Veert ig pat iënten in rem issie werden 
in de studie geïncludeerd. De echtgenoten van de pat iënten werden als 
gezonde cont roles (HC)  gevraagd (n= 38) . De int im a-m edia dikte ( IMT)  
en pulse-wave velocity (PWV)  werden bepaald. We zagen dat  er bewijs 
voor atherosclerot ische schade is in pat iënten m et  AAV, zoals gem eten 
m et  de PWV;  aan de andere kant  werd er geen verschil in IMT 
gevonden. CD4+ CD28null T cellen zij n relat ief verhoogd in AAV en 
geassocieerd m et  vroegere CMV infect ie. We zagen geen relat ie tussen 
CD4+ CD28null T cellen en verhoogde I MT of PWV. 
 
Tot  slot  worden in Hoofdstuk 11 de huidige opvat t ingen van de 
bet rokkenheid van het  im m uunsysteem  in atherosclerose sam engevat ,  
m et  speciale aandacht  voor m ogelij ke im m unologische oorzaken van 
versnelde atherosclerose in AAV. 
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Aan het  einde kom en van een proefschrift  is voor een schrij ver/ -ster  
een goede gelegenheid om  een aantal m ensen te bedanken en voor 
een lezer de plek om  bedankt  te worden. Hier kom en ze!  
 
Prof. Jan Willem  Cohen Tervaert , heeft  m ij  in het  2e studiejaar 
geneeskunde in Groningen enthousiast  gem aakt  voor het  doen van 
onderzoek, eerst  als zogenaam de “ tutor”  in het  Groningse 
onderwij ssysteem , later als begeleider van keuzeproj ecten en 
onderzoeksstages. Jan Willem , bedankt  dat  j e m ij  naar “het  beste 
ziekenhuis van de wereld”  in Boston hebt  gestuurd en dat  ik na m ijn 
studie geneeskunde m eteen als AGIKO in Maast richt  aan de slag kon. 
 
Mijn eerste co-prom otor,  Coen Stegem an, wil ik bedanken voor de no-
nonsense begeleiding die je m ij  in Groningen hebt  gegeven onder het  
genot  van klassieke m uziek. Coen, bedankt  dat  j e m ij  j ouw stat ist ische 
kunsten hebt  geleerd en dat  j e alt ij d t ij d had om  m et  m ij  te 
discussiëren over nieren en vasculit is!  
 
Mijn tweede co-prom otor,  Jan Dam oiseaux, wil ik bedanken voor de 
dagelij kse begeleiding in Maast r icht . Jan, bedankt  voor de gezellige 
t reinreizen die we naar Groningen en Am sterdam  hebben gem aakt !  
 
Ook op de afdeling imm unologie zij n veel m ensen die op hun eigen 
wij ze een bij drage hebben geleverd aan het  totstandkom en van dit  
proefschrift :  
Marjan, dank voor alle j aren als kam ergenote, collega, vriendin en 
koppelaarster en nu ook als paranim f. Heel veel succes m et  j ouw 
prom ot ie binnenkort !  
Bram , dank je wel om dat  j e m e m et  nam e in de eerste m aanden in het  
vreem de Maast richt  op sleeptouw hebt  genom en;  Chris en Pieter,  dank 
jullie voor de gezellige pat iëntbesprekingen en m ij  op het  spoor zet ten 
van nieuwe ANCA pat iënten;  Ellen, dank voor de gezellige uren binnen 
en buiten de afdeling im m unologie -  Katan kent  geen geheim en voor 
ons! ;  Ellis, om dat  j e m e hebt  overtuigd m ijn gevoelens te volgen;   Kim , 
voor haar ondersteuning in FACS en genet ica;  Lucienne, alt ij d 
aanwezig voor een gezellig praat je en hofleverancier van de lekkerste 
wit te wijn die ik ooit  geproefd heb;  Peter, Henk en Harry, voor de 
inwijding in het  tot  dan toe m ysterieuze apparaat , de FACS;  professor 
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van Breda Vriesm an, dank u voor de uren achter de m icroscoop waarin 
u m ij  heel veel hebt  geleerd over nefropathologie;  en Ruud, voor de 
ontelbare ELISAs die je voor m ij  hebt  uitgevoerd en j e posit ieve 
aanwezigheid. 
  
Ook de andere collega’s:  Ad, Anita, Anita, Ariane, Birgit , Dennis, 
Désirée, Francy, José, Maria, Peter,  Pet ra, Pet ra, Silvie, en Wilfred;  de 
dam es (en Jos)  van het  lab klinische im m unologie;  bedankt  voor de 
gezellige jaren in Maast r icht  en voor de bereidheid om  als proefpersoon 
m ee te helpen aan m ijn prom ot ieonderzoek!  
 
Mariska, al 17 jaar ben je m ijn allerbeste vriendin. Bedankt  voor alle 
vakant ies die we sam en hebben beleefd ter ontspanning van een jaar 
hard onderzoeken!  I k ben erg blij  dat  j e nu m ijn paranim f wilt  zij n. 
 
De leden van de beoordelingscom m issie, Prof. dr. P.W. de Leeuw, Prof.  
dr. C.A. Bruggem an, Prof.  dr . P.E. de Jong, Prof.  dr . P.A. Merkel, en 
Prof. dr. C.D. Stehouwer wil ik bedanken voor het  doorlezen en 
vervolgens goedkeuren van m ijn proefschrift . 
 
Hyon, John, and Peter, thank you for your guidance during the 
research I  perform ed at  the MGH, result ing in, what  now appears to be, 
the first  chapter of t his thesis. GuoLi and Charyl, thank you for  
teaching m e m y first  laboratory techniques. 
 
Mijn ouders wil ik bedanken voor hun alt ij d aanwezige steun en geloof 
in m ijn kunnen. Jullie hebben m ij  ondertussen al het  hele land 
doorverhuisd!  Laura, m ijn zussie, ik hoop dat  j e heel erg gelukkig 
wordt  m et  Gerwin en ik hoop dat  de piano nu wat  langer op dezelfde 
locat ie blij ft  staan... 
 
En tot  slot  Dave, lieve Dave, niet  alleen m ijn vriend m aar ook m ijn 
m aat je, zonder Maast richt  (en Marjan)  had ik j e nooit  leren kennen en 
nu bouwen we sam en een toekom st  in Delft , Leiden en Zoeterm eer. 
Dank voor al j e steun en geduld, en hulp om  dit  boekje op t ij d af te 
krij gen. Hopelij k zit ten we over een aantal jaren net  zo sam en aan 
jouw proefschrift !  
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Marjan Carolien Slot  werd geboren te Enschede op 5 juni 1977. Na het  
behalen van haar atheneum diplom a aan het  Stedelij k Lyceum  Zuid 
aldaar in 1995 start te zij  haar studie geneeskunde aan de 
Rij ksuniversiteit  Groningen. Tij dens het  tweede jaar van deze studie is 
zij  begonnen aan de eerste stappen naar het  huidige proefschrift  onder 
begeleiding van Dr. J.W. Cohen Tervaert  en Dr. C.A. Stegem an. Haar 
wetenschappelij ke stage verricht te zij  in het  Massachuset ts General 
Hospital in Boston onder begeleiding van Dr. H. Choi, Prof. Dr. P.A. 
Merkel en Dr. J. Niles. I n 2001 behaalde zij  haar artsexam en in 
Groningen en ze start te in 2002 als assistent  geneeskunde in opleiding 
tot  klinisch onderzoeker bij  het  departem ent  interne geneeskunde, 
afdeling klinische en experim entele im m unologie van het  academ isch 
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